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ABSTRACT  
 
A pathogenic role for synovial fibroblasts has been established based on the study of samples 
originating from patients with longstanding rheumatoid arthritis (RA). To assess whether 
these cells also have such role in early RA and whether they play a part in the resolution of 
inflammatory arthritis, functional and transcriptional characterisation was performed on 
synovial fibroblasts from patients in five distinct outcome groups: normal joints, resolving 
arthritis, very early RA, early RA and longstanding RA.  
 
Functional characterisation revealed differences in migration rates between groups. Migration 
rates of very early RA and longstanding RA synovial fibroblasts were significantly slower 
than those of normal ones. No differences in invasive characteristics were identified. 
 
Transcriptional analysis demonstrated differing transcriptional signatures between very early 
and longstanding RA synovial fibroblasts in both, unstimulated and TNF stimulated samples. 
No differences in the transcriptomic profile of resolving and very early RA cells were 
identified. The study of transcriptional responses to TNF stimulation in each outcome group 
revealed generic changes in response to pro-inflammatory stimuli as well as outcome group-
specific responses.   
 
These data extend previous observations of the pathogenic role of synovial fibroblasts 
indicating that they may play a role in early RA and providing clues to potential targets 
differentiating early and late RA.     
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1 Introduction 
 
1.1 Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a chronic multi system disease of unknown aetiology that 
affects 1% of the population. In RA, the primary pathology localises to synovial joints 
and is characterised by chronic inflammation that can lead to bone and cartilage 
destruction, loss of function and long term disability.  
 
1.1.1 Classification of RA 
RA is a heterogeneous disease with multiple manifestations. The clinical diagnosis of 
RA is based on a history of symmetrical polyarthritis affecting the small joints of the 
hands and feet sometimes in the context of a family history of RA (first degree relative) 
and often associated with raised inflammatory markers and positive antibody testing to 
rheumatoid factor (RF) and anti citrullinated protein antibodies (ACPA).  
 
In order to facilitate recruitment of patients into studies and direct comparisons between 
clinical trials, classification criteria were developed by the American Rheumatism 
Association in 1956 (Ropes et al 1957). These criteria were revised in 1987 (Arnett et 
al. 1988) and have since been widely used for this purpose. Under these criteria patients 
are assessed against 7 items and are said to fulfil classification criteria for RA if 4/7 
criteria are satisfied (Table 1.1). In recent years, these criteria have come under criticism 
as they lack sensitivity in early disease. As a consequence, the American College of 
Rheumatology and the European League Against Rheumatism developed new criteria 
1-2 
 
(Aletaha et al. 2010). The major advantage of the 2010 Rheumatoid Arthritis 
classification criteria is that whilst they can be applied to patients with established 
disease they also allow identification of patients at high risk of chronicity in early 
disease (Table 1.2). Also noteworthy, is the inclusion of ACPA in these classification 
criteria. In clinical practice, their presence or absence in the sera of RA patients is used 
to further sub-classify RA into ACPA positive and ACPA negative disease. This 
distinction is based on evidence that these disease subsets are associated with differing 
environmental and genetic risk factors thus suggesting that they may be caused by 
different pathophysiological mechanisms (Eyre et al. 2012;Klareskog et al. 2006;Linn-
Rasker et al. 2006;Plenge et al. 2005). Furthermore, although both diseases may have 
very similar clinical features at presentation, disease course is markedly different with 
ACPA positive patients displaying a less favourable course characterised by increased 
extra-articular manifestations and excess cardiovascular risk and earlier and more severe 
joint damage (Willemze et al. 2012). 
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Table 1.1 The 1987 American Rheumatism Association revised criteria. 
Criterion Definition 
1. Morning stiffness Stiffness in and around the joints lasting at least 1 hour before 
maximal improvement. 
2. Arthritis of 3 joints At least 3 joint areas simultaneously have had soft tissue swelling 
or fluid observed by a physician. The 14 possible areas are: MCP, 
PIP, wrist, elbow, knee, ankle and MTP joints. 
3. Arthritis of hands At least 1 area swollen in a wrist, MCP or PIP joint. 
4. Symmetric arthritis Simultaneous involvement of the same joint areas on both sides of 
the body (bilateral involvement of PIPs, MCPs, or MTPs is 
acceptable without absolute symmetry). 
5. Rheumatoid nodules Subcutaneous nodules over bony prominences or extensor surfaces 
or in juxtaarticular regions observed by a physician. 
6. Rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid factor by 
any method for which the result has been positive in <5% of normal 
control subjects.  
7. Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints (osteoarthritis changes alone 
do not qualify). 
For classification purposes a patient shall be said to have rheumatoid arthritis if he/she has 
satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been present for at least 6 
weeks. Patients with 2 clinical diagnoses are not excluded.  
 
 
 
 
Table 1.2 The 2010 Rheumatoid Arthritis classification criteria 
Criterion Score 
A. Joint involvement  
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for the classification)  
Negative RF and negative ACPA 0 
Low positive RF or low positive ACPA 2 
High positive RF or high positive ACPA 3 
C. Acute phase reactants (at least 1 test result is needed for classification)  
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms  
< 6 weeks 0 
 6 weeks 1 
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The score of each section (A-D) is added. A score of  6/10 is needed for the classification of 
RA. 
 
 
1.1.2 Pathophysiology  
 
The pathogenesis of RA is complex and incompletely understood. It is postulated that a 
combination of genetic, epigenetic and environmental factors coincide in an individual 
leading to disease. It is generally accepted that exposure of susceptible individuals to 
certain environmental triggers leads to loss of self-tolerance and over time to 
development of inflammatory arthritis.  
 
1.1.2.1 Genetic and environmental factors 
 
The importance of genetics in determining disease susceptibility has long been 
recognised. Disease concordance in monozygotic twins is estimated at 15% with overall 
heritability estimated at 60% (MacGregor et al. 2000). Genome-wide association studies 
have identified risk alleles that are associated with increased disease susceptibility. 
Perhaps the best known of these is the human leucocyte antigen (HLA) system. The 
HLA system is the most polymorphic genetic system in humans and a number of alleles 
have been associated with increased RA susceptibility. Amongst these, alleles that 
contain a common amino acid substitution (QKRAA) at positions 70-74 in the third 
hypervariable region of the DR1 chain within the peptide binding groove  (known as 
the shared epitope)  confer increased susceptibility to RA (Gregersen et al. 1987). This 
and other risk alleles of genes coding for proteins including protein thyrosine 
phosphatase non-receptor type 22 (PTPN22) and cytotoxic T lymphocyte antigen 4 
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(CTLA4) have been associated with increased susceptibility to ACPA positive disease. 
PTPN22 encodes a tyrosine phosphatase  involved in T and B cell activation (Kallberg 
et al. 2007) whilst CTLA4 is involved in down-regulation of T cell activation and 
maintenance of peripheral tolerance (McCoy et al. 1999). Genetic associations to ACPA 
negative disease also exist although they are less well established. An example is the 
proved association between HLA-DR3 and ACPA negative but not ACPA positive RA 
(Verpoort et al. 2005). These observations are important for two reasons. First, they 
lend support to genetic influence in disease and more specifically to the role of the 
immune system as these alleles have functions consistent with immune regulation. 
Second, they help to define disease categories not solely based on clinical 
characteristics but on genetic and antibody profiling (McInnes et al. 2011).  
 
Gene-gene and gene-environment interactions are thought to be key determinants of 
disease pathogenesis. Smoking is the prototypical environmental factor implicated in 
disease. Smoking is a risk factor for RA and in particular for RF positive disease. The 
relative risk of RF positive RA in smokers is 2.2 (95% CI 1.7-3.0) compared to a 
relative risk of RF negative RA of only 0.8 (95% CI 0.6-2). Furthermore, this risk is 
increased by interactions between this environmental factor and genetic ones. Thus, 
smokers carrying one copy of the shared epitope have a relative risk of RF positive RA 
of 7.5 (95% CI 4.2-13.1) whilst those carrying two copies have a relative risk of 15.7 
(95% CI 7.2-34.2) (Padyukov et al. 2004). The interaction between smoking and the 
shared epitope also increases the risk of ACPA positive RA. Smokers with a single copy 
of the shared epitope have a relative risk of ACPA positive disease of 6.5 (95% CI 3.8-
11.4) whilst those with two copies have a relative risk of 21 (95% CI 11.0-40.2) 
(Klareskog et al. 2006). The study of interactions has been extended to other risk alleles 
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and to date the highest relative risk of developing ACPA positive RA is conferred by 
the combination of smoking, double copies of the shared epitope and PTPN22 risk 
alleles (Kallberg et al. 2007).  
 
Infections represent other notable environmental factors implicated in RA pathogenesis. 
Molecular mimicry and the ability of some pathogen products to promote protein 
citrullination have been postulated as possible pathogenic mechanisms. Several studies 
have demonstrated a positive association between RA and periodontitis (de Pablo et al. 
2009;Kinloch et al. 2008;Wegner et al. 2010). Periodontitis is an infectious process 
initiated by Porphyromonas gingivalis and other pathogens and accompanied by a 
chronic inflammatory response. Common features and potential links between both 
conditions include their relapsing/remitting nature and similar prevalence, the presence 
of P. gingivalis in synovial fluid of RA patients and genetic factors underlying disease 
susceptibility (Persson 2012). However, the precise mechanisms that explain this 
association remain to be elucidated. The human microbiome has also been studied in the 
context of disease. The microbiome is defined as the collection of microorganisms that 
populate the human body. As 60-70% of these bacteria reside in the gut, studies have 
focused on these microorganisms in particular. Of particular interest is the observation 
that disease is attenuated in murine models of arthritis if animals are raised in germ free 
conditions. Conversely, introduction of specific gut bacteria induces joint inflammation 
whilst antibiotic treatment can prevent arthritis development in animal models (Horai et 
al. 2000;Rath et al. 1996). Data from human studies have very recently added to these 
longstanding observations. Scher and colleagues undertook sequencing of bacterial 
DNA in faeces of patients with new onset treatment naïve ACPA positive RA of less 
than 6 months duration, treated RA patients with disease duration of more than 6 
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months (chronic RA), treated psoriatic arthritis patients (PsA) and healthy controls and 
found significant differences in bacterial composition between patient groups. A 
specific intestinal bacterium Prevotella copri was identified in 75% of new onset 
treatment naïve RA patients compared to 11.5% of chronic RA, 37.5% of PsA and 21% 
of healthy controls. The expansion of prevotella species was inversely correlated with 
bacteroides species. To elucidate whether P.copri could predispose to increased 
inflammation, antibiotic treated mice were colonised with the bacteria and colitis was 
induced. P. copri colonised mice demonstrated significantly more severe disease than 
their control littermates suggesting that P. copri may be able to support systemic 
inflammation (Scher et al. 2013). 
 
 
The role of autoimmunity in RA has long been proposed owing to the presence of 
autoantibodies in the sera of these patients. Rheumatoid factors (RF) are autoantibodies 
against the Fc portion of IgG proteins. They can be present in the sera of patients 
months or years before the onset of disease and are predictors of joint damage and 
functional disability (Arend et al. 2012;Scott 2000). Antibodies against citrullinated 
peptides (ACPA) are directed against a range of citrullinated proteins including 
fibrinogen, vimentin, -enolase and type II collagen. They too can be present in the sera 
of patients for years before disease onset and are prognostic markers that have also been 
implicated in disease pathogenesis (Willemze et al. 2012). Citrullination is an enzymatic 
process that results in post-translational modification of proteins. It is catalyzed by 
peptidylarginine deiminase (PADI) enzymes that convert arginine residues to citrulline 
(Figure 1.1). Citrullination occurs during several biological processes, including 
inflammation. In RA, citrullination is thought to occur in a variety of locations 
including lungs, periodontal tissue and synovial joints (where PADI enzymes have been 
1-8 
 
found), and may provide a link between genetic and environmental factors and 
autoimmunity. The analysis of fluid from bronchoalveolar lavages from healthy 
smokers and smokers with pulmonary pathology revealed citrullinated proteins in 
smokers but not in non-smokers. The presence of citrullinated proteins was associated 
with higher levels of PADI2. This observation prompted the hypothesis that long term 
exposure to smoking may induce citrullination of self-antigens leading to ACPA 
production in susceptible individuals carrying the shared epitope (Klareskog et al. 
2006). Similarly, P. gingivalis species express PADI enzymes able to citrullinate fibrin 
from periodontal tissue. Thus these citrullinated antigens may become immunogenic in 
patients with periodontitis (de Pablo et al. 2009).  
 
It is likely that other, yet to be defined, autoantibodies against post-translationally 
modified proteins are present in the sera of RA patients. Indeed, antibodies against 
carbamylated peptides have recently been identified in the sera of RA patients. 
Carbamylation is a non-enzymatic post-translational modification that results in the 
conversion of lysine residues into homocitrulline (Figure 1.1). Homocitrulline and 
citrulline are similar in structure but differ in length and the modified residue (lysine in 
the case of homocitrulline and arginine in the case of citrulline). Anticarbamylated 
protein antibodies have been found in 37-45% of ACPA positive RA and 16-20% of 
ACPA negative patients. In the latter group they appeared predictive of disease severity 
(Shi et al. 2011). Unpublished work from our group suggests that autoantibodies against 
acetylated lysine exist in the sera of patients with very early RA compared to those with 
resolving and persistent non RA arthritis.  
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 Figure 1.1 Post-translational protein modification. Diagram depicting the processes of 
citrullination, carbamylation and acetylation. Citrullination occurs when arginine resides are 
deaminated to citrulline. Lysine residues can undergo carbamylation through non-enzymatic 
conversion into homocitrulline or acetylation through addition of acetyl residues. Antibodies 
against citrullinated, homocitrullinated and acetylated peptides are present in the sera of RA 
patients.  
 
 
1.1.2.2 Synovial architecture in health and disease  
 
Normal synovial tissue consists of two layers: the lining, which is in contact with 
synovial fluid, and the sublining. The lining is a thin (2-3 cell deep) and avascular layer 
that lacks a basement membrane and is composed of roughly equal proportions of type 
A (macrophage-like) synoviocytes and type B (fibroblast-like) synoviocytes (also 
known as synovial fibroblasts). The sublining is a thicker and more loosely organised 
layer of type A and type B synoviocytes together with extracellular matrix (ECM) and 
blood vessels (Mor et al. 2005).  
 
In RA the normal synovial architecture is distorted. The usually thin lining layer is 
replaced by a hyperplastic 10-15 cells deep layer. At the synovial-cartilage junction this 
thickened synovial layer can become a mass of “pannus” tissue rich in synovial 
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fibroblasts and osteoclasts that attaches to and invades the adjacent articular cartilage 
and subchondral bone. The sublining synovial layer becomes infiltrated with 
inflammatory cells including T cells, B cells, macrophages, mast cells, and plasma and 
dendritic cells. Increased activity in the synovium is supported by ECM production and 
neoangiogenesis (Taylor et al. 2005). A schematic representation of the cells in the RA 
synovium is shown in Figure 1.2.  
 
 
Figure 1.2 Schematic representation of the diversity of cells found in the RA synovium. The 
lining layer is mainly composed of macrophages and synovial fibroblasts whilst the sublining 
layer is composed of these cells as well as other immune inflammatory cells. Reproduced with 
permission from Juarez et al. 2012. 
 
 
This distorted synovial architecture is responsible for one of the main clinical 
manifestations of disease: joint swelling. Yet somewhat surprisingly, this chronic 
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inflammatory infiltrate is highly organised and governed by complex interactions 
between cells of the innate and adaptive immune systems and resident tissue stroma. 
The role of some of these cells in disease will be discussed next.  
 
1.1.2.3 Cells in the RA synovium 
 
T cells have traditionally been implicated in RA pathogenesis. Their role is suggested 
by genetic susceptibility factors to RA such as the HLA system, PTPN22 and CTLA4. 
Additionally, abatacept (a selective co-stimulation modulator that inhibits T cell 
activation) has demonstrated efficacy in the treatment of RA further emphasising the 
role of these cells in disease. In RA synovial tissue, CD4 T cells tend to locate around 
perivascular cuffs whilst CD8 T cells are located throughout synovial tissue (Kurosaka 
et al. 1983). Historically RA has been considered a predominantly type 1 T helper cell 
(Th1) disease. This stemmed from the observation that arthritis could be induced in 
mice by inoculation with IL-12, a cytokine that promotes differentiation of naïve T cells 
into Th1 cells (Germann et al. 1995). However, it was later shown that it was IL-23 and 
not IL-12 that played an important role in arthritis induction. IL-12 is composed of p35 
and p40 subunits whilst IL-23 is composed of p19 and p40 subunits. To assess the 
relative contribution of each cytokine to disease, three types of mice were created: one 
specifically lacking p35 (IL-12 deficient), another lacking p19 (IL-23 deficient) and a 
third type lacking p40 (IL-12 and IL-23 deficient) and collagen induced arthritis (CIA) 
induced. IL-23 and combined IL-12 /IL-23 deficient mice were protected against 
arthritis development whilst IL-12 deficient mice developed severe arthritis. This 
suggested that IL-23 had a central role in the development of arthritis whilst IL-12 had a 
protective role. IL-23 and IL-12/IL-23 deficient mice developed no IL-17 producing T 
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cells whereas IL-12 deficient mice developed an increased number of these cells 
(Murphy et al. 2003). IL-23 is a cytokine produced by macrophages and dendritic cells 
that, together with other cytokines, supports type 17 T helper cell (Th17) differentiation 
whilst suppressing regulatory T cell (Treg) differentiation.  
 
Thus, Th17 responses and IL-17 production by these cells have been implicated in RA 
pathogenesis. Th17 cells have a key role in the development of autoimmunity in several 
animal models. For instance, IL-6 deficient mice are resistant to antigen induced 
arthritis and autoimmune encephalitis owing to altered Th17 activation and 
differentiation whilst treatment with anti-IL-17 antibodies ameliorates the severity of 
CIA (Stockinger et al. 2007). IL-17 levels are very low in the sera of healthy individuals 
but elevated in the sera of RA patients. Co-culture of IL-17 producing T cells with RA 
synovial fibroblasts induces production of pro-inflammatory cytokines by fibroblasts 
whilst IL-17 production by T cells is increased in co-culture (Cho et al. 2004).  
Infiltrating IL-17 producing T cells can be seen in RA synovial tissues (Chabaud et al. 
1999) and IL-17 blockade suppresses inflammation in the CIA model (Lubberts 2008). 
The potential role of IL-17 blockade as a therapeutic target in RA is currently being 
investigated (Kellner 2013).  
 
In contrast, the regulatory function of RA synovial Treg cells is limited. Tregs have a 
central role in the maintenance of immune tolerance and prevention of autoimmune 
disease. They exert this function through secretion of inhibitory cytokines (i.e. IL-10) 
and reduction of T cell activation through down-regulation of co-stimulatory molecules 
on antigen presenting cells (Broere et al. 1999). Tregs found in the rheumatoid 
synovium appear to have limited regulatory function and are unable to suppress 
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production of pro-inflammatory cytokines by monocytes and activated T cells 
(Ehrenstein et al. 2004). This limited regulatory function has been associated with their 
reduced expression of CTLA4 (Flores-Borja et al. 2008).  Furthermore, RA synovial 
fluid effector T cells are less susceptible to suppression than peripheral blood effector T 
cells (van Amelsfort et al. 2004) which concurs with the observation that strongly 
activated CD4 T cells are resistant to Treg suppression (Baecher-Allan et al. 2002).  
 
The pathogenic role of B cells in RA is supported in clinical practice by the success of 
the CD20-B cell depleting therapy rituximab (Edwards et al. 2004).  Three distinct 
patterns of B cell organisation in the RA synovium have been described. In a study of 
64 synovial tissue samples, diffuse T and B cell infiltration was seen in 56% of patients. 
T and B cells formed aggregates lacking follicular dendritic cells and germinal centers 
in 20% of patients whilst a third subset of patients (24%) showed T and B cell 
aggregates with germinal center-like structures (Takemura et al. 2001). For years, a role 
for these cells in disease pathogenesis was proposed owing to their ability to produce 
antibodies. It is now proposed that their role in disease also extends to antigen 
presentation and cytokine production. In the RA synovium, B cells produce IL-6, IFN 
and lymphotoxin  which indicates that they may have a pro-inflammatory role and 
support B cell development (Pistoia 1997).  
 
Neutrophils are present in relatively low numbers in synovial tissue but are the most 
abundant cell type in synovial fluid. Although their role in disease is not fully elucidated 
they produce prostaglandins, proteases and reactive oxygen species thought to promote 
synovial inflammation (Cascao et al. 2010). Very recently, their role has taken centre 
stage with the description of aberrant NETosis in neutrophils from synovial fluid and 
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peripheral blood of RA patients (Khandpur et al. 2013). NETosis is a process by which 
neutrophils release chromatin fibers producing networks termed neutrophil extracellular 
traps (NETs) that have the capacity to bind pathogens. This process has been described 
in a number of autoimmune conditions where it is thought to play a pathogenic role by 
promoting autoimmunity (Woodman 2013). In RA NETs have been shown to contain 
citrullinated vimentin that is recognised by autoantibodies in these patients. 
Furthermore, ACPA and RF as well as pro-inflammatory stimuli can induce NETosis in 
neutrophils. These observations have led to the proposal of NETosis as a key event in 
disease pathogenesis that promotes and perpetuates autoimmunity and abnormal 
adaptive and innate immune responses (Khandpur et al. 2013). 
 
Macrophages are very abundant in the lining and sublining layers of RA synovial tissue. 
Their role in disease pathogenesis is supported by reduction of sublining layer 
macrophage numbers following successful therapy and positive correlation between this 
reduction and response to treatment as measured by DAS28 (Haringman et al. 2005). 
Macrophages in RA produce chemokines including macrophage inflammatory protein 1 
and monocyte chemoattractant protein, that attract leucocytes into the joint (Kinne et al. 
2000).  They also produce pro-inflammatory cytokines such as TNF and a wide range 
of members of the interleukin family including IL-1 and IL-6 and the granulocyte 
macrophage colony stimulating factor (GM-CSF) (Chu et al. 1991;Chu et al. 1992) 
hence supporting their role in chronic inflammation. Of note, production of some of 
these factors has been localised to the pannus-cartilage junction suggesting a role in 
joint destruction. Indeed, it has been proposed that they exert a direct cartilage 
destructive role through their production of matrix degrading enzymes, an effect that is 
amplified by co-culture  with synovial fibroblasts in murine models (Kinne et al. 2000). 
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The role of synovial fibroblasts in disease is discussed under a separate heading later in 
this chapter.  
 
 
1.1.2.4 Epigenetic regulation 
 
An important role for epigenetic mechanisms in the pathogenesis of RA has been 
described. Initially coined by developmental biologists to refer to the study of how 
genotypes give raise to phenotypes during development, the term epigenetics was 
subsequently used by molecular biologists to refer to heritable changes in gene 
expression that do not arise from changes in the underlying DNA sequence (Bird 2007). 
In recent times, the idea that all epigenetic changes are heritable has been the subject of 
debate (Cortessis et al. 2012) and a broader definition has been proposed that includes 
non-heritable, environmentally induced and reversible modifications (Bird 2007).  
 
A broad range of epigenetic mechanisms have now been described including DNA 
methylation, post-translational modification of histones, microRNAs and long non-
coding RNAs. Epigenetic marks that are associated with specific cellular gene 
expression repertoires and are responsible for their maintenance have been defined. At 
the same time, other epigenetic marks can be dynamic and affected by environmental 
interactions. Exposure to environmental agents such as cigarette smoke, organic 
chemicals, metals, nutritional sources and the microbiome have been associated with 
marked changes in cellular epigenomes, particularly when exposure occurs during key 
developmental periods (Cortessis et al. 2012). Hence, the epigenome may not only 
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provide a tool to understand disease pathogenesis but may also explain environmental 
interactions and provide a powerful tool to modify disease course.   
 
DNA methylation is one of the best studied epigenetic modifications. Addition of a 
methyl group in position 5 of the cytosine ring within cytosine-phosphate-guanine 
dinucleotides is associated with gene silencing. RA synovial tissue and cultured RA 
synovial fibroblasts display global DNA hypomethylation that is associated with up-
regulation of disease relevant genes such as adhesion molecules and matrix 
metalloproteinases (MMPs). Additionally, treatment of normal synovial fibroblasts with 
the DNA methylation inhibitor 5-aza-2-deoxycytidine leads to  up-regulation of disease 
relevant genes (Karouzakis et al. 2009). A distinct DNA methylation signature has 
subsequently been demonstrated for RA synovial fibroblasts that is associated with 
several biological pathways including cell migration, focal adhesion and transmigration 
(Nakano et al. 2013).  
 
The study of non-protein coding genes that act as modulators of gene function has also 
attracted attention. Non-coding RNAs are mRNA molecules transcribed from DNA that 
do not code for proteins. Instead, they are involved in post-transcriptional regulation of 
gene expression through their ability to regulate the stability of protein coding mRNA  
(Perkins et al. 2005). Long non-coding RNAs and microRNAs are amongst the most 
studied non-coding RNAs. 
 
MicroRNAs (miRNAs) are short (21-23bp) RNA fragments that regulate protein 
translation trough RNA-RNA interactions. They exert their regulatory role through 
complementarity of 6-8 nucleotides in the miRNA sequence to the same number of 
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nucleotides in the 3’ untranslated region of their target mRNA. The ability to interact 
with target mRNA on the basis of a small number of nucleotides allows a large number 
of possible interactions which explains how a single miRNA is able to regulate 
hundreds of target mRNAs (Strietholt et al. 2008). Several studies have identified 
altered miRNA expression in plasma of RA patients compared to healthy individuals 
(Ceribelli et al. 2011) and their study also extends to RA synovial fibroblasts. Increased 
expression of miR-155 and miR-146a has been described in cultured established RA 
synovial fibroblasts with the former also being overexpressed in RA synovial tissue and 
blood monocytes. Whilst overexpression of miR-155 was associated with decreased 
expression of MMPs (Stanczyk et al. 2008), overexpression of miR-146a has recently 
been associated with inhibition of osteoclastogenesis in collagen induced arthritis 
(Nakasa et al. 2011).  However, overexpression of miR-146a is not specific to RA and 
has also been described in osteoarthritis (Yamasaki et al. 2009). Overexpression of 
miR-203 by RA synovial fibroblasts has also been demonstrated. In this study forced 
expression of miR-203 in these cells led to up-regulation of MMP1 and IL-6 production 
via the NF-B pathway (Stanczyk et al. 2011).  
 
Very recently a potential role for long non-coding RNAs (lncRNAs) in RA 
pathogenesis has also been proposed. LncRNAs are large (>200bp) RNA molecules that 
have been implicated in a variety of processes including gene expression regulation and 
regulation of biological processes such as cell migration, proliferation and invasion 
(Umekita et al. 2014). Using microarray technology, gene expression patterns of RA 
and OA synovial fibroblasts were analysed. Two hundred and twenty five differentially 
expressed transcripts were identified between groups, a hundred of which were 
lncRNAs. Overexpression of two of these lncRNAs in the RA group was confirmed by 
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polymerase chain reaction (PCR). The validated lncRNAs were small nucleolar RNA 
host gene 1 (SNHG1) and RP11-39708. The function of either lncRNA remains 
unknown at present (Bertoncelj et al. 2013). To assess the effect of pro-inflammatory 
stimuli on lncRNA expression, the authors subsequently analysed expression levels of 
lncRNAs following synovial fibroblast stimulation with TNF and IL-1 for 24 hours. 
The expression of several lncRNAs was influenced by pro-inflammatory stimulation in 
vitro but this response did not differ between RA and OA synovial fibroblasts.  
Silencing of one of these lncRNAs, antisense long non-coding RNA in the INK4 locus 
(ANRIL), resulted in decreased expression of MMP1 and MMP3 mRNA and protein, 
suggesting a role for ANRIL in the invasive characteristics of RA synovial fibroblasts 
(Bertoncelj et al. 2014). Although the study of lncRNAs in this context is on its early 
days and no definite conclusions can yet be drawn from these studies further work 
continues to be done to determine the role of lncRNAs in RA.  
 
In summary, progression to RA is a multistep process that involves numerous factors. It 
is postulated that in the earliest phases of disease (before the onset of symptoms) 
environmental factors affecting susceptible individuals may lead to post-translational 
modification of self-proteins (i.e.  citrullination). These processes are likely to take 
place in a variety of locations including the lungs, periodontal tissue, the joint and the 
bone marrow. Such processes may lead to loss of tolerance and development of 
autoantibodies including RF and ACPA antibodies which can be present years before 
the onset of clinical disease. Over time and presumably mediated by an as yet, unknown 
trigger, loss of tolerance progresses to symptomatic disease (McInnes et al. 2011).  
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1.1.3 Changing concepts: early disease and the window of 
opportunity  
  
As knowledge of disease pathogenesis has advanced, the management of RA has 
experienced a parallel shift.  
For many years, RA was considered a relatively benign disease where damage occurred 
late (Raza et al. 2006) Under this premise, aggressive treatment with drugs that, at the 
time, were felt to be very toxic was not warranted. Instead, cautious introduction of 
sequential monotherapy with non-steroidal anti-inflammatories as first line and disease 
modifying agents (DMARDs) as second line was favoured. This invariably resulted in 
introduction of the most efficacious treatments late in disease (Cush 2007).  
 
Subsequently, longitudinal population based studies changed this perception by 
revealing a high risk of joint damage, disability and mortality in patients with 
uncontrolled RA. Of special importance was a seminal publication by Wilske and Healy 
in 1989 where they proposed “reversing” the treatment pyramid and advocated early 
disease treatment  (Wilske et al. 1989). More recently the concept of a window of 
opportunity in early disease has been proposed. This suggests that a very early, and yet 
not fully defined, phase in disease exists in which treatment leads to significantly better 
outcomes (van der Linden et al. 2010). Using cancer as an analogy, it is postulated that 
during this early phase, the number of diseased cells is smaller and pathogenic 
mechanisms may not be fully established hence providing a window of time when cells 
may be more responsive to treatment (Boers 2003).  
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Since these concepts were proposed, many clinical trials have proved that early 
aggressive treatment leads to significantly better clinical outcomes without an 
unacceptably high adverse side effect profile (Boers et al. 1997;Mottonen et al. 1999). 
Additionally, bone erosions (an important feature of joint destruction) have been found 
to occur in early disease and as a result of active synovitis emphasising the need for 
early aggressive treatment (Raza et al. 2006). Nevertheless the concept of early disease 
remains poorly defined. Whilst most initial clinical trials assessing aggressive 
combination therapy defined early RA as disease of less than 2 years symptom duration 
(Boers et al. 1997;Goekoop-Ruiterman et al. 2005) some lines of evidence suggest that 
the window of opportunity may be limited to the first few months of disease (Raza et al. 
2005). An added difficulty here is the lack of consensus on how disease onset is 
defined. Various definitions of disease onset have been used in the literature including 
symptom onset, start of joint swelling, time of fulfilment of classification criteria for 
RA and time of diagnosis by physician (Raza et al. 2012). Consequently, what might be 
meant by the first 3 months of disease will be very different depending on how disease 
onset is defined (Figure 1.3).  
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Figure 1.3 Schematic representation of differing definitions of the “first 3 months of disease” 
depending on how disease onset is defined. Reproduced with permission from Raza et al. 2012. 
 
 
In a prospective observer blinded case control study, patients with very early RA (of 
less than 3 months symptom duration) in whom DMARD treatment had been initiated at 
a median disease duration of 3 months were compared with patients with late early RA 
(of 12-42 months duration) in whom DMARD therapy had been started at a median 
disease duration of 12 months. Significantly improved clinical and radiographic scores 
were found in the very early RA group compared to the late early RA group (Nell et al. 
2004). At a molecular level, synovial fluid from patients with one or more swollen 
joints and inflammatory joint symptoms of three months or less duration was 
characterised revealing a distinct and transient cytokine profile (Raza et al. 2005). At a 
histological level, changes in microvasculature and synovial tissue have been identified 
in patients with synovitis of less than 6 weeks duration (Schumacher, Jr. et al. 1994). 
This expanding knowledge is reflected in a recent survey of rheumatologists where the 
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majority (84.5%) defined early RA as disease of symptom duration of less than 3 
months (Aletaha et al. 2004).  
 
Widespread acceptance of these concepts amongst health care professionals has led to a 
step change in the management of RA. Early arthritis clinics have been created and 
identification and treatment of early RA has become a clinical priority. Indeed, current 
research efforts can be divided into those directed to the development of new therapies 
and better understanding of disease mechanisms and those dedicated to understanding 
and bridging barriers to early treatment initiation. Limitations to effective early 
treatment still exist and issues such as delayed patient presentation and delayed referral 
to rheumatologists are still being addressed (Raza et al. 2011). In parallel, the search for 
predictors of disease outcome in early undifferentiated inflammatory arthritis and 
response to treatment continues in order to achieve early treatment strategies that are 
tailored to individual patients. In this respect, one of the remaining challenges is the 
correct early identification of patients that present with undifferentiated arthritis but will 
go on to develop RA and their distinction from patients with undifferentiated arthritis 
that will resolve. Whilst the use of the 2010 ACR/EULAR criteria to aid patient 
diagnosis has led to increased identification of patients with RA at an early stage, it is 
also recognised that this approach may lead to overdiagnosis of RA in patients with 
undifferentiated arthritis that is destined to resolve (Cader et al. 2011).  
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1.1.4 Pre-clinical rheumatoid arthritis and disease chronology  
 
It is not only early RA, but the various phases preceding the clinical manifestations of 
disease that have attracted interest over the last few years. The observation that raised 
inflammatory markers and autoantibodies can be present in the sera of patients for some 
time before the onset of clinical symptoms has led to the suggestion that the preclinical 
phases leading up to disease may represent important therapeutic windows in their own 
right.  
 
To facilitate research in this area, unifying terminology has been proposed to describe 
the phases leading up to the development of RA (Gerlag et al. 2012). These phases are 
not necessarily sequential and patients do not go through all phases before developing 
RA. The initial phases (A and B) comprise the presence of susceptibility alleles and 
exposure to environmental factors such as smoking. Phase C corresponds to 
asymptomatic autoimmunity. This phase can precede disease onset by up to fifteen 
years and is characterised by the presence of RF or ACPA in the absence of clinical 
disease. During this phase systemic inflammation can be detected by the presence of 
raised inflammatory markers (CRP) and pro-inflammatory cytokines such as TNF and 
IL-6 (van Steenbergen et al. 2013). Asymptomatic autoimmunity is sometimes followed 
by a period of symptoms without clinical or radiological evidence of arthritis (phase D). 
Alternatively, other individuals may suffer from asymptomatic synovitis characterised 
by absence of symptoms but presence of histological synovitis (Kraan et al. 1998). 
Unclassified arthritis and RA complete these phases (phases E and F).  A schematic 
representation of these phases is shown in Figure 1.4.  
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Figure 1.4 Recommendations for terminology to be used to describe specific phases up to the 
development of RA. The following definitions are recommended when describing individuals in 
prospective studies: (a) genetic risk factors for RA, (b) environmental risk factors for RA, (c) 
systemic autoimmunity associated with RA, (d) symptoms without clinical arthritis, (e) 
unclassified arthritis, (f) rheumatoid arthritis.   
 
 
1.2 The role of synovial fibroblasts in rheumatoid arthritis 
 
Synovial fibroblasts are one of the most abundant cell types in the RA synovium. 
Traditionally considered to have a landscaping function, they have emerged as key 
players in disease pathogenesis over recent years.  
 
Synovial fibroblasts are characterised by their spindle-shaped morphology, ability to 
adhere to plastic in vitro and the absence of macrophage and endothelial lineage 
markers (Wilkinson et al. 1992). Although no specific surface marker for synovial 
fibroblasts has been identified, antibodies against non-specific markers such as cluster 
of differentiation 90 (CD90), cluster of differentiation 44 (CD44), decay accelerating 
factor (DAF), vascular cell adhesion molecule 1 (VCAM1), uridine diphosphoglucose 
dehydrogenase (UDPGD) and prolyl-4-hydroxylase are commonly used for positive 
synovial fibroblast identification (Zimmermann et al. 2001).  
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In recent years, other putative synovial fibroblast markers have been described and the 
expression of some of these makers has been associated with synovial fibroblasts in 
different areas of the synovium, suggesting that these may represent distinct 
subpopulations with specific functions (Figure 1.5). Whilst VCAM1 marks lining layer 
fibroblasts, CD90 and the recently described endosialin (CD248) mark fibroblasts in the 
sublining layer. Prolyl-4-hydroxylase and podoplanin (GP38) are expressed by 
fibroblasts in both layers (Filer 2013). Cadherin-11 is expressed by synovial fibroblasts 
in the lining layer where it mediates homotypic fibroblast adhesion. Overexpression of 
cadherin-11 in cultured RA synovial fibroblasts increases their invasiveness in vitro an 
effect that is ameliorated by treatment of cells with antibodies against cadherin-11 
(Kiener et al. 2009). Cadherin-11 knockout mice display ameliorated joint inflammation 
when inflammatory arthritis is induced (Lee et al. 2007).  A brief description of these 
markers is given in Table 1.3.  
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Figure 1.5 Confocal microscopy image of the RA lining and sublining layers. For reference, 
the histological structure of the synovium is shown in (a), nuclear staining in (b) and 
macrophage staining in (c). GP38 (d) and prolyl-4-hydroxylase (e) are expressed by fibroblasts 
in lining and sublining layers. VCAM-1 is only expressed by synovial fibroblasts in the lining 
layer (f) whilst CD248 only stains sublining layer fibroblasts (g). CD90 is expressed by 
sublining layer synovial fibroblasts and endothelial cells (h). Reproduced with permission from 
Filer 2013.   
 
 
 
 
Table 1.3 Description of cell surface markers. 
Symbol Synonyms Name Description 
CD90 Thy-1 Cluster of differentiation 90 Stem cell marker 
CD44 HCAM Cluster of differentiation 44 Cell-cell interactions 
DAF CD55 Decay accelerating factor Complement system 
regulation 
VCAM1 CD106 Vascular cell adhesion protein 1 Cell adhesion molecule 
UDPGD  Uridine diphosphoglucose 
dehydrogenase 
Synthesis of hyaluronan 
CD248  Endosialin Cell-cell adhesion & host 
defence 
Gp38  Podoplanin Tumour invasion 
Cadherin-11  Cadherin-11 Homotypic cell adhe- 
sion 
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1.2.1 RA synovial fibroblasts as mediators of persistent 
inflammation 
 
The presence of an organised chronic inflammatory infiltrate in the diseased RA 
synovium has been discussed earlier. Our group and others have suggested that stromal 
cells may play a central role in the molecular basis for the persistence of this 
inflammatory response. Just as cancer stroma regulates growth, survival and metastasis 
of transformed clonal cells (Micke et al. 2004) it was proposed that synovial fibroblasts 
would play a similar role in the dynamics of the chronic inflammatory infiltrate 
observed in RA (Buckley et al. 2001).  
 
Normal inflammatory responses are tightly controlled, dynamic processes characterised 
by rapid response to the inflammatory/infectious trigger, highly specialised interactions 
between humoral, cellular and connective tissue elements and expansion of effector 
cells. In the resolution phase of inflammation, the expanded effector cells are cleared 
and normal tissue homeostasis is resumed. Thus, chronic inflammation can be viewed 
as a failure of this resolution phase resulting in inappropriate accumulation of cells 
within tissues (Figure 1.6).  
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Figure 1.6 Inflammatory response. Following an insult, an acute inflammatory response takes 
place. Once the pathogen has been cleared, normal tissue homeostasis is restored by an active 
process that involves clearance of effector cells. If this resolution phase becomes distorted, 
persistent chronic inflammation ensues.   
 
 
RA synovial fibroblasts promote leucocyte recruitment into the joints and are involved 
in the persistence of inflammatory infiltrates through their role in leucocyte survival and 
retention. High levels of neutrophil attracting chemokines including CXCL8 (IL-8), 
CXCL5 (ENA-78) and CXCL1 are expressed by stimulated cultured RA synovial 
fibroblasts (Koch et al. 1991;Koch et al. 1994;Koch et al. 1995). Their involvement in 
monocyte recruitment is supported by constitutive as well as induced expression of 
monocyte chemoattractant protein 1 (MCP1=CCL2) by cultured RA synovial 
fibroblasts (Villiger et al. 1992). Synovial fibroblasts also produce CCL4, CCL5 
(RANTES) and CXCL16, indicating a role in monocyte, lymphocyte and T cell 
recruitment (Hosaka et al. 1994;Nanki et al. 2005;Patel et al. 2001). In addition to 
leucocyte recruitment, synovial fibroblasts support leucocyte survival and accumulation 
in the joint by a variety of mechanisms including inhibition of T cell apoptosis and 
expression of pro-survival and pro-retentive signals. Seminal work in this area includes 
the observation that activated T cells from synovial fluid from RA patients show no 
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evidence of apoptosis despite having a phenotype suggestive of high susceptibility to 
this process (CD45RB
dull
, CD45RO
bright
, Bcl-2
low
, Bax
high
, Fas
high
) (Salmon et al. 1994). 
Interestingly, apoptosis could be induced in vitro indicating that the lack of T cell 
apoptosis observed ex vivo was not an intrinsic feature of these cells but rather may be 
mediated by the microenvironment these cells were in contact with. Indeed, T cells 
could be rescued from induced apoptosis in vitro by co-culture with RA synovial 
fibroblasts. Subsequently, type 1 interferons produced by RA synovial fibroblasts and 
macrophages were identified as the main factors mediating this survival (Pilling et al. 
1999). In vitro, B cell survival is mediated by the expression VCAM1 and CXCL12 
(SDF1) (Burger et al. 2001). RA synovial fibroblasts also express B cell activating 
factor (BAFF) and a proliferation inducing ligand (APRIL) constitutively and in 
response to toll-like receptor 3 (TLR3) stimulation which further supports their role in B 
cell function and survival (Bombardieri et al. 2011). RA synovial fibroblasts are also 
able to support NK cell and neutrophil survival in vitro (Chan et al. 2008;Filer et al. 
2006). Expression of the constitutive chemokine CXCL12 by RA synovial fibroblasts 
contributes to T cell retention in a process that involves up-regulation of CXCR4 
receptors in T cells (Buckley et al. 2000).  
 
 
1.2.2 RA synovial fibroblasts as mediators of cartilage and bone 
destruction 
 
The most compelling piece of evidence supporting a role for RA synovial fibroblasts in 
cartilage invasion and destruction comes from in vivo studies (Lefevre et al. 
2009;Muller-Ladner et al. 1996). In their landmark paper, Muller-Ladner and colleagues 
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cultured RA, OA and normal synovial fibroblasts and dermal fibroblasts and co-
implanted them with normal human cartilage under the kidney capsule of severe 
combined immunodeficient (SCID) mice. As these mice lacked a functional immune 
system, it provided an optimal environment for the study of interactions between human 
fibroblasts and human cartilage obviating the risk of transplant rejection. They 
demonstrated that RA but not OA, normal synovial or dermal fibroblasts attached to and 
invaded normal cartilage. This work is important for a number of reasons. First, it 
demonstrates that invasion of cartilage by synovial fibroblast is disease specific. Whilst 
all RA synovial fibroblast implants (n=5) showed intense invasion into cartilage, OA 
implants (n=5) only showed small isolated regions of superficial cartilage destruction 
and neither normal synovial (n=2) nor dermal (n=3) implants showed cartilage 
destruction. Second, it demonstrates that RA synovial fibroblasts have an intrinsically 
activated phenotype as they are able to exert their deleterious functions in the absence of 
cells and cytokines of the immune system. Third, it supports the notion that this 
phenotype is stable as synovial cells had been cultured for three to six passages prior to 
co-implantation with cartilage. Following on from this work, the authors have 
demonstrated that RA synovial fibroblasts are able to transmigrate and invade 
contralateral intact cell-free cartilage (Lefevre et al. 2009). This has been taken to 
suggest that synovial fibroblast, at least partly, mediate the well-known clinical feature 
of disease “spreading” to different joints.  
 
Synovial fibroblasts produce matrix degrading enzymes including cathepsins B, D and 
L that have been found at sites of invasion in the SCID mouse model (Muller-Ladner et 
al. 1996).  These cells also secrete MMPs including MMP1, 3, 9, 10 and 13 together 
with aggrecanases all of which have been associated with cartilage destruction (Lindy et 
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al. 1997;Okada et al. 1989;Tolboom et al. 2002). Production and secretion of some 
MMPs is regulated by pro-inflammatory stimuli and MAP kinase signalling pathways. 
MMP1 secretion is regulated by JNK following IL-1 stimulation of cultured synovial 
fibroblasts (Han et al. 1999). MMP1 and MMP13 secretion is stimulated by IL-1 and 
TNF and, in the case of MMP1, mediated by ERK (Pillinger et al. 2003). Additionally, 
down-regulation of the tumour suppressor gene phosphatase and tensin homolog 
(PTEN) has been demonstrated to be associated with cartilage invasion. This gene 
encodes a protein that has tyrosine phosphatase activity. Mutations in this gene have 
been associated with cancer invasion. The study of PTEN in RA synovial fibroblasts did 
not reveal gene mutations but demonstrated lack of PTEN expression in the lining layer 
of RA synovial tissue. This was in contrast with staining of normal synovial tissue that 
revealed uniform PTEN expression in the lining and sublining layers. The lack of PTEN 
expression at the sites of invasion (i.e. lining layer) together with the observation of 
negligible PTEN expression by cartilage invading RA synovial fibroblasts in the SCID 
mouse model led to the suggestion that PTEN down-regulation contributes to cartilage 
invasion (Pap et al. 2000a;Pap et al. 2000b).  
 
The pathogenic role of RA synovial fibroblasts extends to bone erosions where they are 
proposed to play a dual role in promoting bone destruction and preventing bone 
formation. Osteoclasts have long been implicated as effectors of bone resorption in RA 
(Fujikawa et al. 1996). Receptor activator of nuclear factor kappa-B ligand (RANKL), a 
TNF superfamily member, is the only known ligand for the RANK receptor and is a key 
effector of monocyte to osteoclast differentiation. RANKL mRNA is expressed in RA 
synovial tissue in the lining layer and at sites of bone destruction and levels of RANKL 
protein expressed by cultured RA synovial fibroblasts correlate with their ability to 
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induce monocyte to osteoclast differentiation, thus strongly supporting a central role in 
joint destruction in RA (Shigeyama et al. 2000). 
 Dickkopf related protein 1 (DKK1), an inhibitor of the wingless (Wnt) signalling 
pathway, directly impairs osteoblast differentiation and indirectly enhances bone 
destruction by increasing RANKL induced osteoclastogenesis (Goldring et al. 2007). 
Synovial tissue sections of patients with established RA display strong DKK1 
expression that localises to synovial fibroblasts (Diarra et al. 2007). Indeed, our group 
has shown that DKK1 expression by RA synovial fibroblasts is tightly regulated by 
glucocorticoid metabolism in vitro (Hardy et al. 2012). Taken together, these data 
support a role for Wnt signalling inhibition in RA bone destruction.  
 
1.2.3 RA synovial fibroblasts and synovial hyperplasia 
 
Synovial hyperplasia is associated with overexpansion of synovial fibroblast 
populations in the lining and sublining layers. Consequently, it has been proposed that 
RA synovial fibroblasts undergo increased proliferation. In favour of this hypothesis are 
up-regulation of genes that are associated with cell cycle and mitosis regulation such as 
ERK and early response gene 1 (EGR1) (Aicher et al. 1994;Schett et al. 2000) and the 
overexpression in RA joints of a number of growth factors that have been shown to 
drive synovial fibroblast proliferation in vitro (Melnyk et al. 1990). c-myc, a proto-
oncogene that has a very important role in cell proliferation, is expressed in RA 
synovium, especially in areas of cell proliferation and proximity to cartilage suggesting 
an important role for this gene in synovial fibroblast proliferation and activity (Qu et al. 
1994). Nevertheless, increased RA synovial fibroblast proliferation in RA synovial 
tissue could not be demonstrated (Nykanen et al. 1978), and RA and OA synovial 
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fibroblasts showed similar growth rates that were slower than that of control dermal 
fibroblasts in vitro (Jacobs et al. 1995). The latter finding is in keeping with our own 
experience of synovial fibroblast in culture (Chapter 3). Therefore, decreased synovial 
fibroblast apoptosis has been proposed as an alternative/complementary mechanism to 
explain fibroblast expansion and dysregulation of several apoptosis pathways has been 
demonstrated.  
 
Although RA synovial fibroblasts express Fas receptor and are able to undergo Fas 
mediated apoptosis in vitro, Fas-induced apoptosis is rarely observed in vivo (Nakajima 
et al. 1995). Subsequently, TNF induced expression of the anti-apoptotic protein FLIP 
by synovial fibroblasts has been observed to protect RA synovial fibroblasts from 
apoptosis. Additionally, down-regulation of FLIP resulted in increased Fas mediated 
apoptosis (Palao et al. 2004). The proto-oncogene B cell lymphoma 2 (Bcl-2) has anti-
apoptotic effects and is expressed in RA synovial tissues where it has been associated 
with increased cell survival (Perlman et al. 2000). Expression of mutants of the tumour 
suppressor protein p53 has been demonstrated in RA synovial tissue and cultured 
synovial fibroblasts that was absent in OA and dermal tissues. Expression was 
associated with fibroblast survival by preventing apoptosis (Firestein et al. 1996). 
Furthermore, inhibition of p53 expression in normal and RA synovial fibroblasts 
resulted in increased cell numbers and enhanced invasive capabilities when these cells 
were co-implanted with normal cartilage in the SCID mouse model (Pap et al. 2001). 
These findings suggested important contributions of p53 mutations to synovial 
hyperplasia and RA synovial fibroblast invasiveness. However, later studies by the 
same group demonstrated that p53 mutations were present only in a small number of 
synovial fibroblasts in the lining layer of the RA synovium (Yamanishi et al. 2002). 
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Subsequent analysis of invasive versus non-invasive synovial fibroblasts revealed no 
differences in the frequency of p53 mutations. It was thus concluded that it was the 
proximity to cartilage, as opposed to the presence of p53 mutations, what might 
determine fibroblast invasiveness (Yamanishi et al. 2005).  
 
The study of TNF induced apoptosis through TNF related apoptosis ligand (TRAIL) has 
produced somewhat conflicting results. TRAIL can bind to a number of receptors 
including the death receptors TRAIL-R1 and TRAIL-R2 and the decoy receptors 
TRAIL-R3 and TRAIL-R4. Some authors have described a lack of TRAIL surface 
receptors in RA synovial fibroblasts and resistance to apoptosis upon TRAIL 
stimulation (Perlman et al. 2003) whilst others have found expression of  TRAIL-R1 
and TRAIL-R2 with low apoptotic rates upon TRAIL stimulation (~30%) and a 
paradoxical increase in TRAIL mediated proliferation of surviving cells through ERK, 
p38 and PI3 kinase mediated mechanisms (Morel et al. 2005). Others have reported 
TRAIL induced apoptosis only when RA synovial fibroblasts are sensitised with the 
histone deacetylase inhibitor Trichostatin A (Jungel et al. 2006). In contrast, apoptosis 
rates of up to 80% upon TRAIL stimulation have been reported (Ichikawa et al. 2003). 
Differences in study design including cleavage of cell surface receptors during 
trypsinisation and differing reagents could explain the discrepancies between these 
studies.  
 
1.2.4 Signalling pathways  
 
The altered behaviour of synovial fibroblasts has been associated with changes in 
signalling pathways and expression of disease related genes.  
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Evidence for the activation of the transcription factor nuclear factor-B (NF-B) in 
synovial fibroblasts is supported by animal and human studies (Marok et al. 
1996;Miagkov et al. 1998). NF-B is activated by pro-inflammatory stimuli and its 
activation induces transcription of genes encoding adhesion molecules, pro-
inflammatory cytokines and MMPs (Vincenti et al. 1998). NF-B activation has also 
been implicated in inhibition of synovial fibroblast apoptosis (Miagkov et al. 1998).  
 
Members of the MAP kinase family have also been shown to be activated in RA 
synovial fibroblasts. Apart from the above mentioned role of JNK and ERK in MMP 
expression, JNK and p38 kinases are activated in cultured fibroblasts by pro-
inflammatory cytokines and have been implicated in the inflammatory process (Bradley 
et al. 2004;Sundarrajan et al. 2003). Expression of activated JNK, ERK and p38 MAP 
kinases in RA synovial tissue has also been demonstrated (Schett et al. 2000). More 
recently, increased JNK, ERK and p38 activity has been shown in synovial tissues of 
patients with treatment naïve early RA (<1 year symptom duration) compared to PsA 
and undifferentiated arthritis. In this study, JNK activation predicted the development of 
RA (de Launay et al. 2012). Of particular interest is the role of MAP kinases in 
activator protein 1 (AP-1) system regulation. AP-1 is a heterodimeric transcription 
factor composed of proteins from the c-fos, c-jun, ATF and JDP families. AP-1 
regulates gene expression in response to pro-inflammatory stimuli and has been 
implicated in up-regulation of MMPs expression by synovial fibroblasts. The study of 
adherent cell extracts from RA synovial tissues demonstrated high AP-1 binding 
activity compared to OA tissues. AP-1 binding correlated with c-fos and c-jun 
expression and disease activity (Asahara et al. 1997).  
 
1-36 
 
1.2.5 Known transcriptional profile 
 
RA synovial fibroblasts display an altered transcriptional profile characterised by up-
regulation of a number of oncogenes, proto-oncogenes and MMPs together with down-
regulation of tumour suppressor genes. Examples have already been described under 
some of the preceding headings and include c-myc, EGR1 and PTEN to name but a few.  
 
Recent advances in microarray expression profiling technology have been applied to the 
study of RA synovial tissues and synovial fibroblasts, significantly expanding 
knowledge in this field. Initial microarray profiling of RA synovial tissue showed 
significant tissue heterogeneity allowing identification of two major pathogenic 
subclasses. One of these classes was characterised by expression of genes involved in 
adaptive immune responses whilst the other featured expression of stromal cell genes 
(van der Pouw Kraan et al. 2003a;van der Pouw Kraan et al. 2003b). Subsequent 
analysis of gene expression profiles of 19 cultured RA synovial fibroblasts also 
identified two main subgroups that matched the tissue findings. Group I synovial 
fibroblasts showed overexpression of oncogenes and genes involved in complement 
activation whilst group II showed expression of collagen related genes and smooth 
muscle actin. These results provide evidence for heterogeneity within RA synovial 
cultures which may relate to differing clinical pictures and levels of inflammation 
(Kasperkovitz et al. 2005). Other authors have confirmed observations of heterogeneity 
within RA tissues and identified relationships between certain RA subsets and response 
to biologic therapy (Dennis et al. 2014). The transcriptional response of cultured RA 
and normal synovial fibroblasts to hypoxia has subsequently been examined proving 
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that hypoxia induces significant changes in transcriptional signatures in both groups 
(Del Rey et al. 2010).  
 
1.2.6 Unanswered questions: the study of early inflammatory 
arthritis and the comparison between early and established 
RA 
 
From the preceding discussion it is clear that the extensive study of the functional and 
transcriptional characteristics of synovial fibroblasts in patients with established RA 
strongly implicates them in disease persistence and joint damage. However, the 
potential involvement of synovial fibroblasts during the early phases of inflammatory 
arthritis has not been addressed.  
 
When designing this study we took a clinical perspective and focused on the chronology 
of inflammatory arthritis. A patient presenting with early inflammatory arthritis would 
have previously had non-inflamed healthy joints. At some point in their life and for 
incompletely understood reasons they developed an inflammatory arthritis. The natural 
history of this arthritis may follow a number of paths: (i) it may resolve spontaneously 
(ii) it may persist as RA or (iii) it may persist as another type of chronic arthritis (Figure 
1.7). 
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Figure 1.7 Chronology of inflammatory arthritis. A patient that presents with early 
inflammatory arthritis (IA) would have had disease free (healthy) joints for years before 
presentation. At a given point in time (time 0) IA develops which can result in a number of 
different clinical outcomes. IA may resolve spontaneously and not recur or it may persist in the 
form of chronic arthritis amongst which RA is included (other types of arthritis excluded from 
the diagram for simplicity).  
 
 
It would thus be very informative to compare and contrast synovial fibroblasts from 
individuals and patients at these different stages. Owing to the known contribution of 
synovial fibroblasts to failed resolution of inflammatory infiltrates in established RA, it 
is tempting to speculate that cells in early disease may play a crucial role in the early 
stages of inflammatory arthritis and may be involved in critical decisions regarding 
persistence versus resolution of inflammatory arthritis. At the same time, it is important 
to define the functional and transcriptional characteristics of fibroblasts from patients 
with early inflammatory arthritis that persists as RA. In particular, the study of cells 
from patients during the first three months of disease would help define their 
characteristics during the early window of opportunity.  
 
Early IANormal Persistent RA Longstanding RA
Resolving disease
Pre- IA
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IA
(0-3 months)
Persistent RA 
(>3 months) (years)
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Normal Resolving VeRA Early RA Established RA 
• Treatment naïve
• 3/12 symptoms
• Persistence as RA
• Treatment naïve
• 3/12-3 yr symptoms
• Persistence as RA 
• Multi treated
• Longstanding RA
• Treatment naïve
• 3/12 symptoms
• Spontaneous resolution
• Non-inflammatory 
joint symptoms
Furthermore, as the precise definition of early RA remains elusive, synovial fibroblasts 
from patients with early RA of more than three months duration will also be studied. 
The study of cells in individuals with non-inflammatory joint symptoms as well as 
patients with established RA completes the design. A schematic representation of the 
five distinct clinical outcome groups to be compared is shown in Figure 1.8. A 
comprehensive description of these patient groups is provided in Chapter 2. 
 
 
Figure 1.8 Clinical outcome groups. Schematic representation of the five clinical outcome 
groups studied in this work. The main differentiating characteristics between groups are shown. 
 
1.3 Hypothesis and aims 
 
 
The central hypothesis of this thesis is that synovial fibroblasts from patients in different 
clinical outcome groups will display different functional characteristics and 
transcriptomic profiles. 
 
The two subhypotheses of greatest interest that I will test in this thesis are:  
 
(a) That functional and transcriptomic differences exist between synovial fibroblasts in 
the Resolving and VeRA groups. This comparison is of particular interest as it may 
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result in identification of key differences between the resolution and persistence of early 
inflammatory arthritis. 
 
(b) That functional and transcriptomic differences exist between synovial fibroblasts in 
the VeRA and Established RA groups. With this comparison I aim to gain insights into 
the progression from early RA to established, destructive disease. 
 
To address these subhypotheses I plan to: 
 
(1) Undertake functional characterisation of synovial fibroblasts in the five clinical 
outcome groups with a special interest in the comparisons outlined in (a) and (b). 
Functional characteristics that will be determined include: migration, invasion and 
proliferation. 
 
(2) Perform transcriptomic analysis of synovial fibroblasts in the five clinical outcome 
groups, with a special interest in the comparisons outlined in (a) and (b). 
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2 Patients, materials and methods 
 
2.1 Patient cohorts, sample collection and selection 
 
2.1.1 Patient and outcome group selection 
 
 
To further our understanding of molecular mechanisms underpinning early 
inflammatory arthritis, I set out to compare the functional and transcriptional 
characteristics of synovial fibroblasts in five distinct clinical outcome groups. This 
approach assumes that any existing differences between samples within each outcome 
group will not outweigh those differences between samples in different outcome groups, 
hence allowing identification of clinically significant phenotypes. Thus, outcome groups 
needed to be composed of clinical cases that were as similar as possible with regards to 
clinical presentation and biochemical parameters. At the same time, these groups should 
be representative of the population studied so that results could be generalised back to 
that population. Appropriate patient sample selection was thus central for the success of 
this project.  
 
Samples from patients in one of the following five clinical outcome groups were used in 
this project: Normal, Resolving, very Early RA (VeRA), Early RA and Established RA.   
Normal controls were defined on the basis of non-inflammatory symptoms in patients 
undergoing exploratory knee arthroscopy. Resolving arthritis was diagnosed in patients 
whose arthritis resolved and did not recur at 18 months follow up. The diagnosis of RA 
was based on fulfilment of the 1987 ARA classification criteria (Arnett et al. 1988).  
Within the RA groups, further distinctions were made according to disease duration at 
the time of sample collection. The VeRA group included patients with treatment naïve 
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inflammatory arthritis of 3 months symptom duration at sample collection whilst the 
Early RA group comprised patients with treatment naïve inflammatory arthritis of 
symptom duration between 3 months and 3 years at the time of sample collection. A 
third RA group was composed by patients with longstanding disease of many years 
duration that were undergoing joint replacement and who had received multiple 
treatments (Established RA). This group corresponds to the same type of clinical 
samples upon which most of the synovial fibroblast literature is based. These five 
outcome groups and their main characteristics are represented in Figure 2.1. 
 
 
Figure 2.1 Clinical outcome groups. Schematic representation of the five clinical outcome 
groups studied in this work. The main differentiating characteristics between groups are shown.  
 
 
2.1.2 Patient cohorts  
 
Patient samples originated from one of three patient cohorts described below. At the 
time of initiation of experiments, all samples had already been collected and were 
available for use. All participants gave informed, written consent before taking part in 
the studies and all studies had appropriate ethical approval (LREC references 
07/H1203/57, 07Q2706/2 and 07/H1204/191). At the time of sample collection clinical, 
Normal Resolving VeRA Early RA Established RA 
• Treatment naïve
• 3/12 symptoms
• Persistence as RA
• Treatment naïve
• 3/12-3 yr symptoms
• Persistence as RA 
• Multi treated
• Longstanding RA
• Treatment naïve
• 3/12 symptoms
• Spontaneous resolution
• Non-inflammatory 
joint symptoms
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biochemical and radiological parameters were recorded including 66 tender and 68 
swollen joint counts, ESR and CRP values, RF and anti cyclic citrullinated peptide 
(CCP) antibody status, 38 joint ultrasound and hand and foot radiographs.   
 
2.1.2.1  Birmingham Early arthritis cohort (BEACON) 
 
 
Patients were recruited from the rapid access clinic for early arthritis at Sandwell and 
West Birmingham Hospitals NHS Trust, Birmingham, UK. Treatment naïve patients 
with early (≤3 months symptom duration) inflammatory arthritis were selected on the 
criteria of one or more swollen joints and inflammatory symptoms (inflammatory joint 
pain and/or early morning stiffness and/or joint related soft tissue swelling). Patients 
with arthralgia but no clinical evidence of joint swelling (assessed by physician) and 
those with evidence of previous inflammatory joint disease were excluded. Patients 
were followed up for 18 months at which point they were assigned to their final 
diagnostic group (Resolving, VeRA or non-RA persistent inflammatory arthritis). The 
diagnosis of VeRA was based on fulfilment of 1987 ARA criteria (Arnett et al. 1988).  
Resolving arthritis was defined as no clinically apparent joint swelling at final follow up 
with no NSAIDs or steroids having been used in the previous three months. Samples 
from patients with non-RA persistent inflammatory arthritis were not analysed in this 
work. Treatment naïve patients with RA (as defined by the 1987 ARA criteria) of more 
than 3 months but less than three years duration were also recruited to this cohort. The 
same inclusion and exclusion criteria as above were used. Samples originating from this 
patient group comprised the Early RA group in the work presented in this thesis.  
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Synovial samples from all patients in this cohort were taken by ultrasound guided 
synovial biopsy. 
 
2.1.2.2 Established RA cohort 
 
Patients with longstanding RA fulfilling the 1987 ARA classification criteria who were 
undergoing joint replacement under the care of Mr. Andrew Thomas at the Royal 
Orthopaedic Hospital NHS Trust were included in the study. Synovial samples were 
obtained intra-operatively. This was designated the Established RA group. 
  
2.1.2.3 Non-inflammatory cohort 
 
Patients undergoing knee arthroscopy for non-inflammatory symptoms in the absence of 
clinical and MRI evidence of joint inflammation under the care of Mr. Martyn Snow 
from the Royal Orthopaedic Hospital were recruited. Most patients were undergoing 
arthroscopy for meniscal tear repair. Patients with inflammatory arthritis and 
osteoarthritis were excluded. Synovial samples from macroscopically normal areas of 
synovium were obtained intra-operatively. Samples were stained with haematoxylin and 
eosin and observed by light microscopy. Synovial tissue sections were evaluated at low 
magnification (10X objective) and scored based on the presence and size of 
mononuclear cell infiltrates. The scoring system was at follows 0: no infiltrates, 1: one 
small non-focal infiltrate, 2: one diffuse inflammatory infiltrate, 3: small focal 
aggregates (both perivascular and interstitial) and 4: large focal aggregates with a radial 
count of at least 10 cells. Only samples with a score of 0 were used in experiments. For 
simplicity, I will refer to samples originating from this cohort as the Normal group. 
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The full demographic and clinical characteristics of patients from whom samples used 
in functional characterisation, proof of concept, SAGE and microarray experiments 
originated are shown in Tables 2.1 to 2.4.  
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Table 2.1 Clinical characteristics of patients from whom samples used in functional characterisation experiments originated. 
 
CCP: cyclic citrullinated peptide antibody; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: c reactive protein; SJC28: 28 swollen joint count, TJC28: 28 tender joint count; 
VAS: visual analogue score; DAS28 ESR: 28 joint count disease activity score (ESR); DMARD: disease modifying antirheumatic drug; M: male; F: female; wks: weeks; yrs: years; n: 
negative; p: positive; na: not available; N/A: not applicable; MTX: methotrexate, LEF: leflunomide; ADA: adalimumab; HCQ: hydroxychloroquine; ETA: etanercept. 
Clinical 
diagnosis 
Code Age Gender Ethnicity Smoking Symptom 
duration 
Site CCP RF SJC28 TJC28 VAS DAS28 
ESR 
ESR CRP Baseline 
erosions 
DMARD 
treatment 
Normal BX069 22 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX070 44 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX081 58 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX082 49 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX083 42 M Asian na na knee n n 0 0 N/A N/A na na no none 
Normal BX085 38 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX089 38 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Resolving BX004 33 M Caucasian Current 3 wks knee n n 2 1 78 3.6 9 6 no none 
Resolving BX008 64 M Caucasian Ex 6 wks knee n n 2 5 46 4.5 24 15 no none 
Resolving BX010 40 F Caucasian Never 4 wks knee n n 7 7 36 3.9 5 0 no none 
Resolving BX024 32 M Caucasian Current 7 wks knee n n 1 1 35 2.9 10 10 no none 
Resolving BX038 45 F Caucasian Current 1 wks knee n n 5 5 83 4.0 4 0 no none 
Resolving BX064 35 M Asian Current 1 wks knee n n 3 1 6 1.6 2 9 no none 
Resolving BX071 41 F Caucasian Current 4 wks ankle n n 2 0 10 1.7 5 9 no none 
VeRA BX003 50 M Caucasian Current 4 wks knee p p 11 13 28 5.7 31 26 no none 
VeRA BX005 70 F Caucasian Ex 5 wks knee n n 5 4 83 5.9 68 26 no none 
VeRA BX013 45 F Black Current 10 wks knee n n 3 3 12 3.9 24 12 na none 
VeRA BX015 48 F Caucasian Ex  2 wks knee n n 6 8 16 3.5 4 102 na none 
VeRA BX027 44 F Caucasian Current 5 wks ankle n n 2 3 32 3.8 18 10 no none 
VeRA BX042 55 M Caucasian Never 4 wks knee p n 4 0 9 3.5 58 45 yes none 
VeRA BX063 74 F Caucasian Ex 9 wks knee p n 3 3 62 4.4 20 32 no none 
Early RA BX016 46 M Caucasian Current 150 wks knee p p 16 13 75 6.6 38 7 na none 
Early RA BX066 67 M Caucasian Current 38 wks knee p p 1 1 74 4.2 29 48 na none 
Early RA BX075 22 F Caucasian Never 52 wks knee n n 6 6 89 6.4 81 79 na none 
Early RA BX086 52 F Caucasian Current 38 wks ankle P P 8 20 69 6.5 26 52 na none 
Early RA BX093 65 M Caucasian Ex 156 wks knee p p 12 3 28 5.3 72 81 yes none 
Established RA RA06SY 60 M Caucasian na 30 yrs knee na P 11 12 50 6.4 54 75 yes SSZ 
Established RA RA15SY 37 M Caucasian na 22 yrs knee na N 3 1 90 5.0 46 50 yes MTX,LEF 
Established RA RA18SY 47 M Caucasian na 23 yrs Knee na p 1 1 10 3.8 57 45 Yes ETA 
Established RA RA19SY 63 F Caucasian na 20 yrs knee na p 4 7 45 4.1 8 8 yes ETA 
Established RA RA20SY 73 M Caucasian na 20 yrs knee na p 7 9 25 4.8 18 na na LEF 
Established RA RA22SY 70 F Caucasian na 30 yrs Knee Na p 7 8 0 4.4 20 na yes ADA 
Established RA RA23SY 58 F Indian na 11 yrs knee na p 17 13 100 6.7 23 na na MTX 
Established RA RA28SY 42 F Caucasian na 20 yrs knee na n 1 0 na na na na yes Gold 
Established RA RA29SY 67 F Caucasian na 7 yrs knee P p 13 9 80 6.6 57 66 yes MTX,ETA 
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Table 2.2 Clinical characteristics of patients from whom samples used in proof of concept experiments originated.  
 
CCP: cyclic citrullinated peptide antibody; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: c reactive protein; SJC28: 28 swollen joint count, TJC28: 28 tender joint count; 
VAS: visual analogue score; DAS28 ESR: 28 joint count disease activity score (ESR); DMARD: disease modifying antirheumatic drug; M: male; F: female; wks: weeks; yrs: years; n: 
negative; p: positive; na: not available; N/A: not applicable; MTX: methotrexate, LEF: leflunomide; ADA: adalimumab; HCQ: hydroxychloroquine; ETA: etanercept. 
 
Clinical 
diagnosis 
Code Age Gender Ethnicity Smoking Symptom 
duration 
Site CCP RF SJC28 TJC28 VAS DAS28 
ESR 
ESR CRP Baseline 
erosions 
DMARD 
treatment 
Resolving BX004 33 M Caucasian Current 3 wks knee n n 2 1 78 3.6 9 6 no none 
Resolving BX008 64 M Caucasian Ex 6 wks knee n n 2 5 46 4.5 24 15 no none 
Resolving BX010 40 F Caucasian Never 4 wks knee n n 7 7 36 3.9 5 0 no none 
Resolving BX024 32 M Caucasian Current 7 wks knee n n 1 1 35 2.9 10 10 no none 
Resolving BX028 74 M Caucasian Current 5 wks knee n n 23 0 55 4.8 45 13 na none 
Resolving BX030 72 M Caucasian Never 8 wks knee n n 4 7 34 3.6 5 0 na none 
Resolving BX038 45 F Caucasian Current 1 wks knee n n 5 5 83 4.0 4 0 no none 
Resolving BX048 35 M Caucasian na 2 wks knee n N 1 1 33 4.0 51 7 no none 
Resolving BX064 35 M Asian Current 1 wks knee n n 3 1 6 1.6 2 9 no none 
Resolving BX071 41 F Caucasian Current 4 wks ankle n n 2 0 10 1.7 5 9 no none 
Resolving BX076 28 M Black Current  6 wks knee n n 1 2 99 4.5 18 8 na none 
VeRA BX003 50 M Caucasian Current 4 wks knee p p 11 13 28 5.7 31 26 no none 
VeRA BX005 70 F Caucasian Ex 5 wks knee n n 5 4 83 5.9 68 26 no none 
VeRA BX011 49 F Caucasian Never 2 wks knee n n 8 9 35 4.7 12 8 na none 
VeRA BX013 45 F Black Current 10 wks knee n n 3 3 12 3.9 24 12 na none 
VeRA BX027 44 F Caucasian Current 5 wks ankle n n 2 3 32 3.8 18 10 no none 
VeRA BX031 43 M Caucasian Ex 9 wks knee n n 4 19 76 6.9 58 0 na none 
VeRA BX040 56 M Caucasian Current 10 wks mcp n p 21 14 50 5.2 5 0 no none 
VeRA BX042 55 M Caucasian Never 4 wks knee p n 4 0 9 3.5 58 45 yes none 
VeRA BX049 48 F Caucasian na 3 wks ankle p p 3 6 29 3.9 10 0 no none 
VeRA BX059 62 F Caucasian Current 16 wks ankle p p 2 4 16 5.32 40 5 yes none 
VeRA BX063 74 F Caucasian Ex 9 wks knee p n 3 3 62 4.4 20 32 no none 
VeRA BX084 49 M Caucasian Never 6 wks mcp p p 12 17 87 6.8 25 18 no none 
Early RA BX016 46 M Caucasian Current 150 wks knee p p 16 13 75 6.6 38 7 na none 
Early RA BX017 61 F Caucasian Ex 30  wks knee n n 6 15 45 4.9 8 9 na none 
Early RA BX021 57 M Caucasian Ex 14 wks knee p p 14 21 50 7.1 56 16 na none 
Early RA BX022 58 M Caucasian Current 16  wks knee p p 7 7 33 4.1 7 0 yes none 
Early RA BX032 46 F Caucasian Current 30 wks ankle p n 4 10 47 5.2 24 32 na none 
Early RA BX055 64 M Caucasian Current  26  wks knee n n 16 14 30 5.4 13 17 na none 
Early RA BX066 67 M Caucasian Current 38 wks knee p p 1 1 74 4.2 29 48 na none 
Early RA BX075 22 F Caucasian Never 52 wks knee n n 6 6 89 6.4 81 79 na none 
Early RA BX077 72 F Caucasian Never 38 wks knee n n 16 21 70 7.5 53 43 na none 
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Table 2.3 Clinical characteristics of patients from whom samples used in SAGE experiments originated. 
Clinical 
diagnosis 
Code Age Gender Ethnicity Smoking Symptom 
duration 
Site CCP RF SJC28 TJC28 VAS DAS28 
ESR 
ESR CRP Baseline 
erosions 
DMARD 
treatment 
Normal BX069 22 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX070 44 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX081 58 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX082 49 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX083 42 M Asian na na knee n n 0 0 N/A N/A na na no none 
Normal BX088 34 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX089 38 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX095 46 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Resolving BX004 33 M Caucasian Current 3 wks knee n n 2 1 78 3.6 9 6 no none 
Resolving BX008 64 M Caucasian Ex 6 wks knee n n 2 5 46 4.5 24 15 no none 
Resolving BX010 40 F Caucasian Never 4 wks knee n n 7 7 36 3.9 5 0 no none 
Resolving BX033 81 F Caucasian Never 7 wks ankle n n 11 16 50 6.7 60 52 no none 
Resolving BX038 45 F Caucasian Current 1 wks knee n n 5 5 83 4.0 4 0 no none 
Resolving BX048 35 M Caucasian na 2 wks knee n N 1 1 33 4.0 51 7 no none 
Resolving BX064 35 M Asian Current 1 wks knee n n 3 1 6 1.6 2 9 no none 
Resolving BX076 28 M Black Current  6 wks knee n n 1 2 99 4.5 18 8 na none 
VeRA BX003 50 M Caucasian Current 4 wks knee p p 11 13 28 5.7 31 26 no none 
VeRA BX005 70 F Caucasian Ex 5 wks knee n n 5 4 83 5.9 68 26 no none 
VeRA BX013 45 F Black Current 10 wks knee n n 3 3 12 3.9 24 12 na none 
VeRA BX014 63 F Caucasian Never 4 wks knee n n 5 1 50 5.1 104 9 na none 
VeRA BX015 48 F Caucasian Ex  2 wks knee n n 6 8 16 3.5 4 102 na none 
VeRA BX027 44 F Caucasian Current 5 wks ankle n n 2 3 32 3.8 18 10 no none 
VeRA BX031 43 M Caucasian Ex 9 wks knee n n 4 19 76 6.9 58 0 na none 
VeRA BX042 55 M Caucasian Never 4 wks knee p n 4 0 9 3.5 58 45 yes none 
VeRA BX063 74 F Caucasian Ex 9 wks knee p n 3 3 62 4.4 20 32 no none 
Early RA BX016 46 M Caucasian Current 150 wks knee p p 16 13 75 6.6 38 7 na none 
Early RA BX018 69 F Caucasian Never 52 wks knee n n 7 7 52 4.6 11 0 yes none 
Early RA BX022 58 M Caucasian Current 16  wks knee p p 7 7 33 4.1 7 0 yes none 
Early RA BX055 64 M Caucasian Current  26  wks knee n n 16 14 30 5.4 13 17 na none 
Early RA BX066 67 M Caucasian Current 38 wks knee p p 1 1 74 4.2 29 48 na none 
Early RA BX075 22 F Caucasian Never 52 wks knee n n 6 6 89 6.4 81 79 na none 
Early RA BX077 72 F Caucasian Never 38 wks knee n n 16 21 70 7.5 53 43 na none 
Early RA BX093 65 M Caucasian Ex 156 wks knee p p 12 3 28 5.3 72 81 yes none 
Established RA RA06SY 60 M Caucasian na 30 yrs knee na P 11 12 50 6.4 54 75 yes SSZ 
Established RA RA15SY 37 M Caucasian na 22 yrs knee na N 3 1 90 5.0 46 50 yes MTX,LEF 
Established RA RA20SY 73 M Caucasian na 20 yrs knee na p 7 9 25 4.8 18 na na LEF 
Established RA RA23SY 58 F Indian na 11 yrs knee na p 17 13 100 6.7 23 na na MTX 
Established RA RA25SY 53 F Caucasian na 30 yrs knee na n 8 11 na na na na yes HCQ 
Established RA RA28SY 42 F Caucasian na 20 yrs knee na n 1 0 na na na na yes Gold 
Established RA RA29SY 67 F Caucasian na 7 yrs knee p p 13 9 80 6.6 57 66 yes MTX,ETA 
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CCP: cyclic citrullinated peptide antibody; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: c reactive protein; SJC28: 28 swollen joint count, TJC28: 28 tender joint count; 
VAS: visual analogue score; DAS28 ESR: 28 joint count disease activity score (ESR); DMARD: disease modifying antirheumatic drug; M: male; F: female; wks: weeks; yrs: years; n: 
negative; p: positive; na: not available; N/A: not applicable; MTX: methotrexate, LEF: leflunomide; ADA: adalimumab; HCQ: hydroxychloroquine; ETA: etanercept. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Established RA RA37SY 55 F Caucasian na 23 yrs knee p n 8 5 85 5.9 45 57 yes none 
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Table 2.4 Clinical characteristics of patients from whom samples used in microarray experiments originated. 
 
Clinical 
diagnosis 
Code Age Gender Ethnicity Smoking Symptom 
duration 
Site CCP RF SJC28 TJC28 VAS DAS28 
ESR 
ESR CRP Baseline 
erosions 
DMARD 
treatment 
Normal BX070 44 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX081 58 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX082 49 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX083 42 M Asian na na knee n n 0 0 N/A N/A na na no none 
Normal BX085 38 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX088 34 M Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX089 38 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Normal BX095 46 F Caucasian na na knee n n 0 0 N/A N/A na na no none 
Resolving BX004 33 M Caucasian Current 3 wks knee n n 2 1 78 3.6 9 6 no none 
Resolving BX008 64 M Caucasian Ex 6 wks knee n n 2 5 46 4.5 24 15 no none 
Resolving BX010 40 F Caucasian Never 4 wks knee n n 7 7 36 3.9 5 0 no none 
Resolving BX024 32 M Caucasian Current 7 wks knee n n 1 1 35 2.9 10 10 na none 
Resolving BX028 74 M Caucasian Current 5 wks knee n n 23 0 55 4.8 45 13 na none 
Resolving BX030 72 M Caucasian Never 8 wks knee n n 4 7 34 3.6 5 0 na none 
Resolving BX033 81 F Caucasian Never 7 wks ankle n n 11 16 50 6.7 60 52 no none 
Resolving BX038 45 F Caucasian Current 1 wks knee n n 5 5 83 4.0 4 0 no none 
Resolving BX048 35 M Caucasian na 2 wks knee n n 1 1 33 4.0 51 7 no none 
Resolving BX054 55 M Caucasian Never 6 wks ankle n n 5 4 91 3.5 2 6 no none 
Resolving BX064 35 M Asian Current 1 wks knee n n 3 1 6 1.6 2 9 no none 
Resolving BX065 37 F Asian Never 7 wks knee n n 2 8 10 3.3 7 0 no none 
Resolving BX071 41 F Caucasian Current 4 wks ankle n n 2 0 10 1.7 5 9 no none 
Resolving BX072 32 M Caucasian Current 10 wks knee n n 1 3 60 3.7 15 0 no none 
Resolving BX076 28 M Black Current 6 wks knee n n 1 2 99 4.5 18 8 no none 
Resolving BX087 27 M Asian Current 4 wks ankle n n 2 2 20 3.8 27 28 no none 
VeRA BX003 50 M Caucasian Current 4 wks knee p p 11 13 28 5.7 31 26 no none 
VeRA BX005 70 F Caucasian Ex 5 wks knee n n 5 4 83 6.0 68 26 no none 
VeRA BX011 49 F Caucasian Never 2 wks knee n n 8 9 35 4.7 12 8 na none 
VeRA BX013 45 F Black Current 10 wks knee n n 3 3 12 3.9 24 12 na none 
VeRA BX015 48 F Caucasian Ex 2 wks knee n n 6 8 16 3.5 4 102 na none 
VeRA BX020 59 M Caucasian na 6 wks knee n n 20 4 50 4.9 14 22 na none 
VeRA BX031 43 M Caucasian Ex 9 wks knee n n 4 19 76 6.9 58 0 na none 
VeRA BX040 56 M Caucasian Current 10 wks mcp n p 21 14 50 5.2 5 0 no none 
VeRA BX042 55 M Caucasian Never 4 wks knee p n 4 0 9 3.5 58 45 yes none 
VeRA BX045 42 F Asian Never 2 wks ankle p p 18 28 100 8.3 54 40 no none 
VeRA BX049 48 F Caucasian na 3 wks ankle p p 3 6 29 3.9 10 0 no none 
VeRA BX063 74 F Caucasian Ex 9 wks knee p n 3 3 62 4.4 20 32 no none 
VeRA BX084 49 M Caucasian Never 6 wks mcp p p 12 17 87 6.8 25 18 no none 
VeRA BX092 48 M Caucasian Ex 4 wks mcp p p 9 8 50 6.0 63 38 no none 
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Established RA RA06SY 60 M Caucasian na 30 yrs knee na p 11 12 50 6.4 54 75 yes SSZ 
Established RA RA15SY 37 M Caucasian na 22 yrs knee na n 3 1 50 5.0 46 50 yes MTX,LEF 
Established RA RA20SY 73 M Caucasian na 20 yrs knee na p 7 9 90 4.8 18 na na LEF 
Established RA RA23SY 58 F Indian na 11 yrs knee na  p 17 13 25 6.7 23 na na MTX 
Established RA RA25SY 53 F Caucasian na 30 yrs knee na  n 8 11 100 na na na yes  HCQ 
Established RA RA28SY 42 F Caucasian na 20 yrs knee na p 1 0 na na na na yes Gold 
Established RA RA29SY 67 F Caucasian na 7 yrs knee p p 13 9 na 6.6 57 66 yes MTX,ETA 
Established RA RA37SY 55 F Caucasian na 23 yrs knee p n 8 5 85 5.9 45 57 yes  none 
CCP: cyclic citrullinated peptide antibody; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: c reactive protein; SJC28: 28 swollen joint count, TJC28: 28 tender joint count; 
VAS: visual analogue score; DAS28 ESR: 28 joint count disease activity score (ESR); DMARD: disease modifying antirheumatic drug; M: male; F: female; wks: weeks; yrs: years; n: 
negative; p: positive; na: not available; N/A: not applicable; MTX: methotrexate, LEF: leflunomide; ADA: adalimumab; HCQ: hydroxychloroquine; ETA: etanercept. 
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2.1.3 Sample collection, coding and validation of phenotype 
 
Synovial samples collected at the time of biopsy or surgery were transferred to universal 
containers and kept on ice until processing (typically within 3 hours of collection). Primary 
synovial fibroblast cell lines were established from these samples as specified in the materials 
and methods section. Each cell line received a unique code comprising a prefix (BX, 
abbreviation for biopsy) and a number (sequentially given according to when the sample was 
collected). This code was used for all lines irrespective of their clinical outcome. The only 
exception to this rule was the code given to Established RA samples obtained from joint 
replacement surgery where the code comprised the prefix RA (for rheumatoid arthritis) a 
number (sequentially given according to when sample was collected) and suffix SY 
(synovial).  
 
The phenotype of all fibroblasts used in this work was validated to confirm that the cells 
being cultured were indeed synovial fibroblasts and not other adherent cells present in 
synovial tissue such as macrophages or endothelial cells. Two criteria were used for 
validation. Synovial fibroblasts were identified by light microscopy on the basis of their 
spindle-shaped morphology (Image 2-1). Additionally, cell surface markers were assessed by 
flow cytometry. Cultured synovial fibroblasts did not express markers of macrophage (CD68) 
or endothelial (CD31) lineage but expressed the synovial fibroblast marker CD90 
(Zimmermann et al. 2001).  
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Image 2-1 Morphology of synovial fibroblasts. Light microscopy images showing spindle-shaped 
morphology. x10 and x40 images shown. 
 
 
2.1.4 Testing of long term cultures for infection  
 
Whenever cells are cultured, a risk of infection exists. Every effort is made to minimise this 
risk by handling cultures under sterile conditions in laminar flow cabinets and by adding 
antibiotics to culture medium. Nevertheless, the risk still exists and is particularly high if cells 
remain in culture for prolonged time periods. Infections may not only affect the viability of 
cultured cells, but if gone unnoticed, they may affect experimental results. Mycoplasma 
species are common contaminants of cell cultures. They are resistant to commonly used 
antibiotics and small and difficult to detect by microscopy, hence specific testing for these 
agents is required. Thus, regular mycoplasma testing was carried out on cell cultures used in 
this work. Testing was performed using a commercially available mycoplasma PCR kit as 
described in the methods section. None of the cultures used in this thesis tested positive. A 
typical image of a negative test is shown in Image 2-2.  
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Image 2-2 Mycoplasma testing. Agarose gel image of an experiment in which seven cell lines were 
tested. A positive control (lane 1) and seven samples (lanes 2 to 8) are shown. The size of the 
mycoplasma DNA fragment amplified (if present) should be 270bp (represented by red arrow in the 
ladder and the white band seen in lane 1). None of the samples tested positive.  
 
 
2.2 Cell culture  
 
2.2.1 Tissue culture reagents 
 
Reagents were purchased from Sigma-Aldrich unless otherwise specified. Reagents used to 
make culture medium included: RPMI 1640 (R0883), 100mM Sodium ortho-pyruvate (SOP) 
(S8636), L-glutamine-penicillin-streptomycin solution (GPS) (G1146) containing 200mM L-
glutamine, 10,000 units of penicillin and 10mg/ml streptomycin, non-essential amino acids 
(NEAA) (M7145) and fetal calf serum (FCS) (F7524). Other reagents used in cell culture, 
recovery, maintenance and storage of cell lines included: 10x stock solution of trypsin-EDTA 
(PAA, L11-003) and dimethyl sulfoxide (DMSO) (D2879). Phosphate buffered saline (PBS) 
was made by dissolving PBS tablets (Oxoid BR0014) in distilled water at a ratio of 1 tablet 
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per 100ml of water. PBS was autoclaved prior to use. Where required for sterilization, 
solutions were filtered through 0.22m filters (Millipore SLGP033RS). Syringes were 
purchased from BD Plastipak. Tissue culture plastics, tubes and flasks were purchased from 
Sarstedt. Cryovials were purchased from Grainer bio-one. For mycoplasma testing the EZ-
PCR mycoplasma test kit (Geneflow 20-700-20) was used. Amplification was performed in 
the BioRad T100 thermal cycler. Materials used for gel electrophoresis included: SYBR safe 
DNA staining (Life Technologies S33102), UltraPure agarose (Life Technologies 16500500), 
UltraPure 10x TBE buffer (Life Technologies 15581-044) and HyperLadder 1kb (Bioline 
BIO-33053). 
 
2.2.2 Medium 
 
Synovial fibroblasts were cultured with complete fibroblast medium composed of: RPMI 
1640, 10% FCS, 1% NEEA, 1% SOP and 1% GPS.  
 
2.2.3 Primary cell cultures 
 
Primary synovial fibroblast cultures were established at the time of biopsy or surgery. Each 
clinical sample originating from a patient gave rise to a cell line. Tissue samples were cut into 
small sections of approximately 1mm
3
 using a sterile scalpel. Sections were suspended in 6ml 
of complete fibroblast medium and transferred into T25 flasks. Lines were incubated at 37°C 
in 5%CO2 and left undisturbed for a week. Subsequently medium was changed weekly.  
 
 
2-56 
 
2.2.4 Cell line maintenance in culture 
 
Synovial fibroblasts were fed once weekly and maintained in culture until confluence. At 
feeding, 66% of the culture medium (referred to as conditioned medium) was discarded and 
replaced with fresh complete medium. Once cells reached confluence they were trypsinised. 
 
2.2.5 Fibroblast trypsinisation (splitting) 
 
Conditioned medium was removed and cells washed with PBS once. The cell monolayer was 
treated with trypsin (diluted 1:5 in PBS) for 5 minutes at 37°C in 5%CO2. Cells were further 
detached mechanically by gently tapping the edge of the flask. They were then observed by 
microscopy to ensure complete detachment from plastic and collected in fresh complete 
fibroblast medium and centrifuged at 300g for 6 minutes. The supernatants were discarded 
and the cell pellets re-suspended in fresh medium and seeded into new flasks. Cells were 
reseeded into new flasks at a lower density applying a 1:3 ratio. Every time a culture was split 
the passage number increased by 1.  
 
2.2.6 Freezing, storage and recovery of samples 
 
At any given time during culture, if cells were not required for immediate use, they were 
stored in liquid nitrogen. Cells were trypsinised as above and washed with fresh medium and   
centrifuged at 300g for 6 minutes. They were subsequently re-suspended in freezing medium 
(composed of 90%FCS and 10% DMSO) and transferred to cryovials. The cryovials were 
placed in a freezing tray to allow gradual temperature reduction and placed in -80°C for at 
least 3 hours. Cells were subsequently transferred to the liquid nitrogen facility. Usually cells 
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were stored at a 1:3 ratio, that is, cells obtained from one confluent T75 flask would be split 
into three cryovials. Some lines were stored at “high density” meaning that all cells from a 
confluent T75 flask would be frozen into one cryovial. Freezing at high density allowed faster 
recovery of cell lines.  
 
When required for culture, cells were retrieved from liquid nitrogen, quickly thawed in a 
water bath at 37°C and re-suspended in fresh complete medium. Cells were centrifuged at 
300g for 6 minutes, supernatants were discarded and cells re-suspended in fresh medium and 
transferred to a T75 culture flask and incubated at 37°C in 5%CO2. Cells were left 
undisturbed for a week before feeding. 
 
2.2.7 Passage number of cells used  
 
One of the advantages of cell culture is that it enables researchers to increase cell numbers. 
However, it has been shown that the gene expression patterns of cultured synovial fibroblasts 
change with increased cell passaging (Neumann et al. 2010). In consequence, all the work 
presented in this thesis was undertaken at low passage numbers. Cells used in functional 
assays were between passage 4 and 6 inclusive. For SAGE experiments cells were cultured to 
passage 5 and stored in liquid nitrogen in preparation for the experiments. Cells used in 
microarray experiments were at passage 3. 
 
2.2.8 Testing of long term cultures for infection 
 
To ensure that cultures were free from infection, mycoplasma testing of cultured lines was 
performed regularly. The EZ-PCR mycoplasma test kit (Geneflow 20-700-20) was used to 
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analyse the supernatants of cultured lines as per manufacturer’s instructions. Briefly, PCR 
amplification was carried out by preparing a reaction mix containing 17.5µl of nuclease free 
water, 5µl of reaction mix and 2.5µl of the test line’s supernatant. Test tubes were placed in 
the thermal cycler and run with the following parameters: one cycle at 94°C for 30 seconds, 
35 cycles at 94°C for 30 seconds followed by 60°C for 120 seconds followed by 72°C for 60 
seconds, one cycle at 94°C for 30 seconds, one cycle at 60°C for 120 seconds and a final 
cycle at 72°C for 5 minutes. Amplified products were subsequently analysed using gel 
electrophoresis. A 2% agarose gel was made by mixing 3g of agarose, 150ml of TBE buffer 
and 135ml of double distilled water. 6µl of SYBR safe DNA gel stain were added to the 
agarose mixture and poured into the cassette and covered with 1xTBE buffer. 5µl of PCR 
products and ladder were loaded to corresponding ports in the gel and electrophoresis run at 
120v for one hour.  
 
 
2.3 Methods: Chapter 3 
2.3.1 Experimental set up and workflow 
 
A minimum of 5 lines per clinical outcome group were analysed in each functional assay with 
the exception of the proliferation assay where 3 lines per outcome group were assessed. To 
maximise the use of cell lines and maintain passage numbers consistent within assays, a 
workflow system was established whereby cells were sequentially analysed in different assays 
following the same order (Figure 2.2). If after analysis in all assays, cells were still viable they 
were stored at high density for any potential future experiments.   
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Figure 2.2 Functional assays workflow. For each patient line, one passage 4 (P4) T75 flask was 
cultured. Cells were first used in the invasion assay (at passage 4). Next cells were analysed in 
parallel cell exclusion zone assay and scratch tests at passage 5. Subsequently, cell proliferation was 
assessed (at passage 6). If remaining cells were viable, they were frozen at high density for future use 
if needed. Between each experiment remaining cells were returned to the incubator to allow growth 
prior to the next experiment.  
 
 
2.3.2 Materials used in functional experiments 
 
For both the cell exclusion zone and scratch test experiments, 6-well plates (BD Falcon 
353046) were used throughout. Tissue culture inserts (Ibidi 80209) were used for creation of 
cell monolayers. Tumour necrosis alpha (TNF) (R&D systems 210-TA-010), transforming 
growth factor beta (TGF) (Peprotech 100-21) and platelet derived growth factor (PDGF) 
(Peprotech 100-14B) were used for stimulation and chemoattraction. Growth factor reduced 
matrigel coated invasion chambers (BD 354483) and 24-well flat bottom with low 
evaporation lid plates (BD Falcon 353504) were used in the invasion assay. Staining of 
invading cells was performed with Diff-Quick (Reagena 102164) after fixation with methanol 
(VWR 20847.307). DIPX mounting medium (Thermo Scientific Raymond Lamb 12658646) 
was used to fix membranes to microscope slides. The medium used in the invasion assay was 
Dulbecco’s modified eagle medium (DMEM) (Sigma-Aldrich D6546) supplemented with 1% 
Freeze at high density
Cell exclusion zone assay
P4
Invasion assay
(P4)
(P5)
Scratch test
(P5)
Proliferation assay
(P6)
(P7)
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GPS and 0.5% bovine serum albumin (BSA) (Sigma-Aldrich A2153). The click-iT EdU flow 
cytometry assay kit (Invitrogen C10418) was used to assess cell proliferation.  
 
2.3.3 Methods used in functional experiments 
 
2.3.3.1 Scratch test  
 
Cell monolayers were seeded on 6-well plates. Grids were taped to the base of the plates to 
serve as reference point. Cells were seeded at a density of 8x10
4 
per well
 
and cultured at 37°C 
in 5% CO2 for a week. At day 8 a single scratch wound was created with a sterile 20μL pipet 
tip. Images of the denuded areas were taken with a digital Olympus inverted phase contrast 
microscope at baseline (Time 0) and 18 hours later (Time 1). The grids at the back of the plate 
were used to divide the wound into 3 longitudinal frames that were recorded. The cell-free 
area was measured using Image J software analysis. The average of three frames was taken. 
The percentage of area covered in 18 hours was calculated using Microsoft Excel with the 
formula:  
 
𝐴0 − 𝐴1
𝐴0
 100 
 
where A0 denotes area  at Time 0 and A1 area at Time 1. A schematic representation of this 
assay is presented in Figure 2.3. 
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Figure 2.3 Schematic representation of the scratch test assay. After culturing cell monolayers for 
seven days a scratch was created with a sterile pipet tip. Images of the cell denuded area were taken 
at baseline and 18 hours later. Image J software was used to measure the area and the percentage of 
area covered was calculated using Microsoft Excel. Image of pipet tip reproduced from 
http://www.usascientific.com/200ul-tipone-yellow-stacks.aspx.  
 
 
2.3.3.2 Cell exclusion zone assay  
 
Cell monolayers were created in 6-well plates by aliquoting cell suspensions either side of a 
tissue culture insert. On day one, a grid was secured to the base of the plate. Culture inserts 
were positioned into the centre of each well and 70µl of cells at a density of 3x10
5
cells/ml 
were aliquoted to each port of the insert and incubated at 37°C in 5% CO2 for 24 hours to 
allow adherence. At day 2, inserts were removed and images were taken at Time 0 (baseline) 
and Time 1 (18 hours later) as specified for the scratch test. A schematic representation of this 
assay is shown in Figure 2.4. For the stimulated assay, the experiments were repeated 
stimulating cells with TNF (10ng/ml) or TGF (1ng/ml) for 48 hours. In these experiments, 
cells were seeded into culture inserts as specified and allowed to adhere for 24 hours. 
Conditioned medium was removed and replaced with fresh complete medium containing 
stimulants. 30 hours later inserts were removed and images taken at Time 0 and 18 hours 
later. Cells were stimulated for a total of 48 hours. Image analysis and area calculation was 
done as specified for the scratch test.  
 
 
Record at Time 0
Image J 
analysis
Culture for 7 days Scratch monolayer Record 18 hours later
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 Figure 2.4 Schematic representation of the cell exclusion zone assay. Cells were aliquoted either 
side of a culture insert and cultured for 24 hours. After removal of the insert a gap had formed 
between both cell monolayers. The cell free gap was imaged at Time 0 and 18 hours later. Data were 
subsequently analysed with image J and Microsoft Excel. Image of tissue culture inserts reproduced  
from http://ibidi.com/xtproducts/en/ibidi-Labware/Open-Slides-Dishes:-Removable-hambers/Culture-
Insert-Family. 
 
 
2.3.3.3 Assessment of cell proliferation  
 
The Click It EdU cell proliferation kit (Invitrogen C10418) was used according to 
manufacturer’s instructions. As the aim of these experiments was to assess cell proliferation 
under the same conditions to which cells were subjected in the cell exclusion zone assay, the 
same experimental set up was used. Hence, culture inserts were positioned in the centre of 
wells in 6-well plates and 70µl of cells at a density of 3x10
5
cells/ml were aliquoted to each 
port of the insert. Cells were incubated at 37°C in 5% CO2 for 24 hours to allow adherence. 
At day 2, culture inserts were removed and 2µM 5-ethynyl-2-deoxyuridine (EdU) added to 
the culture medium. Cells were incubated at 37°C in 5% CO2 for 18 hours and subsequently 
prepared for proliferation analysis. Cells were washed with PBS, trypsinised and re-
suspended in complete fibroblast medium. They were washed with 1% BSA in PBS and fixed 
with 100µl of 4% paraformaldehyde for 15 minutes. Cells were centrifuged at 500g for 5 
minutes and re-suspended in 100µl of saponin wash reagent for a further 15 minutes. After 
another centrifugation step, they were incubated for 30 minutes with pacific blue, washed 
with saponin, filtered and analysed by flow cytometry (Dako Cyan ADP High Performance 
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(Dako, Ely, UK)). Data were analysed using SUMMIT software (Dako). Cell proliferation 
was expressed as percentage of stained cells.  
 
 
2.3.3.4 Invasion assay 
 
In vitro cell invasion was assessed with a transwell assay. Matrigel coated invasion chambers 
were used for this purpose (Figure 2.5). They consist of a 24-well companion plate with cell 
culture inserts that contain an 8µm pore size membrane coated with a thin layer of matrigel 
matrix. Chambers were used as per manufacturer’s instructions. Briefly, 5x104 cells 
suspended in 500µl of serum free 1% GPS, 0.5% BSA DMEM were seeded into each culture 
insert. The lower chambers were filled with 1%GPS, 0.5%BSA DMEM with 50ng/ml of 
PDGF, the latter acting as a chemoattractant. Chambers were incubated at 37°C in 5% CO2 
for 72 hours. Non-invading cells were scraped from the inside of the inserts using a cotton 
bud. Invading cells on the under surface of the membrane were fixed with methanol and 
stained with Diff Quick (Reagena 102164). Membranes were removed with a scalpel blade 
and fixed on microscope slides using DIPX. Cells were observed and counted using a non-
inverted light microscope (Zeiss Axiostar plus). Eight ocular fields per membrane were 
counted.  
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 Figure 2.5 Schematic representation of the invasion assay. Cells were seeded into invasion 
chambers. Cells were cultured for 72 hours to allow invading cells to digest matrigel and migrate to 
the bottom of the transwell. After fixing and staining cells attached to the bottom of the membrane, 
membranes were cut and fixed onto microscope slides that were visualised by light microscopy. 
 
 
2.4 Methods: Chapter 4  
2.4.1 Candidate gene expression analysis with microfluidic cards 
 
384-well custom made microfluidic cards were used to perform 48 gene expression assays 
(Life technologies, TaqMan gene expression arrays). The design of these cards is such that the 
specific gene probes and primers are pre-loaded and stable in the card so that gene expression 
analysis is quick and reliable. The list of gene targets selected for these cards is given in 
Appendix Table 9.1 together with a brief explanation of the relevance of the assessment of 
each target.  
 
2.4.1.1 Sample preparation and RNA isolation for candidate gene analysis  
 
All samples used in these experiments were cultured and treated under identical conditions. 
When cell lines achieved confluence at passage 3, two T75 flasks were taken. Conditioned 
medium was discarded and cells were washed with PBS once. Subsequently one flask was 
treated with 6ml of complete fibroblast medium supplemented with TNF (10ng/ml) whilst 
the other was treated with 6ml of un-supplemented complete fibroblast medium. Cells were 
Fix & stain invading cells at 
the bottom of the transwell
Cut transwell
membrane
Seed cells
into transwell
Fix to microscope slide  & 
count invasion
Culture for 72 
hours
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cultured at 37°C in 5% CO2 for 24 hours. Following the incubation time, supernatants were 
collected and stored. Cells monolayers were washed with PBS and trypsinised as described in 
section 2.2.5. A series of cell aliquots was created for several purposes. Amongst these, an 
aliquot was created with 1x10
4
 cells that were suspended in 350µl of RLT lysis buffer 
(containing guanidine isothiocyanate to immediately inactivate RNases) and stored -80°C for 
subsequent RNA isolation and analysis using microfluidic cards.  
 
Cells that had been stored in 350µl of RLT buffer at -80°C were thawed and RNA extracted 
using the RNeasy kit (Qiagen 74104) according to manufacturer’s instructions. Briefly, cells 
were thawed and 350µl of 70% ethanol added. Samples were applied to the columns and 
centrifuged at 13000g for 5 minutes. Samples were washed with two wash buffers (700µl of 
RW1 and 500µl of RPE) and RNA eluted in 30µl of RNase free water. Eluted RNA was 
further treated with DNA free (Ambion 1906) according to manufacturer’s protocol to ensure 
that only pure RNA was obtained. 1µl of DNAse and 3.5µl of DNAse buffer were added to 
the eluted mRNA sample and incubated at 37°C for 30 minutes. 5µl of DNase inactivation 
reagent was added and incubated with the sample at room temperature for 2 minutes. After 
centrifugation (13000g for 1 minute) the supernatant (RNA) was collected and used in the 
microfluidic experiments.  
 
2.4.1.2 Reverse transcription and real time PCR in microfluidic cards 
 
The Quantitec Probe RT PCR kit (Qiagen 204443) was used for reverse transcription and real 
time PCR according to manufacturer’s instructions. The reaction mix for each sample 
contained: 15μL of RNA, 1μL of reverse transcriptase, 50μL of RT PCR master mix and 
34μL of RNA free water. Each 95μL reaction was loaded into the corresponding port of the 
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card. Cards were centrifuged at 300g for 1 minute, sealed and run in the Applied Biosytems 
7900 HT fast real time PCR cycler. The programme used consisted of 1 cycle at 50°C for 30 
minutes, 1 cycle at  94.5°C for 15 seconds, 40 cycles at 96°C for 30 seconds and 59.7°C for 1 
minute. 
     
2.4.1.3 Gene expression analysis 
 
 
Three housekeeping genes were assayed in the cards: glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), 2 microglobulin and 18S ribosomal RNA (18S). The variation in 
expression levels of each housekeeper was calculated using the coefficient of variation 
method with the formula:  
𝐼𝑄𝑅
𝑀
 100 
 
where IQR represents interquartile range and M median.  This coefficient of variation was 
lowest for GAPDH (5.5%) followed by 18S (6.3%) and 2 microglobulin (6.4%). 
Consequently, gene expression was normalised to GAPDH.  
 
Gene expression was quantified using the 2-delta Ct method (2
-dCt
). First, the threshold cycle 
(Ct) value was set for each gene. Then the delta Ct (dCt) value was calculated by subtracting 
the GAPDH Ct value from the Ct value of the gene of interest. Subsequently a 2
-dCt
 value was 
calculated. Gene expression data were plotted as scattered dot plots. Differential gene 
expression between groups was calculated using Kruskal Wallis and Dunn’s post-test analysis 
on median values. 
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2.4.2 DKK1 ELISA 
 
DKK1 protein levels were measured using the DKK1 ELISA duo set (R&D DY1906) 
according to manufacturer’s instructions. A brief description is given here. All incubations 
were done at room temperature and all samples were done in triplicate. A Nunc maxisorp 96- 
well plate was coated with 100µl/well of capture antibody and incubated overnight. The plate 
was washed and coated with 300µl/well of reagent diluent and incubated for 1 hour. 
Standards were diluted in reagent diluent and samples in complete fibroblast medium at a 25 
fold dilution. 100µl/well of standard or sample were added to the plate and incubated for 2 
hours. The plate was washed and 100µl/well of detection antibody were added and incubated 
for 2 hours. After another washing step, 100µl/well of streptavidin/HRP were added and the 
plate incubated for 20 minutes away from the light. After a wash, 100µl/well of substrate 
solution were added and incubated for 30 minutes away from the light. 50µl/well of sulphuric 
acid was added and the plate read at 450 nm.  
 
Results were calculated as follows. A standard curve was created by plotting the mean 
absorbance of each standard against their concentration and drawing a best fit curve. Using 
regression analysis, the formula for the best fit curve was calculated and applied to each 
unknown sample. Results were multiplied by the dilution factor used (x25). Data were 
expressed as median and interquartile range.  
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2.4.3 Osteoblast differentiation and bone nodule formation 
experiments 
 
2.4.3.1 Collection of supernatants from cultured synovial fibroblasts  
 
 
One Resolving (BX010) and one VeRA line (BX040) were cultured in T75 flasks until 
confluence. Conditioned medium was discarded and cells washed with PBS. Conditioned 
medium was replaced with 6ml of fresh fibroblast medium and cells cultured for 48 hours. 
Subsequently, conditioned medium was collected and stored in 200µl aliquots at -80°C for 
use in osteoblast differentiation experiments.  
 
2.4.3.2 Osteoblast differentiation experiments 
 
 
Commercially available osteoblast precursors (Promocell C-12720) were used in these 
experiments. 2x10
4
cells/well were seeded on 6-well plates with 2ml/well of mineralisation 
medium (Promocell C-27020) to induce osteoblast differentiation. Cells were kept in culture 
for 21 days before assessing mineralised bone nodule formation as a surrogate marker of 
osteoblast differentiation. The experimental set up was as follows: positive and negative 
osteoblast precursor differentiation controls were created by culturing osteoblasts precursors 
with mineralisation and growth medium (Promocell Germany, C-27001) respectively. The 
expected effect was for the mineralisation but not the growth medium to induce osteoblast 
differentiation and mineralised bone nodule formation. A DKK1 positive control was created 
by adding 50ng/ml of recombinant DKK1 (R&D systems 5439-DK-010) to osteoblast 
mineralisation medium. Test samples were treated with osteoblast mineralisation medium 
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containing 25µl of conditioned fibroblast medium from either Resolving or VeRA cell lines 
as appropriate. Following culture for 21 days, cells were stained with alizarin red. Briefly, cell 
medium was discarded and cells washed with PBS twice. Cells were fixed with 10% buffered 
formalin (Sigma HT50-1-1) for 15 minutes and stained with 0.5% alizarin red (Sigma A5533) 
in water (pH4.2) for 15 minutes. Staining was followed by a washing step (using tap water) 
repeated 5 times. Direct observation under light microscopy (Leica inverted light microscope) 
was performed. The number of nodules formed in a 20x field was counted in triplicate and the 
mean of these triplicates taken. To confirm osteoblast differentiation, osteocalcin mRNA 
expression was measured by RT PCR using a Taqman osteocalcin gene assay (Life 
Technologies Hs-01587814_g1). 
 
2.4.4 Synovial fibroblasts-HUVEC co-cultures in flow capture assays 
 
 
Synovial fibroblasts were cultured onto inverted 6-well 0.4µm transwell filter inserts at a 
density of 5x10
5
 for 24 hours. Human umbilical vein endothelial cells (HUVEC) were seeded 
into the inner surface of the inserts at a concentration that would produce confluent 
monolayers in 24 hours.  Cells were co-cultured for 48 hours in complete fibroblast medium 
prior to treatment with 100U/ml of TNF  and 10ng/ml IFN for a further 24 hours. Inserts 
were secured to a plate in a flow chamber system and lymphocytes (at a concentration of 
2x10
6
/ml in PBS containing 0.15% bovine serum albumin and 5mM glucose) perfused for 4 
minutes over HUVEC. The perfusion flow rate used was 0.099ml/min which is equivalent to 
a wall shear rate of 140s
−1
 and wall shear stress of 0.1Pa. After 2 minutes of washout, video 
clips were taken of a number of fields in the central area of the flow chamber. Analysis of the 
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images determined whether lymphocytes were rolling adherent, firmly adherent or 
transmigrating. Lymphocytes were isolated from venous blood from healthy donors.  
 
For analysis of DKK1 levels in co-culture supernatants the R&D systems VersaMAP 
immunoassay was used as per manufacturer’s instructions. Supernatants from cell co-cultures 
were diluted 1:3 in complete fibroblast medium. All incubations were done at room 
temperature on a plate shaker. Briefly, plates were washed with 100µl/well of wash buffer. 
50µl/well of microparticle cocktail were added and incubated for 2 hours followed by 3 
washing steps. 50µl/well of standard or sample were added and incubated for 2 hours. After 
another 3 washes, 50µl/well of antibody cocktail were added and the plate incubated for 1 
hour. After 3 additional washes, 50µl/well of streptavidin-PE were added and incubated for 
30 minutes. After three washes, 100µl/well of wash buffer were added and analysed in the 
Luminex100 instrument using the following settings: 50 events/bead, minimum events: 0, 
flow rate: 60µl/min, sample size: 50µl, doublet discriminator gates at 7500 and 15,500. 
 
 
2.5 Methods: Chapter 5  
2.5.1 Description of SAGE method 
 
Total RNA is isolated using Trizol. Subsequently mRNA is isolated using Oligo (dT) 
magnetic beads. These beads contain oligodT sequences that bind to the polyA tail of mRNAs 
enabling mRNA isolation by magnetic separation. At the same time, the oligodT sequence is 
used as primer for reverse transcription and thus cDNA conversion also takes place on the 
beads. Next the cDNA transcripts are digested using the enzyme Nla III. This endonuclease 
cleaves transcripts at sites where the sequence GTAC is present. As this sequence occurs at 
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approximately every 250bp this is the approximate size of the resulting fragments. Following 
this, barcode adaptor A is ligated to the samples. This adaptor contains a unique barcode that 
enables identification of all transcripts originating from a given sample. It also contains a 
truncated internal adaptor sequence and an EcoP151 restriction enzyme recognition site. 
When EcoIP15I is added, it binds to the recognition sequence and cleaves cDNA 25-27bp 
downstream from the adaptor hence generating a 27bp sequence. The next step is the ligation 
of adaptor B that contains the primers for emulsion PCR. Samples are deposited on glass 
slides where amplification by emulsion PCR takes place. Next, sequencing by ligation is 
performed. This type of sequencing is based on the ability of DNA ligases to bind 
oligonucleotides of complementary DNA strands. Fluorescently labelled oligonucleotides are 
used to probe the unknown DNA sequences. Hybridisation of unknown nucleotides to 
complementary fluorescently labelled nucleotides results in fluorescence emission. Different 
bases can be identified as different colours in the emitted spectrum.  
 
The newly obtained nucleotide sequences (called reads) are then mapped to a reference 
nucleotide sequence database (Reference Sequence database, RefSeq) using specific software.  
This process allows identification of the gene of origin of the tag. By quantifying the number 
of reads available for a given transcript, expression levels can be determined and compared 
between samples (Matsumura et al. 2005). Following sequencing experiments, independent 
confirmation of results is usually performed by validating target gene expression with 
quantitative methods such as real time quantitative PCR (Rajeevan et al. 2001). 
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2.5.2 Reagents and materials used in Chapter 5 
 
 
Preparation of samples for SAGE analysis was done with the following reagents. Total RNA 
purification was performed with Trizol (Ambion 15596-018). Polyadenylated RNA was 
purified by magnetic selection using µMacs mRNA isolation kits (Miltenyi Biotech 130-075-
201). Library generation was performed with the SOLiD SAGE kit with barcoding adaptor 
module (Life Technologies 4452811) and the SOLiD RNA barcode kit, module 1-16 (Life 
Technologies 4427046). Emulsion PCR was performed using the SOLiD EZ bead amplifier 
E20 accessories kit (Life Technologies 4453077) and the SOLiD ePCR kit (Life Technologies 
4400834). Bead enrichment was performed with the SOLiD XD bead enrichment kit (Life 
Technologies 4453663) and components from SOLiD buffer kit (Life Technologies 
4387918). Bead pre-deposition modification was done with SOLiD pre deposition kit (Life 
Technologies 4472967) and slide deposition with SOLiD XD slide and deposition kit v2 (Life 
Technologies 4456997) and components from SOLiD buffer kit (Life Technologies 
4387918). Sequencing was performed using the SOLiD ToP fragment barcoded sequencing 
kit, MM35/5 (Life Technologies 4452696) and components from the SOLiD ToP instrument 
buffer kit (Life Technologies 4452688). Other reagents used in these experiments included:  
DEPC-treated and sterile filtered water for molecular biology (Sigma Life Science 95284), 
formaldehyde solution 37% (Sigma-Aldrich F15587), protease inhibitor cocktail tablets 
(Roche complete mini tablets 11836153001) and ethanol absolute (VWR International 
20821.330). RNA quantity and quality were assessed with the Qubit dsDNA HS assay kit 
(Life Technologies Q32851) and the Quant-iT RNA assay kit (Life Technologies Q32852). 
PCR tube strips of 8 (Fisher Scientific 14230210) were used for real time PCR.   
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2.5.3 Cell culture and storage for SAGE experiments  
 
 
Culture and processing of cell lines for SAGE experiments was performed in a standardised 
fashion. Eight different cell lines were cultured from each outcome group (making a total of 
40 cell lines). Cells were grown under the same conditions until a minimum of 2x10
6
 cells per 
line were obtained. To obtain the RNA quantity required for the SAGE experiments 1x10
6
 
cells per line per experiment was required. Hence, an arbitrary minimum cell number of 2x10
6
 
cells per line was established in order to have spare samples in case any of them were lost or 
damaged during subsequent sample preparation and sequencing. All cell lines were at passage 
5. Once cultured cells were ready to be processed, lines were harvested and counted. Volumes 
were adjusted to 1x10
6
 per ml, washed with 1 ml of PBS once and stored as cell pellets at -
80°C.  
 
2.5.4 RNA isolation, polyA RNA purification and library generation 
 
Following the SOLiD 4 SAGE protocol, total RNA extraction was performed using Trizol 
followed by polyadenylated (polyA) RNA purification with µMacs columns as per 
manufacturer’s instructions. Briefly, samples were thawed and homogenised with 1ml of 
Trizol. They were incubated at room temperature for 5 minutes and 0.2ml of chloroform 
added followed by vigorous shaking, incubation at room temperature for 3 minutes and 
centrifugation at 12,000g for 15 minutes at 4°C to obtain phase separation. The aqueous phase 
was collected and RNA isolation performed by adding 0.5ml of 100% isopropanol, followed 
by incubation at room temperature for 10 minutes and centrifugation at 12,000g for 10 
minutes at 4°C. Supernatants were discarded and pellets washed in 1ml of 75% ethanol, 
vortexed and centrifuged at 7500g for 5 minutes at 4°C. Pellets were air dried and re-
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suspended in 20µl of RNase free water. After incubation at 60°C for 15 minutes the RNA was 
used for polyA RNA purification by magnetic selection using µMacs columns. RNA was 
denaturated by heating at 70°C for 5 minutes. µMacs columns were prepared by rinsing with 
100µl of lysis buffer and 50µl of magnetic oligodT beads were added to the samples.  
Samples were applied to the column where magnetically labelled polyA RNA was isolated by 
placing the columns in the MAC separator. Contaminants were removed through six washing 
steps and cDNA was synthesised. 43.5µl of first strand reaction mixture was added to the 
beads and incubated at 42°C for 3 minutes. 1.5µl of reverse transcriptase was added and 
incubated at 42°C for 2 hours with mild mixing every 15 minutes. This first cDNA strand was 
chilled in ice for 2 minutes and the second strand synthetised by adding the second strand 
reaction mixture and incubating at 16°C for 3 hours. The reaction was stopped by adding 
0.5M EDTA and incubated with wash buffer for 15 minutes. Next Nla III and barcode adaptor 
A ligation was undertaken followed by EcoP15l digestion and barcode adaptor B ligation. A 
PCR was then performed and run to determine the optimal PCR cycles for emulsion PCR.  
 
2.5.5 Assessment of RNA quantity and quality 
 
RNA quantitation was performed with the Qubit fluorometer and the Quant-iT RNA Assay 
kit. Firstly, calibration was undertaken using standards 1 and 2 (included in the kit). Each 
sample was then quantitated sequentially in triplicate, and the mean of triplicates recorded. 
For quality assessment, Agilent RNA 6000 Pico chips were set up and primed as per 
manufacturer’s instructions. RNA samples were diluted to achieve concentrations between 
1ng/µl and 5ng/µl. Samples were heat denaturated and 1µl of each sample was loaded, 
together with the provided RNA 6000 Pico ladder into the chip. The chip was vortexed at 
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2400 rpm, and run on the Agilent 2100 bioanalyser. RNA quality was assessed by means of 
the RNA integrity number (RIN); a RIN value between 8.0 and 10.0 was considered optimal. 
 
2.5.6 Emulsion PCR 
 
 
SAGE libraries were pooled into groups of 8, using barcodes 1-8 for two of the pooled sample 
sets, and barcodes 9-16 for the other two. Pooled library sets were quantitated with the Qubit 
dsDNA HS assay kit, and diluted to a concentration of 43pg/µl. Emulsion PCR was 
performed in each pooled library as per manufacturer’s protocol with a library concentration 
of 0.5pM. Following emulsion PCR, libraries were enriched for P2-containing beads, and the 
3’ ends modified with a terminal transferase reaction. Enriched beads were quantitated with 
the Nanodrop ND-100 spectrophotometer and compared to a previously prepared standard 
curve. 
 
 
2.5.7 Sequencing 
 
Beads were deposited on chambers as per Applied Biosystems SOLiD 4 system instrument’s 
operation guide. 132x10
6
 beads from each pooled library were deposited on SOLiD slides 
using a 4-well deposition chamber. Beads were left to adhere at 37°C for 1 hour. Following 
deposition, non-adhered beads were pipetted off, and the chamber flushed with deposition 
buffer. Slides were washed with slide storage buffer, and fitted into a clean flow cell in the 
SOLiD 4 analyser, which was then filled with prepared 1x instrument buffer. All other 
sequencing buffers were prepared and fitted as per protocol and a 35bp forward/5bp barcode 
SAGE sequencing run initiated.  
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2.5.8 Analysis of SAGE data 
 
Tags were mapped to the Reference Sequence (Ref Seq) database using the Bioscope analysis 
pipeline. Normalisation and gene expression profiling was performed using SOLiD SAGE 
analysis software. Statistical analysis of SAGE expression data was done using edgeR run 
under Bioconductor. 
 
2.5.9 SAGE target validation methods 
 
 
Materials used for RNA isolation and reverse transcription included: µMacs mRNA isolation 
kits (Miltenyi Biotech 130-075-201), isopropanol (AnalaR 102246L), sodium acetate (Sigma 
71196) and glycogen (Invitrogen 10814-010). Reverse transcription was performed using 
SSII reverse transcriptase (Invitrogen 100004925), 5x FS Buffer (Invitrogen y0232), Rnease 
out (Invitrogen 100000840), 0.1M DTT (Invitrogen y00147), 10mM dNTP (Invitrogen 
10297-018) and oligodT beads (Invitrogen 58862). Reagents used in real time quantitative 
PCR included: primer pairs designed by myself and manufactured by Eurofins Operon, 
absolute qPCR SYBR green ROX mix (Thermo Scientific AB-1163/A) and water for 
molecular biology (Sigma-Aldrich 95284). 
 
2.5.10 RNA isolation, precipitation and reverse transcription for real 
time PCR 
 
RNA isolation was performed using the µMacs mRNA isolation kit as per manufacturer’s 
instructions. Samples were thawed and 500µl of lysis buffer added. Samples were thoroughly 
mixed to ensure complete dissolution and centrifuged at 13,000g at 4°C for 3 minutes. 
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Magnetic columns were placed in the MACS separator and equilibrated by rinsing with 100µl 
of lysis buffer. 50µl of magnetic oligodT beads were added to the samples and mixed. 
Samples were applied to the columns where magnetically labelled polyA RNA was isolated. 
Contaminants were removed with two washing steps with 200µl of lysis buffer and a further 
four washes with 100µl of wash buffer. 70µl of elution buffer were added and eluted RNA 
was collected in tubes and kept in ice. Subsequently, RNA was precipitated using 
isopropanol. 70µl of isopropanol, 7µl of sodium acetate and 1µl of glycogen were added to 
each sample and incubated at -80°C for at least 15 minutes. Samples were centrifuged at 
13,000g at 4°C for 15 minutes. Supernatants were discarded and samples washed with 150µl 
of 70% alcohol and centrifuged again. Supernatants were discarded and samples left to air 
dry. Once dried, pellets were re-suspended in 10µl of RNase free water and 1µl of oligodT. 
39µl of reverse transcriptase reaction mix containing 17µl RNase free water, 10µl 5xFS 
buffer, 5µl of DTT, 5µl of dNTP, 1µl of RNase out and 1µl of reverse transcriptase were 
added. Samples were run in the BioRad T100 thermal cycler with the following parameters: 
25°C for 5 minutes, 42°C for 30 minutes and 85°C for 5 minutes. 
 
2.5.11 Real time PCR primer design  
 
 
For each gene to be validated, a specific primer pair was designed using the primer design 
tool in the National centre for biotechnology information (NCBI) website. The unique NM 
number for each gene was entered in the search area and a series of primer pairs were 
obtained. In order to select a good quality primer pair a number of parameters were used 
including: PCR product size of 80-250bp, primer pairs separated by at least one intron and a 
GC content of approximately 55% in each strand (Chuang et al. 2013).  
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Primer pairs selected according to these parameters were tested on Amplifx software 
(available for free download at: http://download.cnet.com/AmplifX/3000-2054_4-
53766.html) before ordering. First, the cDNA sequence of the target gene was introduced in 
the sequence tab. Next, the sequences of the forward and reverse primers were entered in the 
primer list and a “virtual” PCR was run. This allowed identification of the size and position of 
the product and provided information on the quality of the primers with regards to GC 
content, stability and self-annealing. A screenshot of a representative example is shown in 
Figure 2.6. Primer pair sequences were ordered from Eurofins Operon. The primer pair 
sequences of primer pairs used in this work are shown in Appendix Table 9.2.  
 
 
 Figure 2.6 Screenshot showing the use of Amplifx to test primer pair quality. Primer pair sequences 
can be seen in the screenshot in the primer list tab and the PCR product produced from these primer 
pair can be seen at the bottom of the image in blue. On the right hand side quality control parameters 
are displayed including GC content, self-annealing and primer stability. All these parameters are 
satisfactory for the primer pair shown.  
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2.5.12 Real time PCR  
 
Real time PCR experiments were performed in 384-well plates using the Light Cycler 480 
PCR system (Roche). All samples were done in triplicate. Two reaction mixes were created: a 
sample and a primer mix. Sample mixes contained 0.1µl of cDNA, 2.9l of water and 5l of 
SYBR green ROX mix (which contained all components required for PCR with the exception 
of the primer templates) per sample per test. Primer mixes contained 0.1µl of forward and 
0.1µl of reverse primer and 1.8l of water per test. 8µl of sample mix and 2µl of primer mix 
were pipetted into each well to make a total 10µl per test. As a hot-start DNA polymerase was 
used, an activation step (95°C for 15 minutes) was included in the PCR reaction protocol.  
The PCR reaction was carried out with the following parameters: one cycle at 95°C for 15 
minutes (hot-start), 40 amplification cycles at 95°C for 15 seconds followed by 60°C for 1 
minute and a final cycle for the melting curves that consisted of 95°C for 15 seconds, 60°C 
for 1 minute and 95°C for 15 seconds. Gene expression was normalised to GAPDH using the 
2-delta Ct method (2
-dCt
) as previously described. Differential gene expression between 
groups was calculated using Kruskal Wallis and Dunn’s post-test analysis on median values. 
 
Quality control of primer pairs was performed by analysing primer pair products on a gel. For 
each primer pair, a PCR using human genomic DNA (Promega G3041) and Go Taq master 
mix (Promega M7122) was performed. For each primer pair a reaction was made in a PCR 
tube that contained 4µl of cDNA (diluted 1:10), 5µl of Go Taq master mix, 0.5µl of forward 
and 0.5µl of reverse primers. Samples were run on the BioRad T100 thermal cycler using the 
following cycling parameters: 95°C for 3 minutes, 95°C for 30 seconds, 60°C for 30 seconds, 
72°C for 30 seconds, 40 cycles at 95°C for 30 seconds, 72°C for 5 minutes and 4°C thereafter. 
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Once complete, PCR products were run on a 2% agarose gel and run at 120v for one hour as 
specified in section 2.2.8.  
 
2.5.13 TRAIL-R4 Flow cytometry 
 
Expression of TRAIL-R4 protein was determined by flow cytometry. Reagents used in these 
experiments included: PE conjugated anti human TRAIL-R4 (R&D FAB633P), IgG isotype 
control (R&D, IC002P) and cell dissociation buffer (Gibco 13151014). Three Resolving 
(BX004, BX033, BX038) and three VeRA (BX011, BX013, BX063) lines were used in these 
experiments. The TRAIL-R4 expressing hepatic epithelial cell line (AKN-1) was used as 
positive control.  
 
To dissociate cells from their flasks without cleaving cell surface receptors, 12ml of cell 
dissociation buffer were added to T75 flasks and cells incubated at room temperature on a 
plate shaker for 35 minutes. Detached cells were re-suspended in 8ml of medium and 
centrifuged at 500g for 5 minutes. Cell volumes were adjusted to 6x10
4
/ml. 700µl of cell 
suspension were transferred to a tube and washed 3 times with 0.5% BSA PBS. 100µl of 
sample were transferred to each well of a flexiplate and incubated with the corresponding 
TRAIL-R4 or IgG isotype at a concentration of 1:50 and incubated in the dark at 4°C for 45 
minutes. Cells were washed with PBS and re-suspended in 100µl of PBS and transferred to 
flow cytometry tubes containing 400µl of PBS for analysis. Cells were filtered prior to 
analysis in the Dako Cyan ADP High Performance flow cytometer (Dako, Ely, UK). Data 
were analysed using SUMMIT version 4.3 software (Dako).   
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2.6 Methods: Chapter 6  
 
2.6.1 Reagents and materials used in Chapter 6 
 
 
For RNA isolation and preparation of samples for microarray analysis the following reagents 
were used: RNeasy Mini kit (Qiagen 74106), QIAshredder (Qiagen 79656), RNA clean and 
concentrator 25 (Cambridge Biosciences R1018) and 1.5ml LoBind tubes (Eppendorf 
022431021). RNA quantity and quality were assessed with the Nanodrop 2000 
spectrophotometer (Thermo Scientific). For labelling and creation of cRNA the Low Input 
Quick Amp Labeling Kit, Two-Color (Agilent Technologies 5190-2306) was used. Samples 
were hybridised onto Sure Print G3 gene expression 8x60k v2 microarrays (Agilent 
Technologies 039494) and scanned in the Agilent G2505C scanner. Reverse transcription of 
RNA for real time PCR was performed with the iScript cDNA Synthesis Kit (BioRad 170-
8891).   
 
2.6.2 Cell culture, treatment and storage for microarray experiments 
 
 
All samples were cultured and treated under identical conditions. When cell lines achieved 
confluence at passage 3, two T75 flasks were taken. Conditioned medium was discarded and 
cells were washed with PBS once. Subsequently one flask was treated with 6ml of complete 
fibroblast medium supplemented with TNF (10ng/ml) whilst the other was treated with 6ml 
of un-supplemented complete fibroblast medium. Cells were cultured at 37°C in 5% CO2 for 
24 hours. Supernatants were stored and cells washed with PBS and trypsinised as directed. 
0.5x10
6
 cells were stored as pellets at -80°C for subsequent RNA isolation and analysis using 
microarrays.  
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2.6.3 RNA isolation and preparation of samples for microarray 
analysis 
 
RNA isolation was performed with the Qiagen RNeasy and QIAshredder kits as per 
manufacturer’s protocol. Briefly, cell pellets were treated with 350µl of RLT buffer and 
mixed thoroughly to ensure complete dissolution of pellets. Samples were transferred to   
QIAshredder columns and centrifuged for 2 minutes at 16,100g. All subsequent centrifugation 
steps were performed at 10,000g. 350µl of 70% ethanol were added to lysates, mixed 
thoroughly and transferred to RNeasy mini spin columns. Columns were centrifuged for 
15seconds. Flow-throughs were discarded and 700µl of RW1 buffer added. Samples were 
centrifuged for 15seconds. After discarding the flow-through, 500µl of RPE buffer were 
added and samples centrifuged for 15seconds. This step was repeated with a further 500µl of 
RPE buffer and columns centrifuged for 2 minutes. Collection tubes were replaced with new 
ones and samples centrifuged for 1 minute.  Columns were placed in 1.5ml LoBind tubes and 
50µl of RNase free water added to elute RNA. Samples were centrifuged for 1 minute. 
Columns were removed and the eluted RNA was kept in ice and subsequently treated with 
RNA clean and concentrator kit as per protocol. 100µl of RNA binding buffer were added to 
each sample and mixed well. An additional 150µl of 100% ethanol were added, mixed and 
transferred to Zymo-spin column. Samples were centrifuged at 14,000g for 1 minute (the 
same speed was used for all centrifugation steps except the last one). After discarding the 
flow-through 400µl of RNA prep buffer were added and samples centrifuged for 1 minute. 
This was followed by two washing steps with 800µl and 400µl of RNA wash buffer 
respectively and centrifugation for 30 seconds. Columns were centrifuged again in empty 
collection tubes for 2 minutes.  Columns were then transferred to 1.5ml LoBind tubes and 
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30µl of RNase free water added to elute RNA. Samples were left to stand at room temperature 
for 1 minute and subsequently centrifuged at 10,000g for 30 seconds. Eluted RNA was stored 
at -80°C. RNA quantity and quality were measured with the Nanodrop 2000 spectrophotomer. 
RNA quality was assessed by reporting the 260/280 and 260/230 ratios. 2µl of each sample 
were applied to the sensor for testing with 2µl of RNase free water being applied between 
readings to re-calibrate the instrument.  
 
 
2.6.4 Microarray experiment  
 
Sample labelling and microarray hybridisation and scanning were performed by Oxford Gene 
Technology Ltd (Oxford, UK). Briefly, RNA was converted to cDNA and labelled with Cy3 
using the Low Input Quick Amp Two-Color Labeling Kit as per manufacturers protocol. At 
the same time, a control reference RNA (Stratagene human Ref) was labelled with Cy5. Equal 
amounts of test and control cDNA were mixed and hybridised onto Agilent Sure Print G3 
gene expression 8x60k v2 microarrays. Arrays were scanned in the Agilent G2505C scanner. 
Scanned images were analysed with Agilent Feature Extraction Software 10.7.3.1. Platform 
specific pre-processing and normalisation of data using loess normalisation and background 
correction were performed during feature extraction. Loess normalisation is a regression 
technique for dye bias correction that is used in preference to total intensity normalisation 
when test mRNA originates from samples that are closely related. Background correction is 
applied to subtract background from foreground intensity. Quality control report files were 
produced by the external provider and reviewed by myself. All quality control metrics were 
within satisfactory ranges.  
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2.6.5 Analysis of microarray data with Partek Genomic suite 
 
Feature extracted data files were analysed with Partek Genomic suite 6.6. The gene 
expression workflow was used for analysis. Files were imported on green to red ratio 
processed signal and log2 transformed. Attributes for each sample were added including age, 
gender, clinical diagnosis (outcome group), joint of origin and antibody status. After assessing 
sources of variation in the data set, a one way fixed non nested ANOVA model was created to 
identify differentially expressed probes according to different attributes. The significance of 
the differential expression was given by a p value. A false discovery rate (FDR) of <0.05 was 
set to control for multiple testing using the Benjamini Hochberg method (Benjamini et al. 
1995). A fold change for the difference in gene expression was also obtained. Antibody status 
was found not to contribute to variance in the dataset and was thus not included in the 
ANOVA model. 
 
 
2.6.6 Data visualisation using Genesis software 
 
The publicly available Genesis platform (available for download at 
https://genome.tugraz.at/genesisclient/genesisclient_description.shtml) was used for 
visualisation of datasets as heat maps. The green/red expression data of the samples of interest 
was transformed to text format. Gene expression was normalised and genes sorted by 
expression value on trend.  
 
 
 
2-85 
 
2.6.7 Mapping of probes to genome of reference using Ensembl 
 
Mapping of probes to the reference genome was performed with the Ensembl genome 
database project website (available at http://www.ensembl.org/index.html). Probe unique 
identification numbers were entered in the search field and the chromosomal location of the 
probe was identified. Probes with multiple chromosomal locations were excluded from 
candidate gene selection. Next, the chromosomal region was assessed in detail to ascertain 
whether the probe corresponded to annotated genes and whether the gene associated to the 
probe was protein coding (Figure 2.7). Only protein coding genes were included in candidate 
gene selection.  
 
 
 
Figure 2.7 Detailed analysis of chromosomal region of origin of probes. In this example probe 
number A_23_P214080 was mapped to the reference genome (shown as a green square at the top of 
the image).  Below the probe, the gene associated with this probe can be seen (yellow boxes). In this 
example this corresponded to early growth response protein 1 (EGR1). Note that information 
regarding transcript variant (number 001 in this case) and whether the gene is protein coding or not 
is also displayed.  
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2.6.8 Primer pair design and testing  
Primer design was performed using Primer 3 software (available at 
http://bioinfo.ut.ee/primer3-0.4.0/primer3/). Once key genes of interest were identified, their 
cDNA sequence was obtained from Ensembl and entered in the corresponding search filed in 
Primer 3. Where possible, primers were designed on the 3’UTR to avoid truncated sequences.  
Parameters applied to primer pair design and quality testing using Amplifx were as described 
in section 2.5.10. Primer pair sequences were ordered from Eurofins Operon. The primer pair 
sequences of primers used in these work are shown in Appendix Table 9.3.  
 
2.6.9 Reverse transcription and real time PCR 
 
Reverse transcription of RNA was performed with the iScript cDNA synthesis kit as per 
manufacturer’s instructions. From each sample a 10µl reaction mix containing 5µl of RNA, 
0.5µl of reverse transcriptase, 2.5µl of reaction mix and 2µl of water was crated. Samples 
were run on the BioRad T100 thermal cycler using the following parameters: 25°C for 5 
minutes, 42°C for 30 minutes and 85°C for 5 minutes. Once converted, cDNA samples were 
diluted 1:5 in RNase free water. Real time PCR was performed as described in section 2.4.11. 
 
 
Quality control of primer pairs was performed using the melting curve analysis method. For 
each primer pair, a PCR using human genomic DNA (Promega G3041) was performed in 
triplicate as specified in section 2.4.11. The melting curves for the primer pairs used in 
Chapter 6 are shown in Appendix Figure 9.1 and Appendix Figure 9.2. All primer pairs 
demonstrated single peak indicating that only a single PCR product was amplified.  
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3 Functional characterisation of fibroblasts  
 
3.1 Introduction 
 
The in vitro migratory and invasive characteristics of RA synovial fibroblasts have been 
explored in the published literature. In these studies, the cells characterised originated from 
patients with longstanding RA who had received multiple treatments undergoing joint 
replacement for severe disease. Their functional profiles were compared to that of 
osteoarthritis synovial fibroblasts (with a small number of studies using normal synovial 
fibroblasts as comparators).  
 
By functionally characterising synovial fibroblasts I aimed to add to existing knowledge in 
two ways. Firstly, I wished to compare a range of functional characteristics of synovial 
fibroblasts in five distinct clinical outcome groups: Normal, Resolving, Very early, Early and 
Established RA. If successful, this approach might not only allow identification of functional 
differences between cells from patients with differing clinical fates but could also allow 
description of new biomarkers to identify patients at risk of RA at inflammatory arthritis 
onset. This in turn would allow early targeted treatment of patients at risk and avoidance of 
treatment in patients with markers of resolving disease. The study of synovial fibroblasts from 
patients with resolving arthritis as well as those from patients with very early and early RA is 
a novel approach. Despite the wealth of evidence that treatment of RA at very early stages 
results in significantly better long term outcomes, there is a distinct lack of data on the 
function of synovial fibroblasts in early disease. The study of cells at these early stages has 
been hampered by a number of limitations including difficulties identifying and recruiting 
patients with very early and resolving arthritis and the lack of required expertise to obtain 
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tissue samples from these patients. The Birmingham Early Arthritis cohort was conceived to 
overcome these limitations and the systematic collection of early samples has allowed the 
work undertaken in this thesis. The analysis of samples from resolving arthritis deserves 
special mention as this is designed to answer a question that has not previously been posed in 
the literature: what are the functional differences between synovial fibroblasts from patients 
with resolving and persistent inflammatory arthritis? 
 
Secondly, I wished to describe well defined cellular functions using well characterised assays.  
Within the existing literature, several assays have been used interchangeably to describe a 
given cellular function leading to confusion and sometimes contradictory results. For 
instance, synovial fibroblast migration has been assessed by means of scratch tests, transwell 
migration and matrigel invasion assays (Denk et al. 2010;Ng et al. 2010;Tolboom et al. 2005). 
I set out to use assays that would be more suited to the cellular function under study and to 
describe any differences that might be observed between cells from patients in different 
clinical outcome groups.  
 
 
3.2 Functional characterisation of fibroblasts: Experimental 
design 
 
To determine the in vitro migratory and invasive characteristics of synovial fibroblasts three 
different assays were used. The protocols for these assays have been outlined in the methods 
section and the optimisation and results of these experiments are described under subsequent 
headings in this chapter.  
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To ensure that differences between outcome groups could be ascertained, a minimum of five 
cell lines were included in each outcome group. These lines were selected on the basis of 
relative homogeneity of clinical parameters within a given outcome group and all assays were 
performed on the same samples. As it will be seen below, for some groups, the number of 
samples assessed exceeded this minimum. This was done in order to strengthen statistical 
robustness and ensure that observed differences were indeed conclusive. The full clinical 
characteristics of patients whose samples were used in these experiments are given in Table 
2.1. As far as possible passage numbers were kept constant amongst all cell lines used in each 
functional assay. Hence, cells used in the invasion assay were mostly at passage 4, those used 
in the scratch test and cell exclusion zone assays were at passage 5 and those used in the 
proliferation assay were at passage 6 (see Figure 2.2 for schematic representation). A 
maximum difference of 1 passage was allowed between cell lines used in a given functional 
assay.  
 
 
3.3 Functional characterisation of fibroblasts: Results 
3.3.1 Assessment of fibroblast migration 
 
 
Cell migration is central to the development and maintenance of multicellular organisms. In 
health, cell migration is central to embryonic development, immune responses and wound 
healing. In contrast, abnormal or inappropriate cell migration can contribute to disease 
(Horwitz et al. 2003). In RA, inappropriate migration and retention of lymphocytes leads to 
persistent joint inflammation (Buckley et al. 2001). In the context of synovial fibroblasts, 
migration and attachment of fibroblasts in the lining layer of the synovium to adjacent 
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cartilage results in cartilage damage (Muller-Ladner et al. 1996). The description of synovial 
fibroblast migration in different clinical outcome groups may thus unravel important disease 
mechanisms. I studied synovial fibroblast migration by means of two different assays: a 
scratch test and a cell exclusion zone assay.  
 
 
3.3.2 Scratch test 
 
Scratch tests have been used in other disciplines as models of wound healing for epithelial and 
mesenchymal cells and to assess the effect of pharmaceutical compounds (Hulkower 2011). In 
the context of the study of synovial fibroblasts, this test has been used to assess the effect of 
hypoxia and lysophosphatidic acid stimulation and T cell derived conditioned medium on 
migration rates of cultured synovial fibroblasts (Ng et al. 2010;Zhao et al. 2008;Zhu et al. 
2011). The scratch test is one of the simplest approaches to the study of cell migration and 
relies on mechanical disruption of a cell monolayer to create a cell free area that is 
subsequently “filled” by the remaining cells in the monolayer. By measuring the surface area 
of the cell-denuded zone at baseline and a fixed time later, migration rates can be assessed and 
contrasted between different conditions. In these experiments, cell monolayers were seeded 
on 6-well plates and cultured for seven days. At day 8, a scratch was created in the cell 
monolayer with a sterile 20µL pipet tip. The cell-denuded area was recorded at baseline and 
18 hours later. Cell migration was expressed as percentage of area covered in 18 hours (for 
schematic representation see Figure 2.3).  
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3.3.2.1 Assay Optimisation  
 
Although the basic protocol for this assay is well described (Hulkower 2011;Zhu et al. 2011), 
some optimisation steps of this protocol were required for these experiments and are 
described here. Scratch tests have been performed in a variety of multi-well plates containing 
96 wells or fewer. A disadvantage of plates with large numbers of wells is that, at the level of 
magnification required to view the whole length of the cell-denuded area, only one field has 
appropriate optical quality under microscopy for quantification of percentage of area covered. 
As I wished to record and measure at least three optical fields per well (to cover most of the 
length of the cell-denuded area) a 6-well plate format was favoured. 
 
The choice of seeding density (8x10
4
 cells/well) was based on previous experience from our 
study of optimal seeding densities to create synovial fibroblast monolayers on 6 well-plates. A 
series of time-course experiments using two different cell lines (BX089 and BX085) was 
carried out to determine the optimal time point at which cell migration should be assessed 
(Figure 3.1). The aim was to select a time point that would not result in complete coverage of 
the denuded area as that would make comparisons of percentage of area covered between 
samples difficult. A time point of 18 hours was selected on this basis.  
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 Figure 3.1 Scratch test time-course experiments. Percentage of denuded area covered at each time 
point is represented. Two different cell lines assayed (BX089 and BX085) in duplicate. Median and 
range shown.  
 
 
Given that the read out of this assay was the percentage of cell-free area covered in 18 hours, 
it was essential to ensure that the identical cell-denuded area was measured at both time 
points. To achieve this, each wound was artificially divided into 25mm longitudinal frames 
using a grid secured to the base of the plate. Each of these frames was labelled A-G      
(Figure 3.2). Images of the same three longitudinal frames per experiment were obtained at 
both time points by aligning the rectangles seen through the microscope’s eye piece to the 
labelled frames. Three frames per well were recorded at each time point using a digital 
Olympus inverted phase contrast microscope with a 4x objective lens.  
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 Figure 3.2 Diagram representing the use of a grid to enable measurement of identical frames at 
both time points. 25mm grids were photocopied onto acetate, cut to size and taped to the base of the 
6-well plate. By labelling each frame with a letter and aligning this with the rectangles seen through 
the microscope’s eye piece, the same frames were recorded at both time points.   
  
 
3.3.2.2 Scratch test: Results 
 
 
The results of the assay are shown in Figure 3.3. Within a given clinical outcome group 
migration ranged from 15-20% to 40-45% of area covered in 18 hours. Median migration 
values were very similar across clinical outcome groups and ranged from 31 to 44.5%. These 
findings suggested that the rate of migration in response to injury of samples within an 
outcome group was the same as that between samples from different outcome groups. In other 
words, synovial fibroblasts from patients with differing pathologies could not be 
differentiated on the basis of their migratory characteristics when assessed using a scratch 
test. Whilst this might be a true reflection of these cells’ biology I was surprised by the lack of 
differences between outcome groups and set out to find a possible explanation for this.  
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 Figure 3.3 No differential migration between outcome groups in response to injury. Cell migration 
expressed as percentage of area covered in 18 hours. Each dot represents mean of duplicates for each 
cell line. Horizontal bars represent median value for each outcome group. Statistical significance 
assessed by Kruskal-Wallis test with Dunn’s post-test analysis for multiple comparisons.   
 
 
Although scratch tests are simple to perform and allow assessment of cell motility in real 
time, they have been criticised as they suffer from a number of limitations. One such 
limitation is that it can be difficult to reproduce scratches consistently between wells hence 
leading to cell-denuded areas that vary in size and shape (Hulkower 2011). To assess whether 
this limitation might have affected the results, I plotted the scratches’ surface area in all 
replicates (Figure 3.4A). In this histogram, the y axis shows the number of wells and the x 
axis the surface area of the scratches expressed in m2. By doing this, I was able to confirm 
that the surface area of the scratches generated varied widely between replicates and ranged 
from a minimum value of 312,558m2 to a maximum of 642,015m2. This is further 
represented in Figure 3.4B, where two representative images of scratches with very different 
surface areas are shown.  
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 Figure 3.4 Discrepancies in the shape and surface area of scratches between wells. A, Histogram 
representing the distribution of the scratches’ surface area in all samples. The y axis shows the 
number of wells, the x axis shows the area expressed in m2. The area of the scratches ranged from 
312,558m2 to 642,015m2. Clear variability in surface area between wells is demonstrated. B, 
Representative images depicting differences in shape and surface area of scratches between two 
samples. Area x corresponds to the area of the scratch in a given sample (BX010) and measures 
312,558m2 whilst area y corresponds to the area of the scratch in another sample (BX070) and 
measures 480,633m2.  
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This highlighted a significant experimental limitation: by producing different starting 
conditions for different samples, direct comparisons between these samples were 
compromised as we could not ascertain whether any differences or indeed similarities 
between samples were due to the cells’ behaviour or the experimental conditions.  
 
Another factor taken into consideration was the effect that mechanically scratching a cell 
monolayer might have on cell migration. When a cell-denuded area is artificially created by 
scratching, the cells at the edges of this area are damaged. This may result in release of factors 
that may affect migration and may even lead to altered migration of these damaged cells 
(Staton et al. 2009). A number of alternative scratching methods have been proposed to 
overcome this problem such as laser photoablation or electrical wounding (Hulkower 2011). It 
has also been proposed that a washing step between cell wounding and study of cell migration 
may attenuate these effects by removing any released factors and potentially the damaged 
cells at the edges of the cell-free area. The protocol I developed lacked such a step and in 
retrospect I wonder whether the inclusion of a washing step would have improved the assay’s 
performance. In practice this observation meant that assessment of cell migration following 
injury might simply not be the same as assessment of cell migration in the absence of such 
insult, hence I decided to develop an assay that would allow assessment of cell migration in 
the absence of injury. 
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3.3.3 Cell exclusion zone assay  
 
 
The main objectives during the development of this assay were to create identical 
experimental conditions between samples and to avoid mechanical disruption of cells at the 
edge of the cell-free area. To achieve this, I used tissue culture inserts to create a cell 
exclusion zone assay. Culture inserts consisting of two ports separated by a membrane were 
placed in the centre of wells in 6-well plates. Cells were aliquoted into both ports and left to 
adhere for 24 hours. After removal of the inserts, two cell monolayers had been created either 
side of the artificial gap created by the insert’s membrane and migration could be measured 
(for schematic representation see Figure 2.4) 
 
By using this method, the cell-free zone created was of very similar surface area between 
samples. The surface areas of cell-denuded zones created with this and the scratch test are 
contrasted in Figure 3.5. Whilst surface area varied widely between samples using the scratch 
test, this variation was minimised by using the tissue culture inserts method, with surface 
areas ranging from 252,868m2 to 353,854m2.  
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 Figure 3.5 Representation of the surface area of the cell-free zone in the scratch test and the cell 
exclusion zone assay. Whilst the surface area of scratches varied widely between different samples 
using the scratch test, such variation was minimal when using a tissue culture insert to create the cell-
denuded area in the cell exclusion zone assay. Box and whisker plots where box represents median 
and interquartile range and vertical lines represent maximum and minimum values. 
 
3.3.3.1 Cell exclusion zone assay optimisation 
 
A first series of experiments was carried out to determine the optimal seeding density for the 
assay. The manufacturer’s protocol for the tissue culture inserts recommended densities of 3-
7x10
5
cells/ml to achieve confluent monolayers in 24 hours. As in these experiments the 
optimal seeding density should not only be determined by confluence at 24 hours but also by 
ability of achieving complete coverage of the artificial gap between monolayers, a time-
course experiment was designed.  Using the same cell line (RA28SY) three seeding densities 
(3x10
5
, 5x10
5
 and 7x10
5
 cells/ml) were assayed over six time points (18, 24, 36, 48, 66, 72 
hours) (Figure 3.6). Confluence at 24 hours was achieved with all densities. The percentage of 
area covered was very similar in all time points with all seeding densities. Complete coverage 
of the gap was achieved at 72 hours with all seeding densities. As the results for all 
parameters were fairly similar between seeding densities, the lowest seeding density 
(3x10
5
cells/ml) was selected for subsequent experiments to minimise cell wastage.  
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Figure 3.6 Cell exclusion zone assay: determination of optimal seeding density. Percentage of area 
covered at different time points with different seeding densities was assessed. Results obtained were 
very similar for all densities. 
 
 
Next, a series of time-course experiments was performed to determine the optimal time point 
for assessment of cell migration. Two cell lines (RA19SY and BX081) were assayed. The aim 
was to select a time point that would not result in complete coverage of the cell-free gap as 
that would make comparisons of percentage of area covered between samples difficult. Cell 
lines were assessed over six time points ranging from 18 to 72 hours. Both lines showed 
migration at the minimal time point of 18 hours with one of them achieving 70% of area 
coverage at 24 hours (and complete coverage at 48 hours). These results indicated variability 
in area covered between samples but also that some lines might be very fast migrators 
achieving a significant amount of area covered at 18 hours. On this basis and to avoid 
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achieving complete confluence at migration assessment, a time point of 18 hours was selected 
(Figure 3.7).  
 
 
 Figure 3.7 Cell exclusion zone assay: time-course experiment. To determine optimal time point for 
migration assessment, two different cell lines were assayed (RA19SY and BX081) in duplicate over six 
time points. Median and rage represented. Note BX081 achieved 100% of area covered at 48 hours 
and hence there were no further measurements available after that time point. 
 
3.3.3.2 Cell exclusion zone assay: Results 
 
 
Image 3-1 shows the typical images obtained with this assay and Figure 3.8 the overall 
results.  
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Image 3-1 Phase contrast microscope images showing differences in cell migration at 18 hours 
between clinical outcome groups. Maximal differences are observed between Normal and 
longstanding multi-treated Established RA lines. 
 
 
Statistically significant differences in migration were observed between the five clinical 
outcome groups (Kruskal-Wallis, p=0.002). Normal and resolving lines migrated faster than 
RA lines. Median migration ranged from 73.9% in the Normal group, through 60% in the 
Resolving, 45% in Early RA to 20% in VeRA and just under 16% in Established RA. Dunn’s 
post-test analysis showed that statistically significant differences existed between the Normal 
Time 0 18 hours
Normal
Resolving
VeRA
Early RA
Established RA
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and Established RA (73.9% vs. 15.9%, p<0.05) and Normal and VeRA (73.9% vs. 20%, 
p<0.05) groups.  
 
 
 Figure 3.8 Differential cell migration between clinical outcome groups. Decreasing gradient of cell 
migration as outcome group progresses from Normal to disease was observed. Statistically significant 
differences demonstrated between Normal and very early RA (VeRA) and Normal and longstanding 
multi-treated RA lines (Established RA).  Cell migration expressed as percentage of area covered in 
18 hours. All lines done in duplicate. Each dot represents the median value for duplicates for each cell 
line. Horizontal bars represent median value for each clinical outcome group. Statistical significance 
assessed by Kruskal-Wallis test with Dunn’s post-test analysis for multiple comparisons. *p<0.05. 
 
As the synovial microenvironment in RA is distorted and characterised by abundance of pro-
inflammatory cytokines such as tumour necrosis factor  (TNF) and transforming growth 
factor  (TGF), I wished to ascertain whether treatment of synovial fibroblasts with these 
cytokines would have an effect on cell migration. I thus repeated the cell exclusion zone 
experiments following stimulation of cells with TNF (10ng/ml) or TGF (1ng/ml) for 48 
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hours and found no significant differences in migration when compared to the unstimulated 
system. Figure 3.9 shows the results of these experiments. Migration of cells treated with the 
different stimulants has been plotted as fold change relative to the unstimulated controls. A 
fold change of 1 indicates no difference in migration between the test, stimulated sample and 
the unstimulated control. 
 
 
 Figure 3.9 Comparison of stimulated and unstimulated migration between clinical outcome groups. 
Results are expressed as fold change relative to unstimulated control (white bars). Bars represent 
median and interquartile range. Four lines per outcome group assessed. 
3.3.3.3 Assessment of synovial fibroblast proliferation in different 
outcome groups 
 
To confirm that the observed differences were a reflection of differential cell migration rather 
than of differential cell proliferation, the proliferation rate of fibroblasts in the different 
outcome groups was assessed at 18 hours by EdU incorporation. EdU (5-ethynyl-2-
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deosyuridine) is a thymidine analogue that is incorporated into newly synthetised DNA during 
cell proliferation. EdU is fluorescently labelled allowing identification of proliferating cells 
by flow cytometry (Figure 3.10). 
 
 
 Figure 3.10 Proliferation assay: flow cytometry plots. A, Cells were identified on size and 
granularity properties using forward scatter versus side scatter plot. Doublets were excluded by 
gating on forward scatter versus pulse width plot. B, Representative image of positive control (MDCK 
cell line) proliferation at 18 hours. Violet 1 plot shows peak in region 4 (R4) that represents cells that 
have taken up dye. C, Representative image of synovial fibroblast proliferation at 18 hours. Violet 1 
plot shows that cells have not taken up dye, indicating no proliferation at 18 hours. 
 
 
Prior to undertaking these experiments and to ascertain the optimal EdU concentration to be 
used, an EdU titration experiment was done. One cell line (BX086) was used for this 
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experiment. Cells were seeded on a 6 well-plate at a density f 8x10
4
cells/well and treated with 
increasing EdU concentrations ranging from 2 to 10µM as suggested in the manufacturer’s 
protocol. Cell proliferation was assessed at 96 hours (Figure 3.11). The percentage of 
proliferating cells (ranging from 4.8% to 5.4%) was very similar with all EdU concentrations. 
As a result, the lowest concentration of 2µM was selected for subsequent experiments in order 
to minimise reagents’ wastage.  
 
 Figure 3.11 EdU titration. Cells were treated with increasing EdU concentrations (2-10M) for 96 
hours to determine optimal concentration. As proliferation rates were very similar at all 
concentrations, the lowest 2M concentration was selected for subsequent experiments.  
 
 
Subsequent experiments were performed to determine fibroblasts proliferation rates. These 
experiments were undertaken under the same conditions as the cell exclusion zone assay:  
70µl of cell suspension (at a density of 3x10
5
cells/ml cells) were aliquoted either side of a 
tissue culture insert and allowed to adhere for 24 hours. Tissue culture inserts were removed 
at Time 0, EdU added to culture medium and proliferation assessed 18 hours later. The highly 
proliferative Madin-Darby canine kidney epithelial cell line (MDCK) was used as positive 
EdU concentration (M)
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control. The percentage of proliferating synovial fibroblasts in different outcome groups 
ranged from 0% to 0.9%. This was in sharp contrast with the percentage of proliferating cells 
observed in the positive control group (53-78%) (Figure 3.12). These experiments confirmed 
that the observed differences in cell migration were thus not attributable to differential cell 
proliferation.  
 
 
 Figure 3.12 Synovial fibroblasts in all outcome groups display very low and comparable 
proliferation rates at 18 hours. Minimal fibroblast proliferation is seen at 18 hours in all outcome 
groups. Dots represent median value of triplicates for each line. Each dot represents one cell line. 
Horizontal bars represent median values within outcome groups. Three lines per outcome group were 
tested. Note split y axis to include proliferation of positive control. 
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3.3.4 Assessment of fibroblast invasion 
 
A key pathogenic characteristic of RA synovial fibroblasts is their ability to attach to and 
invade cartilage. These properties have been demonstrated in vivo and in vitro. Direct 
invasion of cartilage by RA synovial fibroblasts but not by OA, normal or dermal fibroblasts 
was shown in the SCID mouse model where invading cells produced matrix degrading 
enzymes including cathepsins B, D and L (Muller-Ladner et al. 1996).   
 
In vitro studies have been used to assess the invasive characteristics of human RA synovial 
fibroblasts and synovial fibroblasts from murine inflammatory arthritis models (Kiener et al. 
2009;Laragione et al. 2008;Laragione et al. 2010;Tolboom et al. 2002;Tolboom et al. 2005). 
Human RA synovial fibroblasts displayed higher in vitro invasion rates than OA synovial 
fibroblasts, a feature that correlated with the rate of radiographic joint damage and expression 
of MMPs 1, 3 and 10 (Tolboom et al. 2002;Tolboom et al. 2005).  
 
Building on this knowledge, my aim was to compare the invasive properties of cells in the 
five clinical outcome groups. I hypothesised that synovial fibroblasts from RA patients would 
display more invasive characteristics than those from the Resolving arthritis and Normal 
groups.  
 
 
The invasive characteristics of cells in the five outcome groups were assessed by means of 
matrigel coated chambers as described in the methods section. Briefly, transwells that had 
8µm pores in their membrane and were coated with matrigel matrix were inserted in wells of 
24-well plates. Synovial fibroblasts were seeded onto the inner surface of transwells and 
cultured for 72 hours. Non invading cells on the inner surface of the transwells were removed 
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and membranes detached from the transwells, stained and mounted onto microscope slides. 
Invading cells that had been able to digest the matrigel layer and migrate through the pores 
attaching to the under-surface of the membrane were observed by light microscopy. The 
number of invading cells was compared between groups (for schematic representation see 
Figure 2.5).    
 
3.3.4.1 Invasion assay optimisation 
 
In order for invasion rates to be compared between samples, a robust and reproducible method 
of measuring cell invasion had to be developed. As the pattern of cell invasion in matrigel 
chambers is known to be uneven, with greater invasion at the membrane edges than at the 
centre, it is usually recommended that assessment of cell invasion is done from the central 
membrane area. However, the published literature and the manufacturers’ protocol for the 
assay were imprecise on this point, failing to detail how these measurements should be taken 
and only indicating that counts were taken from the “central membrane area”. As I wanted to 
ensure that in my experiments the identical central area was assessed in all replicates, I 
developed a device that would facilitate this. This “centering device” consisted of a coverslip 
in which the whole membrane area had been drawn with a square in its centre that represented 
the area of the membrane to be counted. By positioning the centering device over each of the 
membranes, I ensured that exactly the same area was counted in all samples (Figure 3.13). 
Eight ocular fields within this square were counted at x20 magnification for each sample. This 
represented 15% of the surface area of the membrane. 
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 Figure 3.13 Diagram of the centering device used to assess cell invasion. Bottom rectangle 
represents a microscope slide with four invasion membranes (light pink circles). The top rectangle 
represents a cover slip in which the membrane area has been drawn together with a rectangle inside 
it. By positioning the cover slip so that the edges of the circle coincide with that of the invasion 
membrane, the exact same area was measured in all samples. Eight ocular fields inside the rectangle 
(corresponding to 2mm
2
) were measured for each sample.  
 
 
Next, a series of time-course experiments was carried out to determine the optimal time point 
to assess cell invasion. Two lines (RA19SY and BX085) were assayed at 24, 48 and 72 hours. 
Minimal invasion was observed at the earlier time point of 24 hours with invasion increasing 
over time reaching the highest invading cell numbers for both lines at 72 hours (Figure 3.14). 
Thus a time point of 72 hours was selected to allow for maximal invasion. This time point 
also coincided with that used in some of the published literature (Tolboom et al. 
2002;Tolboom et al. 2005).  
 
8 x 0.5 mm
0.5 mm
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 Figure 3.14 Invasion assay: time-course experiment. Two different lines were assayed (RA19SY and 
BX085) in triplicate at three different time points (24, 48 and 72 hours). Median and range 
represented. A time point of 72 hours was selected on the basis that it showed maximal invasion.  
 
 
3.3.4.2 Invasion assay: Results 
 
Figure 3.15A shows a typical image obtained in this assay. Under light microscopy and after 
Diff-Quick staining synovial fibroblasts can be visualised as nucleated cells with elongated 
cytoplasm. The pores in the membrane through which cells have migrated are seen as circles 
in the background.   
 
The results of this assay are displayed in Figure 3.15B. Although some lines in the 
longstanding multi-treated RA group displayed very invasive characteristics (with one line 
achieving a migration rate of 460 cells/mm
2 
in 72 hours), overall no statistically significant 
differences between outcome groups were demonstrated (Kruskal-Wallis, p=0.79). 
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Figure 3.15  Invasion assay.  A, Invading synovial fibroblasts are seen in the undersurface of the 
invasion membrane as nucleated cells with elongated cytoplasm. B, No statistically significant 
differences in cell invasion between different clinical outcome groups were observed.  All experiments 
were done in triplicate. Dots represent medians of triplicates for each cell line. Horizontal bars 
represent median invasion value for the clinical outcome group. Invasiveness is expressed as number 
of cells invading the matrigel coated membrane/mm
2
 in 72 hours. Statistical significance assessed by 
Kruskal-Wallis test with Dunn’s post-test analysis for multiple comparisons.   
 
 
3.4 Functional characterisation of fibroblasts:  Overall discussion 
 
This is the first body of work to systematically examine, compare and contrast the functional 
characteristics of synovial fibroblasts in five distinct clinical outcome groups.  
 
The use of a cell exclusion zone assay to study migration of human synovial fibroblasts is a 
novel approach that to the best of my knowledge has not previously been used in this context. 
Using this assay, I observed differential migration between cells from patients in different 
outcome groups that was not secondary to differential cell proliferation. Interestingly, lines 
from very early RA patients (3 months symptom duration) and Established RA behaved 
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similarly with comparable migration rates (20% and 15.9% respectively, p=0.9 by Mann 
Whitney test). Statistically significant differences between these migration rates and those 
from Normal synovial fibroblasts (73.9%) existed indicating that synovial fibroblasts from 
RA patients in these two outcome groups migrate much slower than healthy cells.  
  
When considering these results two immediate questions arise from this observation: (a) what 
are the clinical consequences (if any) of differential migration? and (b) what causes migration 
to be different?  
 
Potential clinical consequences of this behaviour can be hypothesised. As discussed in the 
introductory pages of this thesis, the hyperplastic RA synovium is characterised by expansion 
of fibroblast populations. This effect is thought to be due to a combination of decreased 
apoptosis  and increased local cellular proliferation (although evidence of in vivo proliferation 
is scarce) (Mor et al. 2005). In the light of our results we can also speculate that decreased cell 
migration might contribute to pathological accumulation of synovial fibroblasts in the RA 
synovium. Such a suggestion is of course purely speculative and would require verification of 
differential cell migration in vivo.  
 
In order to explore the potential causes of differential migration we need to briefly consider 
the biological processes underlying migration of adherent cells (Friedl et al. 2012;Yamazaki 
et al. 2005). Cell migration in 2D substrates consists of four successive processes that are 
regulated by key molecules, in particular members of the Rho family of small GTPases (Rac, 
Rho and Cdc42). In response to extracellular stimuli cells are polarised and actin 
polymerisation occurs that results in formation of membrane protrusions (filopodia and 
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lamellipodia). Phosphatidylinositide 3-kinase (PI3K) contributes to cell polarisation whilst 
Rac and Cdc42 proteins are involved in production of membrane protrusions (Etienne-
Manneville et al. 2002). Next, adhesion of the protrusions to the substrate occurs through 
complex integrin-dependent cell-substrate adhesions which are regulated by Rac. 
Subsequently, the nucleus and cell body are translocated by acto-myosin contractile forces. 
Rho has a fundamental role here as it regulates the assembly of contractile acto-myosin 
filaments. Finally, during retraction adhesive structures at the trailing edge are disassembled. 
In 3D migration, ECM remodelling also takes place. Alterations in cell migration can result 
from distortion in any of these steps. There are thus a number of targets we could further 
study to elucidate differential migration mechanisms. Experiments involving inhibition or 
gain of function of Rac, Rho and PI3K would be very informative. Indeed work from Chan 
and colleagues found that Rac is necessary for lamellipodia formation in RA synovial 
fibroblasts (Chan et al. 2007) and the role of PI3K signalling in RA is an area of increasing 
research interest (Reedquist et al. 2006). Further study of integrins, that are already known to 
mediate adhesion of synovial fibroblasts to cartilage (Ishikawa et al. 1996), would also be of 
value in unravelling the causes of differential migration.  
 
The study of the transcriptomic profiles of synovial fibroblasts during migration would be of 
special interest in this context. Gene expression is a dynamic process that varies depending on 
external conditions. For example, as it will be seen in Chapter 6, TNF stimulation 
significantly modified gene expression patterns of synovial fibroblasts in all groups under 
study. Thus, the analysis of gene expression patterns in these cells during migration might not 
only indicate generic pathways involved in synovial fibroblast migration but may provide 
clues to disruption of key migration checkpoints in disease.  
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In contrast to the results of the cell exclusion assay, no differences in cell migration in 
response to scratching were observed. Scratch tests have been used to assess RA synovial 
fibroblast migration under different experimental conditions. Ng and colleagues reported 
increased migration when synovial fibroblasts were cultured under hypoxic conditions (1% 
oxygen). This effect was not observed when cells were cultured under normoxic conditions or 
at 3% and 5% oxygen (Ng et al. 2010). A different group used this assay to assess the effect 
of the signalling molecule lysophosphatidic acid (LPA) on RA synovial fibroblast migration 
reporting increased migration rates upon LPA stimulation (Zhao et al. 2008). Whilst these 
studies were designed to assess differences before and after specific treatments, neither of 
them reported on migration rates of resting RA synovial fibroblasts thus not allowing for 
direct comparison with our results. The potential limitations of this assay have been 
discussed. Regardless of whether these limitations had any effect in experimental conditions, 
it is clear that migration following disruption of a cell monolayer (scratch test) and in the 
absence of such stimuli (cell exclusion zone assay) are different biological processes that are 
likely to require engagement of different cellular networks and machinery. These differences 
may explain why differing cell migration rates between groups were observed with the former 
but not with the latter.  
 
There were no significant differences in cell invasion between outcome groups. The invasive 
characteristics of synovial fibroblasts in vitro have been assessed in human and animal 
studies. Of particular interest in terms of similarity with the work we present, Tolboom and 
colleagues used this assay to compare the invasive characteristics of fibroblasts from patients 
with longstanding multi-treated RA (the equivalent of the Established RA group in this work) 
and control OA fibroblasts (Tolboom et al. 2002;Tolboom et al. 2005). They concluded that 
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RA synovial fibroblasts were significantly more invasive than OA fibroblasts, a feature that 
correlated with the rate of radiographic joint damage. Careful analysis of the results of their 
work reveals that a large variation in cell invasion between lines within a given outcome 
group existed. This variability led the authors to use large numbers of cell lines in each 
outcome group, ranging from 30 to 72 in the RA group and from 17 to 49 in the OA group 
(depending on the study), in order to demonstrate statistically significant differences between 
groups. Variability in invasion rates within outcome groups is also seen in my results. This is 
particularly marked in the Established RA group were invasion rates range from 0 to 460 
cells/mm
2
. Taking this into account it could be argued that in order for us to fully characterise 
differential invasion between these groups a much larger sample size per outcome group 
would be required. In the context of this assay it is also worth noting that although no 
statistically significant differences in invasion between outcome groups were identified, a 
more invasive phenotype is suggested for the Established RA group when looking at the raw 
data (Figure 3.15). If instead of using the absolute cells/mm
2
 data, invasion is assessed as 
percentage of cell lines achieving an invasion cut off of 100 cells/mm
2
 at 18 hours, we find 
that 0% for the Normal, Resolving and Early RA groups achieve this cut off with 20%  VeRA 
group and 50% for the Established RA group.       
 
Alternative methods to assess in vitro synovial fibroblast invasion exist. These include co-
culture of synovial fibroblasts with cartilage particles for 15 days followed by measurement of 
cartilage degradation products (Neidhart et al. 2003) and co-culture of synovial fibroblasts 
with cartilage discs for 14 days followed by histological and immunohistochemical analysis 
(Pretzel et al. 2009). Although it could be argued that the use of these approaches in my 
experimental set up may have been of greater biological relevance, several drawbacks 
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precluded their use. These included the fact that these experiments are lengthy and technically 
challenging and the need to identify a source of cartilage. Chamber systems coated with 
reconstituted cartilage matrix have been used extensively for the assessment of synovial 
fibroblast invasion (Frye et al. 1996;Ray et al. 2001;Tolboom et al. 2002;Tolboom et al. 
2005). The decision to use coated chambers in this work, stemmed from the need to have a 
simple and reproducible assay that would allow high throughput given the large number of 
samples that I wished to assess.  
 
It is also worth noting here that all in vitro experimental designs suffer from limitations as 
they invariably are imperfect substitutes for the in vivo situation. However, whilst in vivo 
experiments may be more physiologically relevant, they are expensive, time consuming, 
technically challenging and ill-suited for the analysis of multiple samples from several 
outcome groups. For these reasons, an in vitro experimental design was favoured to assess the 
functional characteristics of synovial fibroblasts in the five outcome groups of interest.  
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4 Proof of concept: candidate gene approach 
 
4.1 Introduction 
 
Before embarking on time consuming, high cost experiments to determine the full 
transcriptomic profile of synovial fibroblasts in the five different clinical outcome groups, a 
series of smaller scale, candidate gene approach experiments was performed to establish proof 
of concept.  
 
Custom made microfluidic cards were used to perform 48 gene expression assays. Cell lines 
from patients in three clinical outcome groups were assayed: Resolving (n=9), VeRA (n=12) 
and Early RA (n=9). Gene expression analysis was performed on unstimulated synovial 
fibroblasts and parallel samples exposed to TNF (10ng/ml) for 24 hours. A candidate gene 
approach was used during microfluidic card design. Targets already known to be associated 
with key fibroblast functions were selected. These included adhesion molecules (VCAM1), 
chemokines (CXCL12 and CXCL16), cell surface markers (CD248 and PDPN) and matrix 
metalloproteinases (MMP1, MMP2, MMP3, MMP9, MMP13 and MMP14) amongst others. 
A full list of gene expression targets assayed is shown in Appendix Table 8.1. The clinical 
characteristics of patients in each outcome group are shown in Table 2.2. 
 
 
4.2 Candidate gene approach: Results 
 
Out of the 48 genes assayed, three were housekeeping genes (GAPDH, 18S, 2microglobulin) 
and for another one (PADI4) levels expressed by synovial fibroblasts were below the limit of 
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detection of the assay. The results for the remaining 44 genes assayed are shown in Figure 4.1 
and Figure 4.2 (unstimulated and TNF stimulated samples respectively). For certain genes, 
the results were inconclusive because expression values were below the lower limit of 
detection of the assay for several fibroblast lines in each group. In the unstimulated samples 
these included: TLR2, TNSF11, SHOX, LGALS3, MMP9 and MMP13 and in the TNF 
stimulated samples: LGALS12 and SHOX. Statistically significant differences in gene 
expression profiles between outcome groups were observed for three genes: DKK1, SLIT3 
and EGF in unstimulated samples. No differences in gene expression were observed between 
different outcome groups in the TNF stimulated samples. 
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Figure 4.1 Gene expression patterns in unstimulated synovial fibroblasts samples. The expression 
patterns of 44 genes in Resolving (n=9), VeRA (n=12) and Early RA (n=9) unstimulated samples are 
shown. Kruskal Wallis test with Dunn’s post-test analysis for multiple comparisons. *p<0.05.  
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Figure 4.2 Gene expression patterns in TNF stimulated synovial fibroblasts samples. The expression 
patterns of 44 genes in Resolving (n=9), VeRA (n=12) and Early RA (n=9) TNF stimulated samples 
are shown. Kruskal Wallis test with Dunn’s post-test analysis for multiple comparisons. 
 
 
The observation that Dickkopf related protein 1 (DKK1) was differentially expressed between 
outcome groups was of particular interest for two reasons. First, the difference in expression 
was observed between the Resolving and VeRA groups, thus lending support to the 
hypothesis that the study of early samples might provide clues to key genes involved in the 
switch from resolving to persistent disease. Second, DKK1 is an inhibitor of the Wnt 
signalling pathway that has been proposed as a “master regulator of joint remodelling” (Diarra 
et al. 2007). Wnt signalling plays a critical role in osteoblast differentiation and activity, 
driving bone formation. Inhibition of Wnt signalling via DKK1 directly impairs osteoblast 
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differentiation and indirectly enhances bone destruction by increasing RANKL induced 
osteoclastogenesis (Goldring et al. 2007).  In RA patients, serum DKK1 levels are higher than 
in healthy controls or patients with other rheumatic diseases (Wang et al. 2011). Patients 
carrying a genetic variant in the DKK1 gene have higher serum DKK1 levels and more 
progressive joint destruction (de Rooy 2012) suggesting a fundamental role for DKK1 in RA. 
Treatment of murine models of arthritis with anti DKK1 antibodies has shown promise in 
restoring bone loss. Furthermore, synovial tissue sections of patients with established RA 
show strong expression of DKK1 localising to synovial fibroblast (Diarra et al. 2007). Our 
group also  recently reported that expression of DKK1 by synovial fibroblasts is closely 
regulated by the local glucocorticoid metabolism (Hardy et al. 2012). Wnt signalling 
inhibition by DKK1 may therefore be an as yet undefined pathway through which synovial 
fibroblasts influence bone destruction in RA. I therefore decided to investigate this target in 
more detail by determining DKK1 protein levels and by assessing the potential functional 
consequences of differential DKK1 expression between the Resolving and VeRA groups.  
 
 
4.3 Determination of DKK1 protein levels 
 
DKK1 protein levels in the supernatants of cultured synovial fibroblasts were determined by 
ELISA. Although the results appeared encouraging with supernatants from fibroblasts from 
VeRA patients showing higher overall DKK1 levels than those from patients with Resolving 
arthritis, levels of variability within groups were high and differences between groups did not 
achieve statistical significance (median: 23.2 ng/ml vs. 6.6 ng/ml respectively, p=0.07) 
(Figure 4.3). 
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Figure 4.3 DKK1 protein levels in supernatants of cultured synovial fibroblasts. DKK1 levels were 
measured in the supernatants of cultured synovial fibroblast from Resolving (n=9) and VeRA (n=9) 
groups by ELISA. Box and whisker plot where box represents median and interquartile range and 
vertical lines represent maximum and minimum values. Mann Whitney test: p=0.07.  
 
 
4.4 Osteoblast differentiation and bone nodule formation 
experiments 
 
Overexpression of DKK1 mRNA in cultured VeRA synovial fibroblasts compared to 
Resolving synovial fibroblasts with a similar trend at the protein level had been observed so 
far. DKK1 promotes an imbalance in bone homeostasis in favour of bone destruction by 
impairing osteoblast differentiation. We thus hypothesised that co-culture of osteoblast 
precursors with conditioned medium from cultured VeRA synovial fibroblasts would result in 
decreased osteoblast differentiation and bone nodule formation compared to co-culture with 
conditioned medium from Resolving synovial fibroblasts. These experiments were designed 
in collaboration with Professor Mark Cooper (Professor of Medicine, Sydney University) and 
Dr Rowan Hardy (Research Fellow in Endocrinology, Diabetes and Metabolism, University 
of Birmingham). Dr Rowan Hardy performed the experiments.  
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Briefly, commercially available osteoblast precursors were cultured in osteoblast 
mineralisation medium (containing ascorbic acid) in the presence of conditioned medium 
obtained from cultured synovial fibroblasts in the Resolving and VeRA groups. To assess the 
effect of DKK1 on osteoblast differentiation, a DKK1 control was created with recombinant 
DKK1. Positive differentiation controls were established using osteoblast mineralisation 
medium containing non-conditioned fibroblast medium. Negative controls consisted of 
osteoblast growth medium containing non-conditioned fibroblast medium. Formation of 
mineralised bone nodules stained using alizarin red was used as a surrogate marker of 
osteoblast differentiation. Positively stained nodules were observed in the positive control and 
were absent in the negative control as expected. Low numbers of nodules were identified in 
the DKK1 control, indicating that osteoblast differentiation was inhibited.  
 
Nodule formation was observed when osteoblast precursors were co-cultured with 
conditioned medium from both, Resolving and VeRA synovial fibroblasts (Image 4-1). 
Nodule counts were higher in co-cultures with conditioned medium from VeRA synovial 
fibroblasts, a finding that directly opposed our hypothesis. Due to time constraints, these 
experiments had to be abandoned before further replicates could be added to this n=1 in each 
group experiment. Therefore, definite conclusions cannot be drawn from these experiments. 
Furthermore, potential limitations of these experiments must be acknowledged. A possible 
significant experimental drawback was the use of relatively small amounts of fibroblast 
condition medium (25µl). In vitro effects are reported with DKK1 concentrations of 40-
100ng/ml which would not have been achieved in the amount of conditioned medium used. 
Additionally, other soluble factors present in the medium may have had an effect on 
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osteoblast differentiation (i.e. IL-6). It is therefore likely that if these experiments had been 
continued, changes to the experimental protocol would have been made to optimise this assay.  
 
 
 
Image 4-1 Osteoblast differentiation and mineralised bone nodule formation. Light microscopy 
images of mineralised bone nodules produced by differentiated osteoblasts under different conditions. 
Higher bone nodule formation is observed with VeRA medium co-culture compared to co-culture with 
Resolving medium. Images are representative of one experiment with two replicates in each outcome 
group. 
 
 
4.5 Synovial fibroblast-HUVEC co-cultures in flow capture assays 
 
Our group has previously demonstrated that stromal cells regulate lymphocyte adhesion to 
endothelium in an in vitro flow-based migration model. Fibroblasts and human umbilical vein 
endothelial cells (HUVEC) were cultured either side of a 0.4µm pore filter. Co-cultures were 
Positive control DKK1 control
Co-culture with Resolving medium Co-culture with VeRA medium
Negative control
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stimulated with of TNF and IFN for 24 hours. Filters were transferred to a flow chamber 
system through which lymphocytes were perfused. Increased lymphocyte migration through 
the filter was observed when HUVEC were co-cultured with synovial fibroblasts but not with 
dermal fibroblasts controls (McGettrick et al. 2009). In collaboration with Dr Helen 
McGettrick (Arthritis Research UK Career Development Fellow) we decided to analyse 
DKK1 protein levels in the co-culture flow system. These experiments were carried out by Dr 
McGettrick. 
 
DKK1 levels in the supernatants of synovial fibroblast-HUVEC co-cultures were determined 
with a bead based multiplex technique as specified in the methods section. DKK1 protein 
levels were determined in the supernatants of HUVEC alone (n=7) or co-cultured with 
Resolving (n=5) or VeRA (n=5) synovial fibroblasts. DKK1 levels in the supernatant of co-
cultures of HUVEC and Resolving fibroblasts did not differ from those found when HUVEC 
were cultured alone. However, statistically significantly higher levels of DKK1 were observed 
in the supernatant of co-cultures of HUVEC with VeRA synovial fibroblasts compared to 
HUVEC alone (median 1094pg/ml vs. 244.9pg/ml respectively, p<0.01) (Figure 4.4A). 
Furthermore, DKK1 levels in supernatants positively correlated with lymphocyte adhesion 
(Figure 4.4B). Other cytokines assayed in these experiments included IL-8, RANTES, IL-4, 
GRO-alpha, IL-6, IL-1, ENA78, MMP13 and IL-1, none of which showed differences.  
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Figure 4.4 Synovial fibroblast-HUVEC co-cultures. A, DKK1 levels were determined in the 
supernatant of HUVEC cultured alone (n=7) or co-cultured with Resolving (n=5) or VeRA (n=5) 
synovial fibroblasts. No differences in DKK1 levels were observed between HUVEC alone and 
Resolving-HUVEC co-cultures. Significantly higher DKK1 levels were observed in the supernatant of 
VeRA-HUVEC co-cultures than HUVEC alone. Box and whisker plot where box represents median 
and interquartile range and vertical lines represent maximum and minimum values. Differences in 
DKK1 levels between groups assessed with Kruskal Wallis  test. **p<0.01. B, DKK1 levels positively 
correlated with lymphocyte adhesion. Correlation assessed with Spearman test.  
 
 
4.6 Proof of concept: candidate gene approach: Discussion 
 
Proof of concept experiments demonstrated that gene expression profiles of cultured synovial 
fibroblasts segregate according to outcome. These differences were observed in unstimulated 
but not in TNF stimulated cells. Of the 48 genes assayed in the unstimulated samples, 38 
provided robust data. Three out of these 38 genes demonstrated differences in expression 
according to outcome. This gave us confidence that a larger unbiased mRNA transcriptomic 
analysis of these cells would yield interesting results.  
 
Additionally, these data suggest that increased DKK1 production could be a key event in 
progression to RA and occurs early in the disease process. In order to conclusively prove this, 
further work would need to be undertaken that is beyond the scope of this project. 
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5 Transcriptomic analysis by Serial Analysis of Gene 
Expression  
 
5.1 Introduction  
 
Encouraged by the results of the proof of concept experiments, I set out to determine whether 
synovial fibroblasts from patients in the five clinical outcome groups displayed differential 
transcriptional profiles. Serial Analysis of Gene Expression (SAGE) is a high throughput 
Next Generation Sequencing (NGS) technique that enables sequencing of mRNA fragments 
in a parallel fashion. At the time these experiments were designed, this technology (using the 
SOLiD platform from Applied Biosystems) was available through a collaboration with the 
Molecular Development Department that had, together with the Technology Hub, taken over 
joint running of this platform. This, together with bioinformatics expertise available from the 
Technology Hub and Systems Science for Health initiatives, represented an attractive 
approach to experimental design and data analysis. However, this approach proved unfruitful 
and no conclusive results were obtained from these experiments. Nevertheless, the work 
undertaken has been included as a chapter in this thesis as a significant amount of time and 
resources were invested on this venture and key learning points emerged from this process.  
 
 
5.2 Serial Analysis of Gene Expression: The technology 
 
The ability to sequence DNA has been an important contribution to the advancement of all 
disciplines of biological sciences. The initial Sanger sequencing methods were developed in 
the 1970s (Sanger et al. 1975;Sanger et al. 1977) and became the sequencing methods of 
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choice for the subsequent 25 years still remaining in use today. Nevertheless, this field was 
revolutionised in the 2000s with the development of NGS technologies. A variety of NGS 
platforms exist that share a common advantage over the traditional Sanger methods: these 
high-throughput, large scale automated methods enable sequencing of large cDNA volumes in 
short periods of time at a fraction of the cost. NGS platforms include reversible terminator 
technology (Illumina), sequencing by ligation (SOLiD platform from Applied Biosystems), 
pyrosequencing (Roche) and semi-conductor sequencing (Ion Torrent and Proton). The major 
difference between them is the underlying sequencing method which lends each platform their 
characteristic advantages and disadvantages.  Regardless of the method used, NGS platforms 
offer diverse applications including whole genome sequencing, mRNA sequencing, targeted 
sequencing and chromatin immunoprecipitation sequencing. The choice of application is 
dictated by the biological question being addressed. Our goal was to determine the 
transcriptional profile of synovial fibroblasts at mRNA level and thus we used an mRNA 
sequencing pipeline.  
 
Serial Analysis of Gene Expression (SAGE) produces a snapshot of the mRNA populations in 
a given sample. A modified version of the original method developed by Velculescu and 
colleagues in 1995 (Velculescu et al. 1995) was used in the experiments described in this 
thesis (Matsumura et al. 2005). The SAGE method is based on two principles: (i) a short 
(27bp) nucleotide sequence, referred to as a tag, from a defined position within a transcript is 
enough to uniquely identify that transcript and (ii) the expression level of this transcript can 
be determined by the number of times this tag is identified. A simplified schematic 
representation of the SAGE method is shown in Figure 5.1.  
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Figure 5.1 Schematic representation of the SAGE method. mRNA is isolated from the samples of 
interest, fragmented, reverse transcribed and amplified creating cDNA libraries. The cDNA fragments 
are sequenced and the resulting reads are mapped to a reference nucleotide sequence database 
(RefSeq). The number of reads for a given transcript (i.e.  gene A) is quantified providing information 
about expression levels for that gene. Expression data from different samples can subsequently be 
compared during further data analysis.   
 
 
 
 
  
5.3 Serial Analysis of Gene Expression: Experimental design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
To ascertain whether differences in gene expression between synovial fibroblasts in the 
different outcome groups existed, transcriptomic analyses of cell lines in all five outcome 
groups were performed using the SAGE method.  
 
Read
Sample
RNA isolation and fragmentation
Sequencing by ligation
Reverse transcription and library creation
Quantitation & data analysis
Mapping of reads to RefSeqGene A
Read
27 bp tag
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In proposing that differences in gene expression between outcome groups would be identified, 
an assumption was made that any differences in expression between samples within each 
outcome group would not outweigh those differences between samples in different outcome 
groups. However, biological variation between samples of the same and differing outcome 
groups must be considered from the outset and, where possible, strategies to minimise this 
variation should be adopted. A way of strengthening experimental design in this context is by 
increasing the number of biological replicates (samples) in each outcome group. The optimal 
number of samples will vary depending on the biological variability associated with that 
sample. In practice, this consideration often needs to be balanced with cost implications 
associated with these technologies. An accepted approach is to use the same number of 
replicates as that used in prior microarray analysis experiments. Previous experience of 
synovial fibroblast transcriptome analysis in our group demonstrated that six samples per 
group were sufficient for statistical analysis of microarrays to identify differentially expressed 
genes. With this in mind and to increase the strength of the analyses, eight samples per group 
were selected and used in these experiments (making a total of 40 samples). To further 
minimise biological variability, clinical groups were made as homogeneous as possible by 
selecting patients and controls of similar ages, gender and disease duration within and 
between groups. A summary of the clinical characteristics of patients in each outcome group 
is shown in Table 5.1. The full clinical characteristics of these patients are shown in Table 
2.3. 
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Table 5.1 Summary of patient characteristics. 
Clinical Outcome Joint of origin Antibody 
positive 
Disease 
duration 
Gender 
(female) 
Mean age 
(yrs) 
Normal (n=8) 8 knee (100%) N/A N/A 4 (50%) 41.8 
Resolving (n=8) 7 knee (87.5%) 
1 ankle (12.5%) 
0 (0%) 3.8 wks 3 (37.5%) 45.1 
VeRA (n=8) 8 knee (100%) 3 (37.5%) 5.8 wks 5 (62.5%) 56 
Early RA (n=8) 8 knee (100%) 4 (50%) 66 wks 3 (37.5%) 57.8 
Established RA (n=8) 8 knee (100%) 5 (62.5%) 20 yrs 5 (62.5%) 55.6 
Antibody status defined as either RF or CCP positivity; N/A: not available; wks: weeks; yrs: years 
 
 
Synovial cells lines were created from samples from each of these patients. Subsequently, 
lines were cultured under the same conditions and to the same level of confluence and stored 
at passage five as cell pellets for subsequent SAGE processing and analysis. Sample selection, 
culture and preparation for SAGE experiments were performed by myself. RNA extraction 
was performed by myself and Mr Stephen Kissane (Senior Technician at the Technology 
Hub, University of Birmingham). Creation of cDNA, amplification and sample sequencing 
were performed by Mr Stephen Kissane as mandated by the Technology Hub.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
 
5.3.1 Sample quality control 
 
The quality and quantity of the RNA isolated from each sample are key to obtaining good 
quality libraries and sequencing data. Quality control was performed for each sample as 
specified in the materials and methods section. Briefly, RNA integrity was assessed by 
determining the 18S and 28S RNA fractions using gel electrophoresis run in a chip. In the 
absence of RNA degradation, 18S and 28S appear as two distinct electrophoretic bands. If 
degradation has occurred, other bands appear between the two ribosomal bands and before the 
18S band. In addition to visualising the bands, the software associated to the chip calculates 
5-136 
 
an RNA integrity number (RIN) using an algorithm that takes into account not only the ratio 
between ribosomal bands but also the presence of degradation products. RIN values are 
optimal between 8.0 and 10.0. RNA quantity was measured using a Qubit fluorometer 
(Invitrogen) as described. 0.5µg of RNA per sample were used. The mean measured RNA 
amount and RIN value for each sample are shown in Appendix Table 9.4. 
 
Next, cDNA library creation and sequencing was performed as specified in the methods 
section. Following sequencing, a large number of reads per sample were obtained that 
required mapping to the genome of reference and further analysis.  
 
 
5.4 SAGE data: Analysis 
 
Mapping of reads to the genome (also referred to as alignment) and data analysis were 
performed by Dr Paul Badenhorst (Senior Lecturer, Molecular Development Department, 
University of Birmingham). Sequenced reads were mapped to the reference nucleotide 
sequencing database (RefSeq) using the SOLiD SAGE mapping tool software. A brief 
description of the analyses undertaken is given here.  
 
 
5.4.1 Read alignment and data normalisation 
 
Sequencing of a given sample generates a list of all the reads observed in that sample 
(representing transcripts of the genome of origin) and the number of times each of those reads 
is observed (counts). To identify the transcript of origin of a given read, mapping to a 
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reference genome must be performed. The SOLiD SAGE platform we used typically produces 
reads that are 50-75bp in length. Alignment of such short sequences to the whole genome can 
be challenging as there may be a number of equally likely places where these short reads 
might originate from. At the same time, if perfect alignment is performed, biological variation 
(i.e. single nucleotide polymorphisms) will not be identified. Thus, a certain degree of 
mismatch tolerance must be allowed during alignment. One to three mismatches are 
commonly allowed during read alignment. However, with increasing number of mismatches 
the number of mapped reads is increased but the accuracy of mapping is decreased. Up to two 
mismatches were allowed during mapping of these experiments. The output files generated 
following alignment contained the list of each tag, its frequency of occurrence, its RefSeq 
identifier number and (where applicable) a brief description of the identified gene. Three 
transcript categories were identified and represented by three different RefSeq identifier 
numbers known as accession numbers. These were: NM accession numbers (representing 
mRNA products), NR accession numbers (representing non coding RNA) and XR accession 
numbers (representing predicted non coding RNA). The expression levels of each of these 
transcripts were given by the frequency of their occurrence (number of counts).  
 
In order for the counts of a given transcript to represent expression levels of that transcript 
two conditions must be fulfilled: (i) the amount of input material (i.e. mRNA) must be the 
same for all sequenced samples and (ii) the size of the cDNA library must be the same in all 
samples so that the total number of mapped reads is the same in all samples. The first of these 
conditions is achieved during library preparation by sampling equal amounts of material in all 
samples. It is thus essential that library preparation is accurate as this is a common source of 
error in sequencing experiments. As the size of the total number of mapped reads often differs 
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between samples following sequencing experiments, normalisation to total read count is 
usually performed (Dillies et al. 2013). Using EdgeR Bioconductor, data were normalised to 
total read count by applying the following formula to each sample:  
 
𝑛
𝑟
 ?̅?  
where 𝑛 represents the number of counts for a given read, 𝑟 the total number of reads in that 
sample and ?̅? the mean total read count across all samples in the dataset. Following 
normalisation, the counts obtained were a linear representation of the expression levels of a 
given transcript. Following total count normalisation two samples were identified as outliers 
within their given groups as their expression patterns differed significantly from those of the 
remaining samples in their groups. These were: one sample in the VeRA group (BX005) and 
one sample in the Early RA group (BX077). These samples were excluded from subsequent 
differential expression analysis.  
 
 
5.4.2 Differential expression analysis 
 
 
Data analysis, like experimental design, is determined by the biological question being 
addressed. Given the large number of samples and groups examined in the SAGE 
experiments, a variety of analyses could potentially be conducted. Differential expression 
analysis was thus focused on addressing two questions: (i) what are the differences in 
transcriptional profile between very early RA and resolving disease? In other words, what are 
the key genes responsible for the resolution of early inflammatory arthritis? (ii) do RA 
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synovial fibroblasts display the same transcriptional characteristics in early and late disease? 
A schematic representation of the biological question and the clinical outcome groups to be 
compared during analyses is shown in Figure 5.2. 
 
 
 
Figure 5.2 Schematic representation of the proposed differential expression analyses. To identify 
key genes involved in the resolution of early inflammatory arthritis, transcriptomic data from 
Resolving and VeRA groups should be compared. To unravel genes responsible for progression to RA 
and disease chronicity such comparison should involve, VeRA, Early RA and Established RA groups.   
 
Prior to undertaking differential expression analysis, data were visualised using principal 
component analysis (PCA) to ascertain the degree of clustering within outcome groups. A 
PCA plot representative of these analyses is shown in Figure 5.3. Clear clustering of 
Established RA samples along the second component (or dimension) was observed. A degree 
of clustering of VeRA and Early RA samples along the first dimension was also observed. 
However, no clustering of Normal samples, which appeared to be distributed randomly along 
the first dimension, was seen. The lack of clustering raised concerns about the high degree of 
(i) What are the key genes involved in the resolution of early inflammatory arthritis? 
Resolving VeRA
vs.
(ii) What genes are responsible for progression to RA and disease chronicity?
VeRA Early RA Established RA 
vs. vs.
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heterogeneity that may be present in the samples of this outcome group. As a result of this 
observation, all Normal samples were excluded from subsequent data analyses.  
 
 
 
 
Figure 5.3 Principal component analysis plot of Normal, VeRA, Early RA and Established RA 
samples. Clustering of Established RA samples along the second dimension is seen. Some clustering of 
Early RA and VeRA samples along the first dimension is also observed. Normal samples are randomly 
distributed along the first dimension. Samples are represented by numbers (Normal:1-8, VeRA: 9-16, 
Early RA: 17-24, Established RA: 25-32) and surrounded by coloured circles denoting outcome group 
of origin (grey: Normal, orange: VeRA, red: Early RA, purple: Established RA).   
 
 
Next, a general linear model was built to identify significantly differentially expressed 
transcripts between outcome groups. Multiple testing correction was performed and a false 
discovery rate (FDR) of 0.01 was set. The results of these analyses are discussed below, 
Normal
VeRA
Early RA
Established RA
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starting with the analysis of Resolving versus RA persistent early inflammatory arthritis 
(Resolving vs. VeRA comparison). Data mining, pathway analysis and target validation were 
performed by myself. 
 
5.5 Differential expression data analysis: Results 
 
5.5.1 Resolving versus VeRA comparison 
 
Principal component analysis of the transcriptional profile of synovial fibroblasts in the 
Resolving and VeRA groups revealed differences along the first principal component (Figure 
5.4).   
 
Figure 5.4 Principal component analysis plot of Resolving and VeRA samples. Separation between 
samples in each outcome group is seen along the first principal component. Each sample is 
represented by a number (Resolving: 1-8, VeRA: 9-15). Each number is surrounded by a green 
(Resolving) or orange (VeRA) circle representing the outcome group to which they belong.   
VeRA
Resolving
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5.5.2 Data mining strategy 
 
 
A total of 701 transcripts were differentially expressed between both groups (FDR: 0.01).  To 
reduce this data set to a manageable set of key differentially expressed genes for validation, a 
series of data mining strategies was employed. These strategies were employed independently 
and results obtained by all three were combined to select a final set of targets for quantitative 
real time PCR validation. As the purpose of data mining was to identify targets for further 
validation at mRNA and protein levels, non-protein coding RNA and predicted non-coding 
RNA transcripts were excluded from this analysis. In total, 564 transcripts representing 
protein coding genes were analysed.  
 
First, differentially expressed genes were sorted by p value (lowest to highest) and fold 
change (highest to lowest). An arbitrary cut off of 100 was set and the top 100 genes were 
further investigated. Second, a “candidate gene” approach was used whereby I reviewed the 
description of all differentially expressed transcripts and those that seemed interesting in the 
light of published literature of RA and synovial fibroblasts were selected (i.e. CXCL16, 
TNFRSF9). An example of the typical results obtained using these two approaches is shown 
in Figure 5.5. Third, differentially expressed genes were classified into biological categories 
using pathway analysis.  
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Figure 5.5 Data mining strategy. Screenshots showing: A, Top 100 (only top 51 in this screenshot) 
differentially expressed genes ranked by p value and fold change. B, Candidate gene approach where 
functionally interesting genes have been selected for further consideration as potential validation 
targets.  
A
B
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5.5.3 Pathway analysis 
 
 
Using the DAVID functional annotation tool (open online resource available at 
http://david.abcc.ncifcrf.gov/) categorisation of genes into biological groups was performed. 
All 564 differentially expressed transcripts were entered into the software. These transcripts 
were functionally annotated and grouped into functional pathways using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG). Eight functional pathways were identified. 
These pathways related to cellular functions (apoptosis, focal adhesion and tight junctions), 
malignancies (chronic myeloid leukaemia, prostate cancer and melanoma) and cell signalling 
(insulin and TGF beta signalling pathways). Once identified, each pathway was individually 
visualised and those genes within the pathway that had arisen from the list of differentially 
expressed transcripts between Resolving and VeRA synovial fibroblasts were identified and 
selected for further assessment as potential validation targets (Figure 5.6). 
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Figure 5.6 Pathway analysis. Sample image showing apoptosis pathway. Each green square 
represents a gene in the pathway. Those genes marked with a red star arise from the list of 
differentially expressed genes between Resolving and VeRA synovial fibroblasts. For each   pathway, 
the starred genes were identified and added to the final list of potential validation targets. 
 
 
5.6 Target validation 
 
 
Using a combination of these three data mining strategies, 25 protein coding genes were 
selected for final target validation. The protein products of these genes and a description of 
their function are shown in Table 5.2. The fold change in expression levels between 
Resolving and VeRA lines are also given together with the statistical significance of the 
change expressed as p value. All targets were overexpressed in the VeRA compared to the 
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Resolving group. Primer pairs for these targets were designed and quality control tested as 
specified in the methods section.   
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Table 5.2 Gene targets selected for PCR validation.  
Symbol Product Description/Function Fold difference P value 
CAMLG Calcium signal modulating cyclophilin ligand B and T cell homeostasis -4.365 5.04E-09 
CHRD Chordin Bone morphogenetic protein antagonist -4.499 1.12E-09 
COMP Cartilage oligomeric protein Non-collagenous ECM component -4.504 2.41E-06 
COL5A2 Collagen type 5 alpha 2 Collagen assembly regulator -4.570 6.03E-06 
DFFB DNA fragmentation factor B DNA fragmentation & chromatin condensation -4.935 2.32E-06 
E2F2 Transcription factor E2F2 Tumour suppressor & cell cycle regulator -4.631 8.69E-09 
F11R Junctional adhesion molecule A Regulator of tight junction assembly -4.571 6.31E-06 
FGF5 Fibroblast growth factor 5 Oncogene  -4.667 6.35E-06 
FGFR1 Fibroblast growth factor receptor 1 Receptor for several of FGF ligands  -2.651 1.13E-04 
IRAK3 IL1 receptor associated kinase Negative regulator of TLR signalling -4.176 6.09E-07 
cMET Hepatocyte growth factor receptor Proto-oncogene -5.515 2.62E-07 
MDM2 Mouse double minute 2 homolog Negative regulator of p53 -4.038 2.66E-07 
OSMR Oncostatin M receptor Promotes EMT transition -4.504 4.72E-09 
PAK2 P21 activated kinase Apoptosis regulator, cell migration -4.410 6.15E-07 
PDPK1 3-phosphoinositide dependent protein kinase-1 Activator of the AKT/PKB pathway -4.137 2.66E-07 
PIK3CD PI 3 kinase catalytic subunit delta Growth, proliferation, differentiation, motility -4.247 4.37E-06 
PRKCI Protein kinase C iota Negative regulator of apoptosis -2.555 8.82E-05 
PTK2 Protein tyrosine kinase 2 Focal adhesion -2.717 1.61E-04 
RAB3B Ras related protein 3B Oncogene -2.578 5.09E-05 
SNX1 Sorting nexin 1 Epidermal growth factor expression regulator -4.410 4.13E-06 
SOCS3 Suppressor of cytokine signalling 3 Negative regulator of STAT signalling -2.922 7.21E06 
TGFBR1 Transforming growth factor beta receptor 1 TGF beta signalling transduction -2.399 1.79E05 
TRAIL-R4 TRAIL receptor 4 Inhibitor of TRAIL induced apoptosis  -2.342 4.52E-05 
VAMP A Vesicle associated membrane protein A Regulation of tight junctions -2.579 5.09E-05 
XIAP X linked inhibitor of apoptosis Regulation of apoptosis, invasion & proliferation -2.741 8.12E-05 
Fold difference refers to Resolving vs. VeRA
5-148 
 
5.6.1 Real time PCR: Results 
 
Real time quantitative PCR was used for independent target validation, with 21 out of the 25 
primers designed passing quality control testing. The expression levels of these 21 genes were 
tested in all eight samples in each outcome group (Figure 5.7). Levels of expression of TNF 
related apoptosis inducing ligand receptor 4 (TRAIL-R4) were significantly higher in the 
VeRA samples than in the Resolving ones (median: 0.21 vs. 0.05, p=0.04; fold difference: 
4.4). No statistically significant differences were observed between groups in the expression 
of the remaining genes. Whilst the observed validation yield (1 out of 21) was lower than 
expected, given that TRAIL-R4 seemed a plausible and attractive target, subsequent efforts 
were directed to its validation at protein level.  
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Figure 5.7 Target validation. Expression levels of 21 selected genes were assessed by PCR in 
Resolving (n=8) and VeRA (n=8) samples. The expression of TRAIL-R4 was significantly higher in 
VeRA samples than in Resolving ones (median: 0.21 vs. 0.05, p=0.04). Expression levels normalised 
to GADPH using the 2
-dCt
 method. Data shown in scattered dot plots where horizontal lines represent 
medians. Differences in expression between groups assessed with Mann-Whitney test. *p<0.05. 
 
 
5.6.1.1 TRAIL-R4 validation 
 
 
TRAIL-R4 (also known as TRAIL decoy receptor 2 (TRAIL-DcR2)) is a member of the 
TRAIL family of receptors that in contrast to the better studied TRAIL receptors 1 and 2, has 
an inhibitory role in TRAIL induced apoptosis (Degli-Esposti et al. 1997).  
 
TRAIL induced apoptosis of RA synovial fibroblasts has been previously investigated with 
conflicting results. Whilst some authors observed apoptosis rates of up to 80% following 
TRAIL stimulation of RA synovial fibroblasts (Ichikawa et al. 2003), others failed to 
demonstrate apoptosis of these cells upon TRAIL stimulation (Perlman et al. 2003). The 
potential role of TRAIL-R4 has not been studied in this context and thus represented a novel 
and attractive approach. The observation that TRAIL-R4 was overexpressed by VeRA 
samples suggested that inhibition of TRAIL induced apoptosis might be an early event in the 
development of RA and might contribute to the failed resolution of inflammatory arthritis.   
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TRAIL-R4 expression levels were determined by flow cytometry as specified in the methods 
section. To avoid cleavage of this cell surface receptor, an EDTA based cell dissociation 
buffer was used instead of trypsin for cell detachment prior to cytometry. The TRAIL-R4 
expressing hepatic epithelial like cell line (AKN-1) was used as positive control. The three 
lines that showed highest TRAIL-R4 expression in the VeRA group (BX014, BX013 and 
BX063) and the three that demonstrated lowest TRAIL-R4 expression in the Resolving group 
(BX038, BX033 and BX010) were selected for protein validation. The results of these 
experiments are shown in Figure 5.8. TRAIL-R4 expression was observed in the positive 
control as expected. The percentage of synovial fibroblasts expressing TRAIL-R4 in the 
Resolving and VeRA groups was the same (2.5% and 2.6% respectively) and did not differ 
from values obtained for the isotype control (2.3%), indicating no TRAIL-R4 surface 
expression by synovial fibroblasts in either group.  
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Figure 5.8 TRAIL-R4 protein expression assessed by flow cytometry. Levels of TRAIL-R4 were 
determined in Resolving (n=3) and VeRA (n=3) samples. A, Representative flow cytometry plot 
showing TRAIL-R4 expression in positive control samples but not in synovial fibroblasts from either 
group. Test samples shown in light purple, isotype control shown as a grey line. B, Graphical 
representation of results: the percentage of TRAIL-R4 positive cells did not differ between isotype 
control, Resolving and VeRA samples. Statistically significant differences in percentage of positive 
cells were seen between the positive control group and all other groups. Data represented as 
meanSD. One way ANOVA, ***p<0.001. 
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Although mRNA expression is not always a reflection of protein production, the inability to 
validate TRAIL-R4 at protein level together with the low validation yield at mRNA level 
raised suspicions regarding the quality, accuracy and validity of the result obtained from the 
SAGE experiments. A troubleshooting process was consequently started to determine any 
potential sources of errors.   
 
 
5.7 SAGE experiments: Troubleshooting 
 
Potential and not mutually exclusive sources of error considered included: 
1. Errors during library amplification. For example, if clonal artefacts occurred during library 
amplification, sequencing of such artefacts rather than “real” sample tags could have taken 
place leading to inaccurate results.  
2. Errors during sequencing and mapping of reads to the reference genome.  
3. Errors introduced during data analysis: for example during statistical analysis of 
differentially expressed genes or during application of data mining strategies. 
4. Errors during PCR validation.  
 
This list is by no means exhaustive but used as an illustration of potential sources of bias. It 
also illustrates how identifying some of these biases may not be entirely straightforward. The 
aim of the troubleshooting exercise was to ascertain whether the SAGE experiment results 
were accurate or whether alternative methods of acquiring transcriptional profiles (for 
example by undertaking microarray experiments) should be sought. To ascertain this, a final 
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attempt to validate SAGE data was made based on observations made by Dr Paul Badenhorst 
during data analysis.    
 
During PCA analysis it had been noted that samples from the Established RA group quite 
clearly clustered away from the remaining samples in the data set. Concerns arose that these 
may be the only samples that were biologically different from a transcriptional profile 
perspective and that differences between other groups had artefactually arisen during 
statistical analysis (Type I error). Under this premise the only samples that were biologically 
different from the rest were those belonging to the Established RA group. Thus it followed 
that if the data obtained from SAGE experiments were correct and regardless of whether 
spurious differences had been identified between other groups (i.e. Resolving and VeRA), 
robust differences between Established RA and other groups existed and could be 
independently confirmed.  
 
To test this hypothesis I attempted independent validation by PCR of differentially expressed 
genes between the Resolving and Established RA group. The list of differentially expressed 
transcripts between these groups was ranked by p value (lowest to highest) and fold change 
(highest to lowest). Protein coding genes with the highest statistical confidence and highest 
fold change were selected as PCR targets to improve the yield of PCR validation. This 
strategy yielded the following targets: beta actin (-actin), 18S ribosomal RNA (18S), 
calcium binding protein P22 (CHP), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
hepatocyte growth factor receptor (cMET), 3-phosphoinositide dependent protein kinase-1  
(PDPK1) and Ras related protein 3B (RAB3B). 
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Reviewing these targets, a striking observation was made: three genes traditionally considered 
as reference housekeeping genes (-actin, 18S and GAPDH) were differentially expressed 
between outcome groups. If independently verified by PCR, this may be the reason for the 
failed attempt to validate SAGE data at PCR level as quantitation of PCR data was done 
relative to GAPDH. Hence, efforts were directed to determine an optimal housekeeping gene 
for quantitation of PCR data on synovial fibroblasts.  
 
 
5.7.1 Determining an optimal housekeeper 
 
The relative quantitation method 2-delta Ct method (2
-dCt
) was used for the quantification of 
results obtained from PCR experiments. Here, expression levels of the gene of interest are 
expressed relative to expression levels of a reference housekeeping gene. An optimal 
housekeeping gene will be expressed at constant levels in all cells under study and under 
different conditions. In practice this means that the choice of optimal housekeeper depends on 
the cells being studied. Determining an optimal housekeeper should thus be an integral part of 
PCR quantitation.  
 
To determine expression levels of housekeeping genes a comparative method could not be 
used as a circular problem would arise whereby expression levels of one housekeeping gene 
would be calculated relative to another housekeeping gene with no knowledge of the gold 
standard. To overcome this limitation expression levels were assessed in two ways: by 
looking at the distribution of cycle threshold (Ct) values and by calculating the average fold 
change in expression from the mean. First, the Ct values of all samples for a given gene were 
5-156 
 
plotted to assess their distribution (displaying median, 25
th
 and 75
th
 percentile and range). An 
optimal housekeeper would be one that showed minimal variation in its distribution across all 
samples. It is important to note here that although Ct values will vary with RNA amounts, by 
analysing all samples in the same experiment, the effect of differing RNA amounts would be 
the same in all genes. Second, average fold changes in expression from the mean were 
calculated. At a PCR reaction efficiency of 100%, 1 cycle (expressed as Ct in real time PCR) 
corresponds to a 2 fold change in gene expression (as PCR is an exponential reaction: gene 
expression is 2
n
 where n is the number of cycles=Ct). An optimal housekeeper will not have 
more than a two-fold change in expression between samples (corresponding to one PCR 
cycle) and the smallest maximum fold change. Variability in gene expression was thus 
expressed as average fold change from the mean and maximum fold change representing 
standard deviation and ranges respectively (Dheda et al. 2004).  
 
 
Commonly used housekeeping genes were selected for the experiment. These included: -
actin, 18S, GAPDH, ubiquitin C (UBC), hydroxymethylbilane synthetase (HMBS), ribosomal 
protein L13a (RPL13a), 2-microglobulin (B2M), hypoxanthine phosphorybosyltransferase 
1(HPRT1) and succinate dehydrogenase complex subunit A (SDHA). Some of them (-actin, 
GADPDH and 18S) had been identified as differentially expressed between Resolving and 
Established RA synovial fibroblasts during SAGE analysis.  
 
Results are shown in Figure 5.9. When variability in gene expression was plotted as a 
distribution of Ct values, small variation was seen for 18s, GAPDH, UBC and RPL13with 
larger variation being observed for -actin and SDHA. However, it was difficult to determine 
which housekeeper showed the least variation on the basis of the distribution alone. Analysis 
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of fold change data gave an answer to this. Genes displaying fold changes of 2 included 18S, 
GAPDH, UBC, HMBS, and RPL13a. Of these GAPDH showed the lowest maximum fold 
change (1.7) and was thus selected as optimal housekeeper for subsequent PCR quantitation.  
 
Figure 5.9 Housekeeping genes real time PCR results. Expression levels of housekeeping genes were 
assessed in Normal (n=3), Resolving (n=3), VeRA (n=3), Early RA (n=3) and Established RA (n=3) 
samples. Top graph: the distribution of Ct values for each gene is shown in a box and whisker plots 
(box: median, 25th and 75th percentile; whiskers: maximum and minimum values). Genes showing 
least variation in distribution include 18S, GAPDH, UBC and PRL13a. Bottom graph: variability in 
gene expression represented in bar graphs where the columns represent average fold change from the 
mean and the error bars the maximum fold change. Horizontal discontinued blue line represented the 
cut off fold change value of 2. GAPDH displays the lowest variability followed by UBC, RPL13a and 
18S. For gene abbreviations see text. 
18
S
G
A
D
P
H
U
B
C
H
M
B
S
R
P
L
13
a
B
2M
B
ac
ti
n
H
P
R
T
1
S
D
H
A
0
1 0
2 0
3 0
4 0
C
t 
v
a
lu
e
18
S
G
A
D
P
H
U
B
C
H
M
B
S
R
P
L
13
a
B
2M
B
ac
ti
n
H
P
R
T
1
S
D
H
A
0
2
4
6
8
1 0
F
o
ld
 c
h
a
n
g
e
5-158 
 
5.7.2 Resolving versus Established RA comparison 
 
In addition to aiding selection of an optimal housekeeper, these experiments demonstrated 
small variation on two of the housekeepers identified as differentially expressed between 
Resolving and Established RA samples by SAGE (18S and GAPDH) and marginally larger 
variation in another (-actin: average fold change from the mean: 2.4, maximum fold 
change:3). These observations contradicted the SAGE results and suggested that the results 
obtained from SAGE experiments might not be accurate. Nevertheless to fully confirm this, 
expression levels of putative differentially expressed genes between Resolving and 
Established RA samples derived from SAGE data were assessed by PCR. No differences in 
gene expression between groups were seen for any of these genes (Figure 5.10).  
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Figure 5.10 Assessment of differentially expressed genes between Resolving and Established RA. 
Expression levels of the top 8 genes identified as differentially expressed between both groups were 
assessed by PCR in Resolving (n=8) and Established RA (n=8) samples. Expression levels normalised 
to GADPH using the 2
-dCt
 method with the exception of GAPDH that was normalised to 18S. Data 
shown in scattered dot plots where horizontal lines represent medians. No differences in expression of 
any of the genes were seen between groups. Differences in expression between groups assessed with 
Mann-Whitney test.  
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5.8 SAGE data: discussion  
 
The results obtained from the SAGE experiments were not possible to validate and appeared 
to contradict unbiased assessment of housekeeping gene expression. It was therefore decided 
that conclusions regarding the transcriptomic profile of the samples analysed could not be 
drawn. It is likely that a combination of errors occurred during these experiments that 
rendered these data unusable. It is worth noting that in the twelve months that have passed 
since these experiments were undertaken this platform has been abandoned at the University 
of Birmingham in favour of the Illumina system that provides higher coverage and more 
accurate results. This is in keeping with current trends in the sequencing field where the 
reversible terminator technology platform developed by Illumina is superseding other 
platforms.  
 
A number of learning points emerged from this process. The importance of determining an 
optimal housekeeping before embarking on quantification of PCR data is perhaps one of the 
most valuable ones. We also learnt that when outsourcing experiments, it is important to 
ensure that strict quality control is applied to all experimental steps by the external provider. 
The ability to troubleshoot and identify any deviation from correct protocols should also be 
available as well as accountability for such deviations.  
 
The failure of this approach meant that an alternative method of performing transcriptomic 
analyses had to be sought.  
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6 Transcriptomic analysis using microarray technology 
 
6.1  Introduction  
 
Given the difficulties encountered with SAGE technology, an alternative method for 
undertaking transcriptomic analysis was sought. Microarray technology has long been 
established as a powerful method for the study of gene expression (Trevino et al. 2007). 
Microarrays produce a snapshot of the transcriptome of a given sample with high accuracy 
and resolution and allow comparisons of gene expression patterns between samples. At the 
time these experiments were designed, experience of microarray use in our group included the 
transcriptomic analysis of paired synovial, dermal and bone marrow fibroblast samples in RA 
and osteoarthritis and the transcriptomic analysis of macrophages from wild type and dual 
specificity protein phosphatase 1deficient mice. All experimental work and analyses described 
in this chapter were carried out by myself except where indicated.  
 
 
 
6.2 Microarray technology 
 
A two colour microarray was used as described in the materials and methods section. 
Hybridisation of samples and scanning of microarrays were performed by an external 
provider (Oxford Gene Technology Ltd, UK). Briefly, mRNA was reverse transcribed to 
cDNA and labelled with a fluorescent dye: Cy3 for the labelling of test samples (emitting 
green fluorescence on excitation) and Cy5 (emitting red fluorescence on excitation) for the 
labelling of the reference cDNA control (Stratagene human reference DNA). Equal amounts 
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of both test and control cDNA were simultaneously hybridised onto arrays containing 50,599 
long (60-mer) features. After hybridisation and scanning, green/red fluorescence ratios were 
obtained that represented the expression levels of each feature in the test samples relative to 
the controls.  
 
 
6.3 Microarray technology: Experimental design  
 
The importance of biological replicates within outcome groups to strengthen experimental 
design has already been discussed in the context of SAGE experiments. A study of the effect 
of replication on microarray experiments suggested that a minimum of five replicates per 
condition should be used to obtain reliable statistical results (Pavlidis et al. 2003). Previous 
experience of human synovial fibroblast transcriptome analysis in our group demonstrated 
that six samples per group were sufficient for statistical analysis of microarrays to identify 
differentially expressed genes. Thus, we set six as the minimum number of samples per group 
to be analysed but decided to study as many samples as available in each outcome group to 
increase representativeness within groups. At the same time, we chose not to include samples 
from the Early RA group (disease of >3 months duration at presentation) in the analysis. This 
helped in reduction of heterogeneity in the RA group whilst still enabling us to address the 
two main research questions: (i) what are the differences in transcriptional profile between 
very early RA and resolving disease? (ii) do RA synovial fibroblasts display the same 
transcriptional characteristics in early and late disease? 
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In contrast to the SAGE experiments, microarray experiments were performed on 
unstimulated samples as well as parallel samples exposed to TNF (10ng/ml) for 24 hours. 
The rationale for this approach was to study resting cultured synovial fibroblasts as well as 
fibroblasts that had been cultured in a pro-inflammatory environment that resembled the 
inflammatory milieu seen in the synovium in inflammatory joint disease. Moreover, the 
addition of these samples to the experimental design allowed us to address a third research 
question: (iii) what effect does TNF stimulation have on the transcriptomic profiles of 
synovial fibroblast in different outcome groups?  
 
A schematic description of the four outcome groups studied is shown in Figure 6.1. The 
biological questions being addressed and the clinical outcome groups to be compared during 
differential expression analyses are shown in Figure 6.2. A summary of the clinical 
characteristics of patients in each outcome group is shown in Table 6.1. The full clinical 
characteristics are shown in Table 2.4. 
 
 
 
Figure 6.1 Representation of the four groups compared in microarray experiments. Samples in 
Normal (n=8), Resolving (n=16), VeRA (n=14) and Established RA (n=8) groups were compared. 
The main differentiating attributes between groups are shown in the figure. Parallel unstimulated and 
TNF stimulated samples were processed.  
Normal Resolving VeRA Established RA 
• Treatment naïve
• 3/12 symptoms
• Persistence as RA
• Multi treated
• Longstanding RA
• Treatment naïve
• 3/12 symptoms
• Spontaneous resolution
• Non-inflammatory 
joint symptoms
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Figure 6.2 Schematic representation of the proposed differential expression analyses. To identify 
key genes involved in the resolution of early inflammatory arthritis, transcriptomic data from 
Resolving and VeRA groups will be compared. To unravel genes responsible for differences between 
early and late RA analyses will involve VeRA and Established RA groups. To compare responses to 
TNF stimulation between groups, differential expression analysis of unstimulated and TNF stimulated 
samples in each group will be performed.    
 
 
 
 
 
Table 6.1 Summary of patient characteristics. 
 Normal 
(n=8) 
Resolving 
(n=16) 
VeRA 
(n=14) 
Established RA 
(n=8) 
Mean age (yrs) 43.6  45.6 52.5 55.6 
Female gender  4 (50%) 5 (31%) 7 (50%) 5 (63%) 
Joint of origin 8 Knee (100%) 12 Knee (75%) 
4 Ankle (25%) 
9 Knee (64%) 
2 Ankle (14%) 
3 MCP (22%) 
8 Knee (100%) 
Antibody positive 0 (0%) 0 (0%) 8 (57%) 6 (75%) 
Mean DAS28ESR  - 3.8 4.8 5.9 
Disease duration N/A 5 weeks 5 weeks 20 years 
Antibody status defined as either RF or CCP positivity; N/A: not available. 
(i) What are the key genes involved in the resolution of early inflammatory arthritis? 
Resolving VeRA
vs.
(ii) What genes differentiate early from late RA?
VeRA Established RA 
vs.
(iii) What effect does TNF stimulation have on different outcome groups? 
Unstimulated
vs.
TNF stimulated
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Sample preparation and RNA extraction for microarray experiments were performed as 
specified in the methods section. All samples analysed were at passage 3.  
 
 
6.3.1 Sample quality control 
 
RNA isolation was performed prior to outsourcing of samples for microarray processing. The 
initial RNA isolation and clean up experiment is described here.  
 
Specific RNA quantity and quality requirements were determined by the external provider. 
RNA quality was determined using the absorbance method by the 260/280 and 260/230 
indexes. Requirements per sample were as follows: 500ng of total RNA, 260/280 ratio >1.8 
and 260/230 ratio >1.5. 
 
In the initial experiment, RNA was isolated from four samples and its quantity and quality 
measured with the Nanodrop 2000 spectrophotomer (Table 6.2). Whilst the amount of RNA 
recovered was sufficient in all cases and all samples displayed a 260/280 ratio >1.8, two of 
them had unsatisfactory 260/230 ratios (below the 1.5 cut off).   
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Table 6.2 Measured RNA concentration, volume and 260/280 and 260/230 ratios of initial four 
samples. Blue rows indicate samples that achieved the quality cut off, red ones represent samples that 
did not. 
Sample Total RNA 
Concentration 
(ng/µl) 
Volume (µl) 260/280 ratio 260/230 ratio 
1 128.6 30 2.04 2.03 
2 138.5 30 2.04 1.73 
3 158.2 30 2.05 0.84 
4 152.7 30 2.08 0.33 
 
 
 
These results led us to perform an additional cleaning step after RNA isolation to improve 
sample quality. We used a column based cleaning kit that consisted of a unique cleaning 
buffer that was added to each sample together with ethanol to create optimal binding 
conditions and was run on a fast spin column. After cleaning, the 260/230 ratios improved to 
2.22 and 2.04 (samples 3 and 4 respectively). This cleaning step was applied to all samples to 
ensure consistency in sample preparation. The total RNA concentration and ratios for all 
samples are represented in Appendix Table 9.5.  
 
 
6.4 Microarray experiments: Data analysis 
 
Following processing of samples by the external provider, microarray data were analysed 
using a commercial software package (Partek Genomics Suite, version 6.6) and the publicly 
available Genesis platform and Ensembl genome database project website.  
 
Before describing data analyses and results, it is important to highlight the following. Agilent 
probes are designed to detect specific transcripts. Assuming that they function correctly, 
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increased signal intensity from a given probe indicates an increased level of expression of a 
specific transcript. Throughout this chapter I will refer to changes in expression of transcripts 
rather than the more correct, but awkward, description of changes in probe signal intensity. 
 
 
6.4.1 Microarray data analysis with Partek Genomic Suite 
 
Data analyses were performed using the gene expression workflow in Partek Genomic Suite. 
Agilent human gene expression microarray raw data files were imported into Partek Genomic 
Suite using the green/red ratio input parameter and applying log2 transformation to the output 
values. The green/red ratio was used to ensure sample data (green) were normalised to 
reference data (red). A log2 transformation was applied for ease of interpretation of ratio 
values <1. Next, attributes specifying the characteristics of the patients from whom the 
samples were obtained were added to each sample. These included: age, gender, clinical 
diagnosis (outcome group), joint of origin of the sample and antibody status. Exploratory data 
analysis was performed by means of principal component analysis (PCA), histogram plots 
and quality control metrics. Differential expression analyses were done with the analysis of 
variance (ANOVA) technique.  A one way fixed non-nested ANOVA model was built on the 
entire dataset to identify differentially expressed transcripts according to different attributes. 
The significance of the differential expression was given by a p value. A false discovery rate 
(FDR) of <0.05 was set to control for multiple testing using the Benjamini Hochberg method. 
A fold change for the difference in gene expression was also obtained. Antibody status was 
found not to contribute to variance in the dataset and was thus not included in the ANOVA 
model. 
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6.5 Microarray experiments: Unstimulated samples results 
 
6.5.1 Principal component analysis 
 
The PCA plot of all unstimulated samples, colour coded according to clinical outcome group 
of origin, is shown in Figure 6.3. Although some degree of clustering was seen amongst 
samples in the Normal group, clustering according to outcome group was not clear cut. This 
indicated that outcome group was not responsible for the biggest variation in the dataset, with 
other attribute or attributes being responsible for this. PCA data were visualised according to 
age, gender, antibody positivity and joint of origin in turn, but no clear clustering could be 
seen in the PCA plots according to any of these attributes (Figure 6.4).   
 
 
 
 
 
6-169 
 
Figure 6.3 PCA plot of Normal, Resolving, VeRA and Established RA unstimulated samples (two 
different rotation angles of the same plot shown). A degree of clustering was seen amongst Normal 
samples although clustering was not clear cut. This suggested that attribute or attributes other than 
clinical diagnosis contributed to the biggest variation in the dataset. Normal (n=8), Resolving (n=15), 
VeRA (n=13) and Established RA (n=7). 
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Figure 6.4 PCA plots of unstimulated samples visualised according to other attributes. Samples 
represented according to Age, Gender (Female n=20, Male n=23), Antibody status (Positive defined 
as positive to either RF or CCP; Positive n=12, Negative n=8, only VeRA and Established RA 
samples depicted) and joint of origin (Ankle n=6, Knee=35, MCP=2). No clustering was seen 
according to any of the attributes. MCP: metacarpophalangeal joints. 
 
Age Gender
Joint of originAntibody status
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The sources of variation in the dataset were plotted in a pie chart (Figure 6.5). Clinical 
diagnosis (outcome group) accounted for 24% of the variation, joint of origin for 7% and 
gender and age for 1% each. Antibody status did not have an effect in the observed variation. 
67% of the variation was unexplained suggesting that other attributes not included in the 
model were responsible for a significant amount of data variation. This unexplained variation 
includes inherent inter-individual biological variation between samples.  
 
 
 
Figure 6.5 Sources of variation in the unstimulated samples data set. Pie chart representing sources 
of variation. Clinical diagnosis (outcome group) accounted for 24% of the variation, joint of origin for 
7% and age and gender for 1% each. 67% of the variation remained unexplained. Unexplained 
variation most likely represents inter-individual biological variation.   
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6.5.2 Differential expression analysis 
 
 
To identify differentially expressed transcripts according to different attributes, differential 
expression analysis was performed. The number of differentially expressed transcripts 
according to each of the attributes is shown in Table 6.3. By doing this analysis, in addition to 
the number of transcripts differentially expressed, an output file with the transcript’s identifier 
number, fold difference in expression and p value was obtained.  
 
 
Table 6.3  Differential expression analysis of unstimulated samples. Attributes are shown in the first 
column with the number of differentially expressed transcripts according to varying attributes in the 
second column. 
Attribute Number of differentially expressed 
transcripts 
Gender 69 
Joint 317 
Age 32 
All outcome groups 1096 
 
 
 
Differential expression analysis according to gender and joint of origin is represented 
graphically in Figure 6.6. Clear differences in expression patterns could be seen between 
samples from female and male patients and between samples from different joints of origin.    
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Figure 6.6 Graphical representation of differential expression analysis. Top: heat map depicting 
differential expression between samples from female (n=20) and male (n=23) patients. Bottom: heat 
map representing differential expression between metacarpophalangeal (MCP) (n=2), knee (n=35) 
and ankle (n=6) joints. Three clear patterns of gene expression can be seen depending on the joint of 
origin. Columns represent samples, rows represent transcripts. Yellow represents underexpressed 
transcripts, blue overexpressed ones.  
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Upon examination of the results of the differential expression analysis according to gender an 
interesting observation was made. Two samples originating from male patients and one from 
a female patient appeared to have opposite expression patterns to the remaining samples in 
their respective groups. Figure 6.7 shows a representative example of this phenomenon with 
two genes. X inactive specific transcript (XIST) is a gene involved in X chromosome 
inactivation which is normally up-regulated in females. Zinc finger protein Y linked (ZFY) 
encodes a transcriptional factor that is usually up-regulated in males. In the example shown, 
the pattern of gene expression is reversed in two “male” and one “female” samples. The 
characteristics of the patient samples were checked in the patient database and it was 
ascertained that these samples indeed belonged to a female and two males respectively. Thus, 
it was assumed that mislabelling had occurred at some stage during sample preparation. In 
consequence these three samples were excluded from subsequent analysis of both 
unstimulated and TNF stimulated data. They corresponded to one Resolving (BX072), one 
VeRA (BX084) and one Established RA (RA29SY) samples. In consequence the final 
number of samples analysed were as follows Normal (n=8), Resolving (n=15), VeRA (n=13) 
and Established RA (n=7). 
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Figure 6.7 Differential expression of XIST and ZFY in female and male samples. X inactive specific 
transcript (XIST) and Zinc finger protein Y linked (ZFY) were identified as differentially expressed 
between male and female samples. XIST expression was higher in females than males whilst the 
expression of ZFY was higher in males. However, one of the samples in the female group and two in 
the male group displayed expression patterns that were opposite to those of the remaining samples in 
their group. Each dot represents a sample. Red dots represent samples from female patients, blue dots 
samples from male patients.  
 
 
The observation of differentially expressed transcripts according to joint of origin was of 
particular interest. Seminal work from Chang and colleagues demonstrated that fibroblasts 
from different organs display characteristic gene expression patterns suggesting that they are 
distinct differentiated cell types (Chang et al. 2002). More intriguingly, when gene expression 
profiles of fibroblasts from the same organ are analysed by unsupervised hierarchical 
ZFYXIST
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clustering, clear differences in expression programmes are seen according to their anatomical 
origin. For instance, dermal fibroblasts from upper limbs cluster together and separately from 
those from lower limbs. When dermal fibroblasts from multiple locations in same individuals 
are analysed, instead of clustering together (as they belong to the same organ from the same 
individual) they cluster with cells from different individuals but from an equivalent 
anatomical location. This positional demarcation is associated with specific patterns of 
homeobox (HOX) gene expression (Rinn et al. 2006). The homeobox family of genes is 
involved in determining positional identity along the antero-posterior axis during 
development of invertebrate and vertebrate animals  (Krumlauf 1994). In humans the HOX 
genes are located in clusters (denoted A to D) on four different chromosomes (HOXA 
chromosome 7, HOXB chromosome 17, HOXC chromosome 12, and HOX D chromosome 2) 
(Scott 1992).   
 
The finding of a gene expression signature according to joint of origin was both novel and in 
keeping with this previous work and suggested that synovial fibroblasts also possess 
positional identity and that differences exist between cells from different joints. I decided to 
capitalise on this observation and attempt independent verification by PCR. To select key 
genes for verification, the list of 317 differentially expressed transcripts was ranked by p 
value (lowest to highest) and the top four differentially expressed genes (four members of the 
HOX family of genes located in the C cluster: HOXC10, HOXC6, HOXC9 and HOXC8) 
were selected for target validation.  
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The microarray expression data for these genes are plotted in Figure 6.8. Higher expression 
levels of the four target genes were seen in samples originating from ankle and knee joints 
compared to metacarpophalangeal (MCP) joints.  
 
Figure 6.8 Expression levels of selected target HOXC genes assessed by microarray. Raw 
microarray data representing expression levels of HOXC10, HOXC6, HOXC9 and HOXC8 in ankle 
(n=6), knee (n=35) and MCP (n=2) joints. Higher expression levels of all genes were seen in samples 
originating from ankle and knee joints compared to MCP joints. Expression levels expressed as 
arbitrary fluorescence units (FU).  
 
 
Encouragingly similar results were obtained on PCR analysis. Expression levels of all four 
genes were higher in samples originating from ankle and knee joints compared to MCP joints 
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(Figure 6.9). Although these differences did not achieve statistical significance, the results 
gave an indication that independent validation may be achieved if sample numbers were 
increased.  
 
 
Figure 6.9 Expression levels of selected target HOXC genes assessed by PCR. Expression levels of 
HOXC10, HOXC6, HOXC9 and HOXC8 were assessed in ankle (n=3), knee (n=3) and MCP (n=2) 
joint samples by PCR. Higher expression levels of all genes were seen in samples originating form 
ankle and knee joints. Expression levels expressed with the 2
-dct
 method relative to GAPDH.  
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6.5.3 Differential expression analysis: Resolving versus VeRA 
comparison 
 
We hypothesised that synovial fibroblasts may be involved in failed resolution of 
inflammation in early inflammatory arthritis and would retain an imprint of this involvement 
after in vitro culture. To test this hypothesis I compared the transcriptomic profile of 
Resolving and VeRA synovial fibroblasts. No transcripts were identified as differentially 
expressed between these groups. The lack of differences between both outcome groups is 
further emphasised when these groups are visualised using PCA (Figure 6.10). 
 
 
 
Figure 6.10 PCA plot of Resolving and VeRA unstimulated samples (two different rotation angles 
of the same plot shown). No clustering of samples within the same outcome group was seen. 
Resolving (n=15), VeRA (n=13). 
Resolving VeRA
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6.5.4 Differential expression analysis: Early versus Late RA 
comparison 
 
We also hypothesised that differences exist in gene expression patterns of synovial fibroblasts 
in very early (VeRA) and Established RA that may be responsible for or a consequence of the 
progression to disease chronicity. Differentially expressed transcripts between these groups 
were demonstrated in this analysis.  
 
The number of differentially expressed transcripts varied depending on the fold difference cut 
off applied: from 73 transcripts at a fold difference of 1.5 to 40 transcripts at a fold difference 
of two.  
 
 
6.5.5 Data filtering and identification of protein coding genes   
 
Independent validation of results by PCR is an important component in the pathway leading 
to the verification of results in microarray experiments. To select key genes for PCR 
validation, data were filtered according to two commonly used approaches. First, transcripts 
were selected on the basis of fold difference and only those transcripts that showed a fold 
difference in expression of 2 between both outcome groups were selected for validation. 
Second, transcripts not denoting protein coding genes were filtered out. The rationale for this 
approach was to select targets for which commercially available reagents existed so that we 
might be able to validate findings at the protein level in tissue samples. To ascertain whether 
probes corresponded to protein or non-protein coding genes, the Ensembl genome database 
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project website (http://www.ensembl.org/index.html) was used to map probes to the reference 
genome. An example of a non-protein coding probe is shown in Figure 6.11. 
 
 
 Figure 6.11 Mapping of a probe to the reference genome identifies a non-protein coding gene. 
Example of non-protein coding gene identified through genome mapping. Differential expression 
analysis between VeRA and Established RA identified probe A_33_P3423285 (green square box at the 
bottom of the image). This probe was mapped to three transcript variants of the same gene (SETD5-
antisense RNA 1). All these variants were long non coding RNAs and did not code for protein 
products. Subsequently, SETD5-anstisense RNA 1 was not selected for target validation.  
 
 
Using these filtering and mapping strategies, 20 protein coding genes were identified. 11 of 
these were overexpressed and 9 underexpressed in VeRA compared to Established RA. The 
raw microarray expression data for these genes are shown in Figure 6.12. The full list of 
differentially expressed transcripts (including non-protein coding ones) at a fold difference of 
2 is shown in Appendix Table 9.6.  The raw microarray expression data for these genes in all 
outcome groups are shown in Appendix Figure 9.3.  
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Figure 6.12 Expression levels of selected target genes assessed by microarray in unstimulated 
samples. Raw microarray data representing expression levels of 20 target genes in unstimulated VeRA 
(n=13) and Established RA (n=7) samples are represented. Expression levels expressed as arbitrary 
fluorescence units (FU).  
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Primer pairs for each gene were designed using Primer 3 and quality control tested using the 
melting curve method as specified in the materials and methods section. The expression levels 
of these 20 genes were tested in eight samples in each outcome group by PCR and are shown 
in Figure 6.13. 
. 
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Figure 6.13 Expression levels of 20 selected target genes assessed by PCR. Differences in gene 
expression levels were assessed in unstimulated VeRA (n=8) and Established RA (n=8) samples.  
Expression levels of CD300A, EGR1, KMT2E and MME were significantly higher in VeRA than in 
Established RA samples. Expression levels of HAS3 were significantly higher in Established RA than 
VeRA samples. Expression levels represented with the 2
-dct
 method relative to GAPDH. Data shown in 
scattered dot plots where horizontal lines represent medians. Differences in expression between 
groups assessed with Mann-Whitney test. *p<0.05, **<0.01.  
 
 
Five genes were independently verified by PCR as differentially expressed between VeRA 
and Established RA samples. Four of them were overexpressed in VeRA compared to 
Established RA samples. These were: early growth response protein 1 (EGR1), membrane 
metalloendopeptidase (MME), cluster of differentiation 300A (CD300A) and lysine specific 
methyltransferase 2E (KMT2E).  In contrast, the expression of hyaluronan synthase 3 (HAS3) 
was lower in VeRA compared to Established RA samples. Table 6.4 shows the tested genes 
with their chromosomal location, fold difference in expression levels between VeRA and 
Established RA lines, the statistical significance of the difference  (expressed as p value) as 
well as the fold difference and p value of the difference of those genes validated by PCR.  
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Table 6.4 Chromosomal location, fold change and p value of 20 selected differentially expressed genes between unstimulated VeRA and Established 
RA. 
 
 
Name Chromosomal location Fold difference  
VeRA vs. Est. RA 
p value Validates in RT PCR (fold difference, p value) 
CD300A 17: 72,477,870-72,477,929 2.582 3.955E-05 Yes (3.664, 0.0039) 
EGR1 5: 137,804,891-137,804,950 2.875 2.579E-05 Yes (5.271, 0.0019) 
HAS3 16: 69,151,369-69,151,428 -4.179 6.410E-05 Yes (-2.223, 0.0379) 
KMT2E 7: 104,654,395-104,654,454 9.405 3.175E-05 Yes (2.155, 0.0499) 
MME 3: 154,898,216-154,898,275 4.004 1.403E-05 Yes (3.289, 0.0148) 
ALX1 12: 85,677,449-85,677,508 -3.132 1.614E-06 No ( 1.047, 0.7209) 
DFNB31 9: 117,240,601-117,240,660 2.622 3.888E-05 No (1.721, 0.4412) 
FMN1 15: 33,442,032-33,442,091 -2.232 2.722E-05 No (2.492, 0.0621) 
FOSB 19: 45,978,205-45,978,264 4.479 3.152E-05 No (2.432, 0.5054) 
HLX 1: 221,055,600-221,055,659 3.001 1.823E-06 No (2.294, 0.1049) 
ISLR2 15: 74,428,824-74,428,883 4.578 5.649E-06 No (1.145, 0.5737) 
ISM2 14: 77,941,303-77,941,362 2.347 6.897E-05 No (1.010, 0.5054) 
LRIG1 3: 66,429,597-66,429,656 -2.507 6.478E-05 No (-1.767, 0.2345) 
MIA2 14: 39,716,981-39,717,040 -2.132 1.558E-05 No (1.001, 0.9591) 
MPPED2 11: 30,601,870-30,601,929 -2.23 1.013E-05 No (1.382, 0.3821) 
OLFM1 9: 137,987,788-137,987,847 2.161 2.936E-05 No (1.071, 0.5054) 
OR2H1 6: 29,431,909-29,431,968 -2.716 3.261E-06 No (1.690, 0.6454) 
PABPC1L 20: 43,550,312-43,550,371 2.437 1.309E-06 No (1.436, 0.2786) 
SKAP1 17: 46,210,830-46,210,889 -2.179 2.163E-06 No (-1.010, 0.9591) 
TTC9C 11: 62,503,254-62,503,313 -3.671 3.897E-05 No (0.2786, 1.274) 
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6.6 Microarray experiments: TNF stimulated samples results 
 
The same analyses were applied to TNF stimulated samples. As the rationale for these 
analyses has already been described, only the results are discussed below.  
 
6.6.1 Principal component analysis 
 
Samples did not cluster according to outcome group when PCA was performed (Figure 
6.14) suggesting that unidentified attributes other than outcome group account for the 
greatest variation in this data set. Data were also visualised using PCA plots according 
to age, gender, antibody positivity and joint of origin in turn but no clustering was 
observed in the PCA plots according to any of these attributes (Figure 6.15).  
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Figure 6.14 PCA plot of Normal, Resolving, VeRA and Established RA TNF stimulated 
samples (two different rotation angles of the same plot shown). No clear clustering of samples 
according to outcome group was seen along the two principal components. This suggested that 
attributes other than clinical diagnosis contributed to the biggest variation in the dataset. 
Normal (n=8), Resolving (n=15), VeRA (n=13) and Established RA (n=7). 
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Figure 6.15 PCA plots of TNF stimulated samples visualised according to other attributes. 
Samples represented according to Age, Gender (Female n=20, Male n=23), Antibody status 
(Positive defined as positive to either RF or CCP; Positive n=12, Negative n=8, only VeRA and 
Established RA samples depicted) and joint of origin (Ankle n=6, Knee=35, MCP=2). No 
clustering was seen according to any of the attributes. MCP: metacarpophalangeal joints. 
 
 
 
Age Gender
Joint of originAntibody status
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The sources of variation in the dataset were plotted in a pie chart (Figure 6.16). Clinical 
diagnosis (outcome group) accounted for 26% of the variation, joint of origin for 7% 
and gender and age for 1% each. 65% of the variation remained unexplained suggesting 
that other attributes not included in the model accounted for data variation (including 
inter-individual biological variation between samples). Antibody status did not 
contribute to variation.  
 
 
 
 
Figure 6.16 Sources of variation in TNF stimulated samples. Pie chart representing sources of 
variation. Clinical diagnosis (outcome group) accounted for 26% of the variation, joint of 
origin for 7% and age and gender for 1% each. 65% of the variation remained unexplained. 
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6.6.2 Differential expression analysis  
 
The results of differential expression analysis are shown in Table 6.5.  
Table 6.5 Differential expression analysis of TNF stimulated samples. Attributes are shown in 
the first column and the number of differentially expressed transcripts according to varying 
attributes in the second column.  
Attribute Number of differentially expressed 
transcripts 
Gender 67 
Joint 249 
Age 16 
All outcome groups 1336 
 
 
 
To focus analysis on answering the two main questions of interest, two group 
differential expression analyses were performed. 
 
 
 
6.6.3 Differential expression analysis: Resolving versus VeRA 
comparison (TNF stimulated samples) 
 
To test the hypothesis that synovial fibroblasts may be involved in failed resolution of 
early inflammatory arthritis, we compared the transcriptomic profile of synovial 
fibroblasts in the Resolving and VeRA groups. No differentially expressed transcripts 
were identified. The lack of differences between both outcome groups was further 
emphasised when these groups were visualised using PCA (Figure 6.17). This was in 
keeping with results obtained from the analyses of unstimulated samples.  
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 Figure 6.17 PCA plot of Resolving and VeRA TNF stimulated samples (two different rotation 
angles of the same plot shown). No clustering of samples within the same outcome group was 
seen. Resolving (n=15), VeRA (n=13). 
 
 
 
 
 
 
 
 
 
 
 
Resolving VeRA
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6.6.4 Differential expression analysis: Early versus Late RA 
comparison (TNF stimulated samples) 
 
Next, the comparison between both RA groups was performed to ascertain key 
differentially expressed genes between early and late disease. This comparison yielded 
184 transcripts when a fold difference of 1.5 was used as a cut off and 79 transcripts at a 
fold difference of 2. A heat map representing the 79 differentially expressed transcripts 
at a fold difference of 2 is shown in Figure 6.18.   
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Figure 6.18 Graphical representation of differentially expressed transcripts at a fold 
difference of 2. Heat map depicting differential expression between TNF stimulated samples 
from VeRA (n=13) and Established RA (n=7) patients. At a fold difference of 2, 79 transcripts 
are differentially expressed between the groups. This can be seen as two clearly differing 
patterns between outcome groups. Columns represent samples, rows represent transcripts.  
 
 
 
 
6-196 
 
6.6.5 Data filtering and identification of protein coding genes  
 
Data filtering and selection of protein coding genes were done as specified for the 
unstimulated samples. An additional filtering strategy was applied to target selection 
based on what was learnt from previous PCR validation of unstimulated samples. I 
observed that none of the genes that had expression values below 100 in the raw 
microarray data were validated by PCR. As one of the known limitations of microarrays 
is that they are unable to accurately measure weakly expressed genes (Tarca et al. 
2006), the apparent difference in expression might have represented background 
expression. Hence I did not include weakly expressed genes (with intensity values 
below 100) in the target selection process. Data filtering yielded 14 protein coding 
genes with a fold difference in expression between groups of 2 and expression levels 
above 100 fluorescence units. The microarray expression data for these 14 genes are 
shown in Figure 6.19. Five of these genes (MME, HAS3, EGR1, FOSB and HLX) were 
in common with those from unstimulated data analysis. The full list of differentially 
expressed transcripts (including non-protein coding ones) at a fold difference of 2 is 
shown in Appendix Table 9.7. The raw microarray expression data for these genes in all 
outcome groups are shown in Appendix Figure 9.4.  
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Figure 6.19 Expression levels of selected target genes assessed by microarray in TNF 
stimulated samples. Raw microarray data representing expression levels of 14 target genes in 
TNF stimulated VeRA (n=13) and Established RA (n=7) samples are represented. Expression 
levels expressed as arbitrary fluorescence units (FU).  
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PCR primers were designed and quality control tested as described. PCR was performed 
using eight samples in each outcome group and results are shown in Figure 6.20. Six out 
of the 14 genes were independently validated by PCR. Expression levels of all these 
genes were higher in VeRA than in Established RA samples. The validated genes 
included early growth response protein 1 (EGR1), c-FOS (FOS), homeobox protein 
engrailed 1 (EN1), hairy and enhancer of split 1(HES1), LIM and senescent cell antigen 
like domain 3-like (LIMS3L) and cysteine serine rich nuclear protein 1 (CSRNP1).  
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Figure 6.20 Expression levels of 14 selected genes assessed by PCR. Differences in gene 
expression levels were assessed in TNF stimulated VeRA (n=8) and Established RA (n=8) 
samples. Expression levels of CSRNP1, EGR1, EN1, FOS, HES1 and LIMS3L were significantly 
higher in VeRA than in Established RA samples. Expression levels expressed with the 2
-dct
 
method relative to GAPDH. Data shown in scattered dot plots where horizontal lines represent 
medians. Differences in expression between groups assessed with Mann-Whitney test. *p<0.05, 
**<0.01, ***<0.001. 
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6.7 Microarray analysis: Effect of TNF stimulation on gene 
expression signatures 
 
To assess the effect of TNF stimulation on gene expression, differential expression 
analysis of unstimulated and TNF stimulated samples within each outcome group were 
performed. Clear separation between unstimulated and TNF stimulated samples in each 
outcome group was demonstrated using PCA (Figure 6.21).  
 
 
Figure 6.21 PCA plots visualised according to TNF status. Clear separation of unstimulated 
and TNF stimulated samples within each group was seen. Normal (n=16), Resolving (n=30), 
VeRA (n=26) and Established RA (n=14).   
 
 
Differential expression analysis allowed identification of differentially expressed 
transcripts according to defined attributes. A summary of the results of these analyses is 
shown in Table 6.6. 
  
Unstimulated TNF stimulated
Normal Resolving VeRA Established RA
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Table 6.6 Differential expression analysis of unstimulated versus TNF stimulated samples in 
each outcome group. Attributes are shown in the first column and the number of differentially 
expressed transcripts according to varying attributes are shown in subsequent columns.  
Attribute Number of differentially expressed transcripts 
 Normal Resolving VeRA Established RA 
Gender 57 554 271 109 
Age 20 2412 1879 1985 
TNF status 2767 1910 1764 1308 
Joint of origin - 221 762 - 
 
 
Next, pathway analysis was performed using the DAVID functional annotation tool as 
described. Transcripts where expression had changed in response to TNF stimulation in 
each group were entered in the functional annotation tool. Pathways identified as 
involved in TNF response in each outcome group are shown in Table 6.7. Many of the 
pathways were in common between the four outcome groups (i.e. signalling through 
IL1R and HIV-I-Nef, cells and molecules involved in acute inflammatory response), or 
were common to three or two of the groups, whilst some were unique to certain groups.  
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Table 6.7 Pathway analysis of differentially expressed transcripts between unstimulated and TNF stimulated samples in each group.  
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To further dissect TNF responses in each outcome group, the lists of transcripts whose 
expression had changed in response to TNF (2767 transcripts in the Normal group, 1910 
transcripts in Resolving, 1764 transcripts in VeRA and 1308 in the Established RA 
group) were compared.  The number of transcripts up- and down-regulated in response 
to TNF in each outcome group is shown in Figure 6.22. 
 
Figure 6.22 Number of transcripts up- or down- regulated by TNF stimulation in each 
outcome group. 
 
 
To determine whether these transcripts were in common or unique to each of the groups 
a cord diagram was created (Figure 6.23). A total of 649 transcripts were in common 
between all 4 groups, 521 transcripts were in common between 3 groups, 531 between 2 
groups and 1275 unique to a given group. Out of these 1275 transcripts unique to each 
outcome group, 806 were in the Normal group, 207 in Resolving, 135 in the VeRA and 
127 in the Established RA group.  
Normal Resolving VeRA Established RA
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Figure 6.23 Cord diagram of TNF responses. Graphical representation of transcripts whose 
expression levels changed in response to TNF stimulation. Some genes were unique to each of 
the outcome groups whilst others were in common between two, three or all four of the outcome 
groups.   
 
 
Examples of genes in common between all four groups included tumour necrosis factor 
alpha induced protein 3 (TNFAIP3), TNFAIP3-interacting protein 1 (TNIP1), nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor epsilon (NFKBIE), 
intercellular adhesion molecule 1 (ICAM1), interferon alpha beta receptor beta chain 
(IFNAR2), solute carrier family 39 member 14 (SLC39A14) and GTP cyclohydrolase 1 
(GCH1). The patterns of expression for these genes in the microarray experiment are 
shown in Figure 6.24. This group includes genes known to be rapidly induced by TNF 
and involved in the NF-B signalling pathway and negative regulators of TNF 
signalling. Genes in common between the four outcome groups could be interpreted as a 
6-205 
 
generic synovial fibroblast response to inflammation whilst those unique to a given 
group may represent specific responses and their further study is warranted.  
 
The top 50 uniquely changed transcripts in response to TNF stimulation in each group 
are shown in Tables 6.8 to 6.11. Amongst these transcripts, there was a selection of 
protein coding genes as well as long non-coding RNAs, small nucleolar RNAs, 
microRNAs and uncharacterised sequences. Out of the top 50 transcripts in the Normal 
group, TNF stimulation resulted in up-regulation of 24 and down-regulation of 26 
transcripts. In the Resolving group 34 transcripts were down-regulated following TNF 
stimulation whilst 18 were down-regulated in the VeRA group. TNF stimulation 
resulted in down-regulation of 30 out of these 50 transcripts in the Established RA 
group.  
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Figure 6.24 Examples of genes up-regulated by TNF stimulation in all outcome groups.  
Graphs showing microarray expression data for genes that are up-regulated following TNF 
stimulation in all outcome groups. Unstimulated and TNF stimulated data are shown for each 
outcome group. Expression levels expressed as arbitrary fluorescence units (FU). 
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Table 6.8 Top 50 differentially expressed transcripts in response to TNF stimulation unique 
to Normal samples at a fold difference of 2 and FDR<0.05. 
 
Gene symbol Gene name Fold change p value 
LOC728705 Uncharacterised LOC72805 -2.2 5.94E-10 
LOC93622 Morf4 family associated lncRNA -2.1 2.43E-09 
TMEM189 Transmembrane protein 189 2.0 3.19E-09 
COX17 Cytochrome oxydase copper chaperone 2.5 4.84E-09 
CLIP4 CAP-GLY domain containing linker protein family 4 -2.3 1E-08 
ASAP2 Development and differentiation enhancing factor 2 -2.6 1.14E-08 
PRMT1 Protein arginine N methyl transferase 1 2.3 1.56E-08 
CCDC6 Coiled coil domain containing 6 -2.1 2.12E-08 
WARS Tryptophanyl-tRNA synthetase 3.2 2.17E-08 
HSCB HscB mitochondrial iron-sulfur cluster co-chaperone 2.1 2.35E-08 
ITGAE Integrin alpha E  -2.1 2.5E-08 
SNX30 Sorting nexin family member 30 -2.0 3.72E-08 
PPTC7 T cell activation protein phosphatase 2 2.0 4.86E-08 
OSMR Oncostatin M receptor 3.0 5.35E-08 
ZFYVE21 Zinc finger FYVE domain containing 21 -2.5 5.69E-08 
LYPLAL1 Lysophospholipase-like 1 -2.2 6.44E-08 
HECTD1 HECT domain containing E3 ubiquitin protein ligase 1 -2.1 8.29E-08 
SETDB2 SET domain, bifurcated 2 -2.2 1.01E-07 
THC2520792 CTD-2301A4.5 (non-coding) 2.1 1.12E-07 
PPCS Phosphopantothenoylcysteine synthetase 2.1 1.19E-07 
ZNF177 Zinc finger protein 177 -2.4 1.24E-07 
XBP1 X-box binding protein 1 2.6 1.35E-07 
CREB3 Basic leucine zipper protein 2.4 1.37E-07 
XLOC_004626 Uncharacterised X LOC004626 2.3 1.52E-07 
LGI1 Leucine-rich glioma inactivated -1  -19.4 1.61E-07 
RHOG Ras homolog family member G 2.0 1.65E-07 
SNHG7 Small nucleolar RNA host gene 7  -2.3 1.66E-07 
LOC100507100 Uncharacterised LOC100507100 -2.6 2.29E-07 
XLOC_007607 Uncharacterised X LOC007607 2.1 2.33E-07 
OSBPL7 Oxysterol binding protein-like 7 -2.2 2.36E-07 
SMS Spermine synthase 2.0 2.37E-07 
XLOC_006513 Uncharacterised X LOC006513 -2.2 2.6E-07 
ELOVL5 ELOVL fatty acid elongase 5 2.1 2.61E-07 
GYS1 Glycogen synthase 1 2.4 2.68E-07 
C9orf46 Plasminogen receptor C terminal lysine transmembrane protein 2.4 3.01E-07 
PSMD9 Proteasome 26S subunit non-ATPase 9 2.1 3.06E-07 
PDDC1 Parkinson disease 7 domain containing 1 -2.0 3.31E-07 
MBLAC2 Metallo beta lactamase domain containing 2 -2.2 3.35E-07 
LOC100506870 Uncharacterised LOC100506870 -2.5 3.78E-07 
FAS FAS cell surface death receptor 2.2 3.84E-07 
TBC1D9 TBC1 domain family member 9 2.4 4.01E-07 
SLC11A2 Solute carrier family 11  member 2 2.0 4.02E-07 
SH3BP4 Transferrin receptor trafficking protein -2.4 4.16E-07 
MANF Mesencephalic astrocyte derived neurotrophic factor 2.7 4.56E-07 
XLOC_003870 Uncharacterised X LOC003870 -2.1 4.92E-07 
MRPS25 Mitochondrial ribosomal protein S25 -2.1 5.07E-07 
ZDHHC7 Zinc finger DHHC type containing 7 -2.3 5.09E-07 
HSPA13 Heat shock protein 70kDa family member 13 2.0 5.11E-07 
ALAD Aminolevulinate dehydratase -2.1 5.23E-07 
ACOT13 Acyl-CoA thioesterase 13 -2.0 5.26E-07 
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Table 6.9 Top 50 differentially expressed transcripts in response to TNF stimulation unique 
to Resolving samples at a fold difference of 2 and FDR<0.05. 
Gene symbol Gene name Fold change p value 
PTPRJ Protein tyrosine phosphatase receptor type J 2.11362 1.03E-10 
SASH1 SAM and SH3 domain containing 1 -2.09532 5.21E-08 
AK091302 Phosphodiesterase 5A -4.49662 1.76E-06 
A_33_P3296348 Uncharacterised mRNA 2.96171 2.56E-06 
SHROOM3 Protein shroom 3 -2.13088 3.25E-06 
XLOC_009813 Uncharacterised X locus 009813 -2.62791 4.87E-06 
TNS3 Tensin 3 2.20952 6.44E-06 
ZAR1L Zygote arrest 1 like 2.34863 7.05E-06 
MGC16121 MIR503 miRNA -2.15621 8.6E-06 
SDC2 Syndecan 2 -3.51871 9.02E-06 
XLOC_004072 Uncharacterised X locus 004072 -5.93241 9.23E-06 
LOC285419 Uncharacterised  lncRNA  -2.99693 1.05E-05 
LOC100506012 PPP5 TPR Repeat domain containing Protein -2.29491 1.53E-05 
CCDC85A Coiled coil domain containing 85A -3.25485 1.61E-05 
XLOC_l2_008031 Uncharacterised X LOC008031 2.05424 1.85E-05 
KRT24 Keratin 24 -3.97843 1.96E-05 
XLOC_002078 Uncharacterised XLOC002078 -2.4614 2.6E-05 
SPTLC3 Serine palmitoyltransferase long chain base subunit 3 -2.0087 2.9E-05 
XLOC_008005 Uncharacterised X LOC008005 2.17022 3.09E-05 
LOC100129518 Uncharacterised lncRNA -2.21534 3.44E-05 
FLJ35024 Uncharacterised lncRNA -2.13125 3.85E-05 
MOK MOK protein kinase -2.73359 4.04E-05 
XLOC_000939 Uncharacterised X LOC000939 -2.02395 4.08E-05 
XLOC_008380 Uncharacterised XLOC008380 2.35173 4.54E-05 
FAM201B Family with sequence similarity 201 member B lncRNA -2.28476 4.55E-05 
XLOC_l2_015336 Uncharacterised X LOC015336 -2.24234 4.77E-05 
LOC349196 Uncharacterised LOC349196 -2.20997 4.8E-05 
SESN3 Sestrin 3 -2.01093 5.42E-05 
ZNF474 Zinc finger protein 474 -3.08044 5.73E-05 
KY Kyphoscoliosis peptidase 2.88235 5.99E-05 
XLOC_l2_000910 Uncharacterised X LOC000910 2.4936 7.04E-05 
THC2620859 Uncharacterised protein THC2620859 2.25279 7.12E-05 
CHD5 Chromodomain helicase DNA binding protein 5 -2.28212 7.97E-05 
BCO23640 RP11-43505 lncRNA -2.67536 9.16E-05 
UBE2Q2P2 Ubiquitin conjugating enzyme E2Q family member 2 lncRNA -2.26122 9.4E-05 
AF461896 DNA damage regulated autophagy modulator 1 2.30362 9.46E-05 
ANGPTL4 Angiopoietin like 4 -2.14536 0.0001 
NLGN4Y Neuroligin 4 Y linked 2.297 0.000114 
IL6R IL6 receptor -2.1495 0.000115 
A_33_P3312187 Uncharacterised mRNA 2.78986 0.00012 
C6orf164 C6orf164 lncRNA -2.26356 0.000126 
THC2772049 RP11-358M11 lncRNA -2.47335 0.000145 
SYT1 Synaptotagmin-1 -2.71172 0.000148 
SHISA9 Shisa family member 9 3.28885 0.000154 
LOC100132057 Phosphodiesterase 4D lncRNA -2.24219 0.000158 
CAPZB Capping protein (actin filament) muscle Z line beta 2.51007 0.000163 
LOC729175 Uncharacterised LOC729175 2.17269 0.000174 
XLOC_008390 Uncharacterised  X LOC008390 -2.0173 0.000182 
XLOC_006174 Uncharacterised X LOC006174 -2.44379 0.000185 
XLOC_005808 Uncharacterised X LOC005808 -2.41793 0.000188 
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Table 6.10 Top 50 differentially expressed transcripts in response to TNF stimulation unique 
to VeRA samples at a fold difference of 2 and FDR<0.05. 
Gene symbol Gene name Fold change p value 
STAT4 Signal transducer and activator of transcription 4 2.23957 5.5E-08 
H2AFY2 H2A histone family member Y2  2.02283 6.95E-08 
ATL2 Atlastin GTPase 2 2.32867 1.57E-07 
FTH1P16 Ferritin heavy popypeptide 1 pseudogene 16 (non-coding) 2.10018 2.52E-07 
LOC100507139 Uncharacterised LOC100507139 -3.35589 1.09E-06 
EIF4E3 Eukaryotic translation initiation factor 4E family member 3 -2.0007 1.23E-06 
TRIM47 Tripartite motif containing 47 2.18239 2.2E-06 
PDE4DIP Phosphodiesterase 4D interacting protein 2.02616 3.59E-06 
LOC100507492 Uncharacterised LOC100507492 2.46682 5.3E-06 
NEDD4L Neural cell expressed developmentally down-regulated 4 like 2.06896 8.62E-06 
XLOC_013812 Uncharacterised X LOC_013812 3.74262 9.65E-06 
AK130724 Uncharacterised AK130724 2.36981 1.02E-05 
AC093668.2 AC093668.2 (non-coding) -2.24355 1.36E-05 
RABEPK Rab9 effector protein with kelch motifs 2.02678 1.38E-05 
FAM66E Family with sequence similarity 66 member E lncRNA -2.42283 1.65E-05 
YPEL2 Yippee like 2 2.0532 1.9E-05 
CACHD1 Cache domain containing 1 2.18833 3.12E-05 
SIRPG Signal regulatory protein gamma 2.11617 3.49E-05 
CCDC113 Coiled coil domain containing 113 -2.0549 4.16E-05 
SOX12 SOX12 transcription factor -2.23007 4.54E-05 
MCM3AP-AS1 MCM3AP antisense RNA -2.21962 5.9E-05 
XLOC_004366 Uncharacterised X LOC004366 -2.20628 6.47E-05 
XLOC_013898 Uncharacterised X LOC013898 2.72977 7.34E-05 
EMCN Endomucin -2.85231 7.45E-05 
AHR Aryl hydrocarbon receptor  2.2445 0.000104 
ANKLE1 Ankyrin repeat and LEM domain containing 1 2.60215 0.000128 
SPINT1 Serine peptidase inhibitor 2.26922 0.00013 
IL24 Interleukin 24 7.28097 0.000144 
RIMS3 Regulating synaptic membrane exocytosis 3 -2.19637 0.000148 
XLOC_l2_015565 Uncharacterised X LOCl2015565 -2.81286 0.000158 
FTH1P27 Ferritin heavy popypeptide 1 pseudogene 27 (non-coding) 2.11174 0.000166 
TAC4 Tachykinin 4 2.62731 0.000182 
XLOC_009895 Uncharacterised X LOC009895 -2.17766 0.000239 
EPS8L1 Epidermal growth factor receptor 8 related protein 1 2.66009 0.000243 
SLC2A13 Solute carrier family 2 member 13 2.42306 0.000244 
C9orf47 C9orf47 protein 3.16618 0.000267 
CBLN2 Cerebellin 2 precursor 4.20478 0.000281 
LOC100505841 Zinc finger protein 474 like -2.16491 0.000294 
HDAC2 Histone deacetylase 2 2.02141 0.000321 
CTD-2210P24.4 Uncharacterised (protein coding) -2.32628 0.000325 
XLOC_l2_006152 Uncharacterised LOCl2006152 -2.0085 0.000335 
LINC00314 Long intergenic non protein coding RNA 314 2.00459 0.000375 
CMBL Carboxymethylenebutenolidase homolog -2.43618 0.00039 
ATOH7 Atonal homolog 7  2.39881 0.000398 
LOC644242 Uncharacterised LOC644242 2.59678 0.000405 
XLOC_l2_008434 Uncharacterised XLOCl2008434 -2.37384 0.000474 
RASGRP3 RAS guanyl releasing protein 3  2.74654 0.000503 
DLGAP1-AS2 DLGAP1 antisense RNA 2 lncRNA 2.07843 0.000533 
RPTN Repetin -3.02305 0.000541 
LOC100128905 Uncharacterised LOC100128905 3.38463 0.000569 
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Table 6.11 Top 50 differentially expressed transcripts in response to TNF stimulation unique 
to Established RA samples at a fold difference of 2 and FDR<0.05. 
Gene symbol Gene name Fold change p value 
PICALM Phosphatidylinositol binding clathrin assembly protein 2.00067 3.21E-07 
BAZ1A Bromodomain adjacent to zinc finger domain 1A 2.06722 2.12E-06 
C16orf57 C16orf57 protein 2.52146 1.35E-05 
TYSND1 Trypsin domain containing 1 -2.1195 1.49E-05 
FRMD4B FERM domain containing 4B -4.26581 1.62E-05 
LOC100506775 Uncharacterised LOC100506775 -3.67598 3.33E-05 
SOCS3 Suppressor of cytokine signalling 3 -2.1503 6.26E-05 
RBPJ 
Recombination signal binding protein for Ig kappa J 
region -2.12403 6.62E-05 
RGS11 Regulator of G protein signalling 11 -2.13328 9.82E-05 
ENST00000419668 Uncharacterised antisense RNA (lncRNA) 2.39408 0.000112 
PTCH1 Protein patched homolog 1  3.10862 0.00012 
TRNP1 TMF1 regulated nuclear protein 1 -2.03988 0.000214 
CAMK2N2 
Calcium/calmodulin dependent protein kinase II inhibitor 
2 2.48083 0.000215 
EPS8L2 Epidermal growth factor receptor 8 related protein 2 -2.12781 0.000222 
SEMA3A Sema domain 2.02347 0.000226 
FLOT1 Flotillin 1 -2.09533 0.000253 
DIRAS3 DIRAS family GTP binding Ras like 3 2.19735 0.000254 
ABCC2 ATP-binding cassette sub-family C member 2 -2.50083 0.00026 
GADD45B Growth arrest and DNA damage inducible  beta -2.21493 0.000265 
PITX1 Paired like homeodomain 1 -2.72665 0.000288 
ROGDI Rogdi homolog  -2.09194 0.000291 
CALD1 Caldesmon 1 -2.08523 0.000291 
SIX1 SIX homeobox 1 -2.06961 0.000308 
ANP32E Acidic nuclear phosphoprotein 32 family member E 2.09761 0.000316 
TGFB2 transforming growth factor beta 2 2.95298 0.000348 
XLOC_010743 Uncharacterised X LOC010743 -2.17223 0.00036 
TP53I11 Tumor protein p53 inducible protein 11 -2.00228 0.000383 
ADARB1 Adenosine deaminase -2.73162 0.000384 
PPFIA4 Protein tyrosine phosphatase receptor type F polypeptide  -2.10584 0.000398 
SYTL4 Synaptotagmin like 4  2.0833 0.000418 
SLC10A7 Solute carrier family 10 member 7 2.0037 0.000421 
CEP68 Centrosomal protein 68kDa -2.00998 0.000433 
ATXN1L Ataxin 1 like -2.23874 0.000434 
UPK3B Uroplakin 3B -2.52761 0.000455 
HGF Hepatocyte growth factor  2.38923 0.000513 
BANK1 B cell scaffold protein with ankyrin repeats 1 -2.57534 0.000525 
XLOC_l2_015849 Uncharacterised X LOCl2015849 -2.61968 0.000546 
PPP4R1L Protein phosphatase 4 regulatory subunit 1 like 2.13661 0.000586 
LOC100505783 Uncharacterised LOC100505783 -2.77272 0.000601 
DHRS9 Dehydrogenase reductase member 9 9.77488 0.000663 
LOC100130417 Uncharacterised LOC100130417 -2.45918 0.000674 
HOXD3 Homeobox D3 -2.53443 0.000676 
GALNTL1 Galactosamine N-acetylgalactosaminyltransferase like 1 -2.01615 0.000716 
ZEB1-AS1 ZEB1 antisense RNA 1 -2.02723 0.000718 
SHISA2 Shisa family member 2 5.55278 0.000724 
AK126423 PDZ domain containing ring finger 3 3.06186 0.000763 
DNAI2 Dynein, axonemal intermediate chain 2 2.50696 0.000786 
SSR4P1 Signal sequence receptor delta 1 long non coding RNA -2.2062 0.000792 
AF085654 Immunoglobulin heavy variable 5-78 2.29593 0.000826 
ENST00000354995 Uncharacterised protein 2.40941 0.000863 
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6.8 Microarray experiments: Discussion 
 
This is the first body of work to systematically characterise the transcriptomic profile of 
cultured synovial fibroblasts in four distinct clinical outcome groups: Normal, 
Resolving, very early RA (VeRA) and Established RA.   
 
Published work in this field includes the  transcriptomic profiling of Established RA and 
Normal synovial fibroblasts analysed using RNA sequencing technologies (Heruth et al. 
2012). Unstimulated cultured synovial fibroblasts (n=2 in each group) were expanded to 
passage 2 before RNA extraction and sequencing. A total of 277 genes were identified 
as differentially expressed between both groups. The majority of these genes had not 
been previously described in this context. Although informative, the small sample size 
in that study raises questions about the validity of these data and whether findings could 
be generalised. Del Rey and colleagues studied the transcriptomic profile of Normal and 
Established RA synovial fibroblasts (n=6 in each group) using microarray expression 
profiling (Del Rey et al. 2010). This group compared gene expression patterns of 
unstimulated synovial fibroblasts cultured under normoxic and hypoxic conditions. 
They demonstrated significant changes in gene expression patterns in both groups 
induced by hypoxia. When they compared transcriptomic profiles between both groups 
under normoxic conditions, they identified 223 differentially expressed transcripts. 
However, in their publication, these genes were not analysed further.   
 
In a study of similar design to ours, Kasperkowitz and colleagues analysed the 
transcriptional profile of 19 cultured synovial fibroblast lines from patients with 
Established RA. Using unsupervised hierarchical clustering, they identified two distinct 
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synovial fibroblasts groups (I and II, with group II being further subdivided into IIa and 
IIb) based on differential expression of 484 genes. Group I was characterised by high 
expression of genes such as insulin like growth factor binding protein 5 (GFBP5) and 
insulin growth factor 2 (IGF2),  genes involved in complement activation and  
oncogenes (MYB , TEM8 and RAB31). Group II fibroblasts were characterised by high 
expression of transforming growth factor beta (TGF) which was particularly 
pronounced in the IIb subgroup where cells also showed increased expression of TGF 
response genes such as collagen type 4 alpha 2 (COL4A2) and alpha smooth muscle 
actin (SMA). Indeed, expression of SMA (a myofibroblast marker) was confirmed in 
independent samples at mRNA and protein levels and localised to the lining layer of the 
synovium. These results provide strong evidence for heterogeneity within RA synovial 
fibroblast cultures which may relate to differing clinical phenotypes (including for 
example the degree of erosiveness of the arthritis) and levels of inflammation 
(Kasperkovitz et al. 2005). This paper followed previous work from the same group 
where study of synovial tissue from Established RA patients using microarrays had 
shown heterogeneity of gene expression patterns allowing identification of different 
pathogenic RA subsets (van der Pouw Kraan et al. 2003). More recently other groups 
have independently confirmed observations of heterogeneity within RA tissues. Dennis 
and colleagues identified 4 different RA subsets (which they termed myeloid, lymphoid, 
low inflammatory and fibroid), based on gene expression signatures of 49 Established 
RA synovial tissues. They subsequently tested the ability of these differing phenotypes 
to predict response to anti TNF treatment by applying these pre-defined gene sets to a 
separate patient cohort from the Gene Expression Omnibus (GEO) data repository. In 
doing this, they identified that expression of the myeloid phenotype at baseline was 
significantly higher in patients with a good EULAR treatment response at 16 weeks 
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(Dennis et al. 2014). Another group analysed microarray data from the GEO repository 
corresponding to synovial tissue samples from osteoarthritis (OA), RA and Normal 
joints (5 samples in each group). A statistical model was created to identify groups of 
genes that were differentially co-expressed in two group comparisons (RA vs. OA, RA 
vs. Normal and OA vs. Normal). A weighting system was developed to identify the 
transcription factors that most significantly contributed to differentiating RA from 
Normal and OA groups  (Li et al. 2013). One of the identified transcription factors is in 
common with one identified by us, as discussed later in this chapter.  
 
In addition to the above mentioned studies, data from candidate gene studies provide 
further information about the gene expression profile of Established RA synovial 
fibroblasts. Broadly, their expression phenotype is characterised by up-regulation of 
oncogenes and proto-oncogenes, adhesion molecules and MMPs and down-regulation 
of tumour suppressor genes.  
 
The aim of my study was to add to the existing knowledge in two ways: (1) to unravel 
molecular mechanisms differentiating the resolution of early inflammatory arthritis 
from its persistence as RA; (2) to gain insights into RA pathogenesis, in particular 
progression from early RA to established, destructive disease.  
 
We hypothesised that by comparing Resolving and VeRA samples we would identify 
key genes responsible for the resolution of early inflammatory arthritis. However, no 
differences in gene expression signatures between these two outcome groups were 
found in either the unstimulated or the TNF stimulated samples. There are a number of 
reasons that might explain why differential expression was not observed between these 
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outcome groups. It is possible that differences in expression between these groups exist 
at the time of biopsy but these are lost during synovial fibroblast culture. Evidence 
supporting a stable fibroblast phenotype is provided by studies demonstrating different 
gene expression profiles in fibroblasts from different organs that have been cultured for 
multiple passages (Chang et al. 2002). The stability of the Established RA synovial 
fibroblast phenotype in vitro has been previously studied. One of the most compelling 
pieces of evidence in favour of its stability comes from the demonstration that RA 
synovial fibroblasts that have been cultured for multiple passages in vitro display an 
invasive phenotype when co-implanted with normal human cartilage in the SCID mouse 
model in the absence of T cells and any other human cells (Muller-Ladner et al. 1996). 
Additionally, a study designed to address this issue supports stability of expression 
profile during early passages. Established RA synovial fibroblasts were cultured from 
passages 1 to 8 and their gene expression profile analysed using cDNA arrays at each 
passage. Expression profiles remained constant between passages 1 to 5 (defined as 
<10% differentially expressed genes between passages) but diverged significantly from 
passages 5 to 8 (>10% of differentially expressed genes with each passage) (Neumann 
et al. 2010). Based on this evidence, we designed our microarray experiments so that we 
would study cells at an early passage (passage 3) to minimise the effect of culture.  
Nevertheless, the possibility that some or all of the phenotype may have been lost in 
culture should still be acknowledged, particularly when considering cells in the 
Resolving and VeRA groups as it is not known how stable the synovial fibroblast 
phenotype is at such an early stage of disease.   
 
In this respect, it is also worth noting that a major assumption of our hypothesis is that 
the fate of patients (resolution of inflammatory arthritis versus progression to RA) is 
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already decided at the time of biopsy (within 3 months of symptom onset). However, it 
is entirely possible that critical decision points between these two paths occur at a later 
stage or that there is not a single decision point but rather a gradual accumulation of 
changes over a longer time period. As discussed in the introductory pages of this thesis, 
the debate regarding the timing of the window of opportunity still continues. Whilst we 
chose to define this window as disease of less than 3 months duration, other researchers 
use definitions of 6, 12 and even 24 months. As we did not analyse samples from 
patients with disease duration other than less than 3 months, we are not able to draw any 
conclusions regarding other time periods.  
 
A way of overcoming these limitations would be to undertake ex vivo study of gene 
expression profiles at the time of biopsy to abolish any potential culture bias in gene 
expression. If this was combined with the study of samples at different time points from 
symptom onset, this might become a powerful approach to unravelling disease 
mechanisms in early disease. Whilst this approach would have been technically 
challenging at the time these experiments were designed, it would now be possible, 
albeit costly, to do so. Such an approach might encompass ex vivo isolation and sorting 
of synovial fibroblasts and storage until a diagnosis could be assigned followed by 
analysis of transcriptomic profiles. An alternative ex vivo approach would be the study 
of synovial tissue although the disadvantage of this approach is the inability to study a 
cell type in isolation.  
 
Assuming that the phenotype of synovial fibroblasts is indeed imprinted and stable in 
culture, our inability to identify differentially expressed genes between Resolving and 
VeRA patients may be, at least partly, explained by one of the well described 
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limitations of microarray data analysis. During differential expression analysis of 
microarray data, as comparisons are made across large numbers of genes, the likelihood 
of finding differentially expressed genes by chance increases with increasing number of 
genes. Hence, a statistical approach is used to control the number of false positives 
identified this way: the false discovery rate. However, controlling for false positives can 
result in increased false negatives, especially for genes where the difference between 
groups is small. Hence by using FDR, one decreases false positive rates but at the cost 
of increasing false negatives (Park et al. 2010). So, it could be that differences of small 
magnitude exist between both groups but we are unable to identify them in our analysis.  
 
Taken together the results of the differential expression analysis between Resolving and 
VeRA samples may be considered to mean that no differences of large magnitude exist 
in the gene expression signatures between these groups. This may be because synovial 
fibroblasts do not have a key role early in disease, and that such a role only becomes 
apparent later in disease after continued exposure to a pro-inflammatory environment. 
Another possibility is that such differences only become apparent in fibroblasts from the 
early stages of disease when these cells are exposed to certain conditions such as during 
migration or when co-cultured with other cell types.  
 
In order to investigate the question of whether significant transcriptomic changes occur 
between the earliest and later stages of disease, we compared VeRA and Established RA 
synovial fibroblasts, identifying different transcriptomic signatures. In this case, and 
despite the caveats outlined above, differences were of adequate magnitude to be 
identified. When considering the significance of these results it may be postulated that 
differences in gene expression are related to disease chronology (i.e. early disease 
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versus late disease). Under this assumption, further in depth study of differentially 
expressed genes may provide clues to molecular mechanisms involved in progression to 
chronicity.  
 
However, varying disease severity between groups may also be responsible for the 
observed differences. Disease course in RA can range from mild, waxing and waning, 
non-destructive to aggressive, rapidly progressive and destructive disease. Traditionally 
the study of synovial fibroblasts has focused on analysis of samples originating from the 
latter patient subset. This is replicated in our Established RA group where samples from 
patients with aggressive disease course undergoing joint replacement surgery have been 
studied. Although every effort was made to match the groups as closely as possible, it is 
undeniable that differences between groups exist and are evidenced by differing DAS28 
ESR scores at baseline (mean 4.8 in VeRA vs. mean 5.9 in Established RA) and the 
presence of erosions at baseline (1 out of 9 patients in which these data were available 
in the VeRA groups vs. 6 out of 6 patients in which these data were available in 
Established RA group). In this context, the effect of treatment on gene expression 
profiles must also be considered. Although patients in the Established RA group were 
receiving a relatively small number of therapies at the time of sample collection by 
today’s standards (most patients were on DMARD monotherapy with one patient not on 
treatment), both concurrent and previous treatment would inevitably have affected 
synovial fibroblasts and their microenvironment. This is in stark contrast to patients in 
the VeRA group who were DMARD naïve. From a pragmatic point of view, one should 
recognise that it may be difficult to unravel the relative contributions of disease 
chronology, disease severity and treatment as in practice they tend to be inextricably 
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linked. For example, patients with longer disease duration would almost inevitably have 
had more treatment than those with shorter disease duration.  
Acknowledging the considerations thus far outlined, detailed study of identified targets 
is warranted. Proposed targets for further study include CD300A, CSRNP1, EGR1, 
EN1, FOS, HAS3, HES1, KMT2E, LIMS3L and MME that have already been 
independently validated by PCR. Table 6.12 shows these genes with a short description 
of the functions associated with their proteins and their disease associations. For the 
benefit of the reader the patterns of expression of these genes in the microarray 
experiments are illustrated in Figure 6.25. 
 
Some of the proteins encoded by these genes have not been previously described in the 
RA literature. Of relevance, CD300A is a protein involved in immune regulation and 
CSRNP1 has been associated with carcinomas (Borrego et al. 2013; Ishiguro et al. 
2001). Others have been studied in the context of RA. Of particular interest are EGR1 
and MME. EGR1 is a transcription factor that activates target genes involved in cell 
differentiation and mitosis. Li and colleagues identified EGR1 as a key transcription 
factor differentiating RA from OA and Normal synovial tissue samples  (Li et al. 2013). 
In another study, EGR1 was shown to be expressed by synovial fibroblasts in RA 
synovial tissues. Cultured RA synovial fibroblasts expressed higher levels of EGR1 
mRNA compared to OA synovial fibroblasts. As EGR1 is involved in cell proliferation, 
proliferation rates were assessed but no increased proliferation was observed (Aicher et 
al. 1994). Instead overexpression of EGR1 in immortalised human fibroblasts has been 
associated with activation of type I and type II collagen genes and of tissue inhibitor of 
metalloproteinases (TIMP 1, 2 and 3) (Aicher et al. 2003;Alexander et al. 2002). 
Interestingly, EGR1 has also been shown to act as a negative regulator of inflammatory 
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responses in cultured RA synovial fibroblasts (Faour et al. 2005). Putting this together it 
is tempting to speculate that reduction of EGR1 expression over the course of disease 
(from VeRA to Established RA) may result in increased MMP production and enhanced 
inflammatory responses.  
 
MME is a zinc dependent enzyme that inactivates peptides by cleaving the amino side 
of hydrophobic residues. It is expressed by common myeloid progenitors but also by 
lymphoblasts in acute lymphoblastic leukaemia where surface expression of MME is 
used as diagnostic marker. This enzyme can be released to the extracellular space and 
increased levels have been found in the plasma and synovial fluid of RA patients 
compared to OA patients and healthy controls (Matucci-Cerinic et al. 1993) as well as 
in RA synovial tissue where it was postulated to be produced by synovial fibroblasts 
(Sreedharan et al. 1990). More recently, another MME family member, MMEL1 has 
been associated together with CTLA4 with increased RA susceptibility in the Han 
Chinese population (Danoy et al. 2011). Although it is not clear what precise role this 
gene may play in RA, its further study would be very informative.  
 
Excess production of hyaluronic acid has been proposed as a contributor to RA 
progression. Whilst usually involved in maintaining joint homeostasis, excess 
production of this acid occurs during inflammation and has been associated with a series 
of pro-inflammatory roles such as acting as a chemoattractant, inducing 
neoangiogenesis and inducing expression of pro-inflammatory molecules by endothelial 
cells and leucocytes (reviewed in Stuhlmeier 2005). Hyaluronic acid is produced by 
three enzymes; hyaluronan synthases 1, 2 and 3 (HAS1, HAS2 and HAS3). HAS2 and 
HAS3 are constitutively expressed by cultured RA synovial fibroblasts and HAS1 
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expression can be induced by stimulation of cultures with TGF. Glucocorticoid 
treatment results in suppression of HAS1, HAS2 and HAS3 mRNA expression through 
MAP kinase dependent mechanisms whilst leflunomide suppresses hyaluronic acid 
production by cultured RA synovial fibroblasts in a dose dependent manner by blocking 
HAS1 induction (Stuhlmeier et al. 2004;Stuhlmeier 2005). Our finding of increased 
HAS3 expression by Established RA synovial fibroblasts is in keeping with these data 
and may indicate that increased hyaluronic acid production is an important feature in the 
progression to chronicity in RA.  
 
Comparing gene expression profiles between unstimulated and TNF stimulated samples 
in each outcome group allowed us to address a third research question: is the effect of 
TNF stimulation on transcriptional signatures generic or are there outcome group-
specific responses to TNF? 
 
The results of these analyses revealed clear changes in gene expression signatures in 
response to TNF. Several pathways were involved in TNF responses. Whilst many of 
them were in common between all groups, others were unique to some groups or in 
common only between early inflammatory arthritis groups with a few unique to a given 
outcome group. Thus, similarities in TNF response between groups were identified that 
we propose represent a generic synovial fibroblast response to pro-inflammatory 
stimuli. These include genes rapidly induced by TNF and involved in the NF-B 
signalling pathway and negative regulators of TNF signalling.  
 
TNF responses that appeared unique to individual outcome groups were also identified.  
The in depth study of these unique signatures may provide new exciting data in this 
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area. To take this work forward, the next step should be to validate microarray results at 
mRNA and protein levels. Of note, within the top 50 uniquely changed transcripts in 
response to TNF in the Resolving group there was a very high proportion of 
uncharacterised and non-protein coding regulatory genes. Whilst in itself this makes the 
further study of these transcripts significantly more challenging, this may also be an 
indicator of the higher degree of regulation that these cells are subjected to or able to 
exert which may be associated with a role in the resolution of inflammatory arthritis.  
 
Amongst these non-protein coding regulatory genes there are several lncRNAs. The 
study of lncRNAs is an exciting new field in synovial fibroblast research that is in its 
infancy as demonstrated by the fact the available publications are only in abstract 
format. Thus careful consideration and further work in this direction would significantly 
add to this area. Work undertaken by Steffen Gay’s group demonstrated differential 
lncRNA expression between resting, unstimulated OA and RA synovial fibroblasts 
(Bertoncelj et al. 2013). Subsequent analysis of lncRNA expression patterns in response 
to 24 hour TNF and IL1 stimulation revealed no differences in response between 
these groups. LncRNAs whose expression varied in response to TNF included 
metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and growth arrest 
specific 5 (GAS5) both down-regulated following stimulation and antisense long non-
coding RNA in the INK4 locus (ANRIL) whose expression was up-regulated upon 
stimulation (Bertoncelj et al. 2014). To compare these results with ours, I assessed 
whether expression levels of these lncRNAs had changed in response to TNF in our 
dataset. Whilst expression of ANRIL was not modified by TNF in any of the groups, 
expression of MALAT1 and GAS5 were down-regulated in all four groups studied.  
Whilst no conclusive interpretations can be made from these findings and reproduction 
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of these results at PCR level would be required for their validation, it is nevertheless 
interesting to find similar responses to TNF stimulation in the different outcome groups 
assessed in both studies which may indicate that down-regulation of these transcripts is 
a generic synovial fibroblast response to TNF stimulation. 
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Figure 6.25 Expression levels of validated genes in unstimulated and TNF stimulated 
samples in all outcome groups.  Graphs showing microarray expression data for genes that 
were validated by PCR. Unstimulated and TNF stimulated data are shown for each outcome 
group. Expression levels expressed as arbitrary fluorescence units (FU). 
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Table 6.12 Differentially expressed genes between VeRA and Established RA validated by PCR. 
Symbol Name & Description Disease associations 
CD300A  Cluster of differentiation 300A. 
 Cell surface protein in leukocytes, monocytes & 
neutrophils. 
Involved in immune response signalling (Borrego 2013). 
CSRNP1  Cysteine serine rich nuclear protein 1.  
 Proposed as tumour suppressor gene. 
Decreased expression in lung, liver, colon and kidney carcinomas (Ishiguro et al. 2001).  
 
EGR1  Early growth response 1.  
 Transcriptional regulator involved in cell 
differentiation & mitosis.  
 
Associated with prostate and breast cancer where it promotes progression & glioblastoma where it inhibits 
tumour growth (Yang et al. 2003). 
 
EGR1 has been identified as a key differentially expressed transcription factor that distinguishes RA from OA 
and Normal synovial tissue (Li et al. 2013).  
 
EGR1 is constitutively expressed by Established RA synovial fibroblasts. Its expression has been associated 
with induction of type I and type II collagen genes and activation of tissue inhibitors of metalloproteinases 
(TIMP 1, 2 and 3) (Aicher et al. 1994;Aicher et al. 2003;Alexander et al. 2002). 
EN1  Homeobox protein engrailed 1 
 Role in controlling pattern formation during 
development.   
Associated with congenital central hypoventilation syndrome (Weese-Mayer et al. 2003). 
 
FOS  FBJ murine osteosarcoma viral homolog (also known 
as cFOS). 
 Transcription factor: component of the AP-1 complex. 
AP-1 regulates gene expression in response to pro-inflammatory stimuli and has been involved in up-
regulation of MMP expression by synovial fibroblasts. Study of adherent cell extracts from RA synovial 
tissues demonstrated high AP-1 binding activity compared to OA tissues. AP-1 binding correlated with c-fos 
and c-jun expression and disease activity (Asahara et al. 1997).  
 
HAS3  Hyaluronan synthase 3. 
 Enzyme involved in synthesis of hyaluronic acid: 
degradation product readily produced at inflammation 
sites that facilitates cell migration.  
 
 
HAS3 (together with HAS2) is constitutively expressed by cultured RA synovial fibroblasts. Expression is 
suppressed by glucocorticoid treatment. In contrast HAS1 is not constitutively expressed but expression can be 
induced by TGF (Stuhlmeier et al. 2004).  
 
Leflunomide suppresses hyaluronic acid production by cultured RA synovial fibroblasts in a dose dependent 
manner by blocking HAS1 induction (Stuhlmeier 2005).  
HES1  Hairy and enhancer of split-1. 
 Key gene of the Notch signalling cascade. The target 
genes of this pathway remain poorly defined. 
Abnormal expression of members of the Notch pathway has been shown in T cells from RA patients (Ng et al. 
2001). 
 
Identified as IL1 target gene in chondrocytes where it influences cartilage matrix remodelling genes 
(Ottaviani et al. 2010). 
KMT2E  Lysine specific methyltransferase 2E. 
 Histone methyltransferase that specifically mono- and 
dimethylates lysine at position 4 of histone H3 
Involved in haematopoiesis regulation.   
 
RA synovial fibroblasts cultured under hypoxic conditions display higher protein levels of another histone 
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(K4H3). 
 Specific tag for epigenetic transcriptional activation. 
 
mark: methylation of lysine at position 27 of histone H3 (K27H3) (Heron et al. 2014). 
LIMS3L  LIM and senescent cell antigen like domains 3 like. 
 Member of the LIM family of proteins: involved in 
cytoskeletal organisation.  
The function of this protein remains undefined in the literature. Other members of the LIM family of proteins 
have been implicated in regulation of lamellipodia production and adhesion in mouse embryonic fibroblasts 
(Feng et al. 2005). 
MME  Membrane metalloendopeptidase. Also known as 
cluster of differentiation 10 or neprylisin. 
 Inactivates peptides by cleaving their amino side.  
 Examples of targeted peptides: glucagon, substance P, 
neurotensin. 
Cell surface marker used for the diagnosis of acute lymphocytic leukaemia.  
Also associated with Burkitt’s lymphoma, hairy cell leukaemia, myeloma and Alzheimer’s disease.  
 
Increased MME levels in plasma and synovial fluid of RA patients compared to OA patients and healthy 
controls (Matucci-Cerinic et al. 1993).  
Increased MME levels in RA synovial tissue (postulated to be produced by synovial fibroblasts) (Sreedharan et 
al. 1990). MME family member, MMEL1 has been associated together with CTLA4 with increased RA 
susceptibility in the Han Chinese population (Danoy et al. 2011).  
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6.9 Further considerations and future work 
 
Gene expression is a dynamic process that changes in response to environmental 
stimuli. In an attempt to study the response of synovial fibroblasts in different outcome 
groups to a pro-inflammatory microenvironment we stimulated cells with TNF for 24 
hours. Although informative, this approach is merely an in vitro model that does not 
fully replicate all environmental cues synovial fibroblasts encounter in the joint. 
Obvious limitations of this approach are the arbitrary definition of TNF stimulation 
time and the lack of other environmental factors such as hypoxia, interactions with other 
cells and cartilage and other factors that may be critical but are yet to be defined. For 
these reasons, more complex in vitro and in vivo models should be used to complement 
this work. A good starting point would be the study of gene expression profiles of 
synovial fibroblasts from different outcome groups when co-implanted with normal 
cartilage under the kidney capsule of SCID mice.  
 
In an attempt to relate gene expression to synovial fibroblast biology, we used 
differential expression analysis. This type of analysis allows characterisation of 
molecular differences associated with specific biological effects. This type of analysis 
can be seen as hypothesis generating and allows description of putative targets for 
further study. However, other approaches to the analysis of microarray data exist and 
would provide additional information from the microarray experiments performed in 
this thesis. Class prediction analyses could be undertaken in order to aid biomarker 
detection. Such analyses may provide clues to group of genes that would predict 
progression to persistent RA in early inflammatory arthritis. This would be of great 
clinical relevance as knowing which patients are more likely to develop RA from 
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disease onset would promote early and aggressive treatment of this patient group and 
prevent aggressive treatment of those patients in whom such predictive factors are 
absent. Unsupervised classification analysis may also prove very informative. So far, 
we have described hypothesis based approaches to data analysis in which assumptions 
are made regarding the expected results. By undertaking unsupervised analysis this 
limitation would be overcome.  
 
Following differential expression analyses, attempts were made to take this work further 
into validation steps. Thus, microarray expression data were validated by real time 
quantitative PCR. Nevertheless, it should be acknowledged that by using this approach, 
potentially very interesting targets may have been overlooked. During data filtering for 
gene target selection non-protein coding genes were excluded. Whilst this is a 
commonly used approach that has the major advantage of selecting targets for which 
reagents are readily available (Jaluria et al. 2007), it would have invariable resulted in 
loss of key information. Amongst those genes not selected for PCR there were long 
non-coding RNAs, small nucleolar RNAs and small nuclear RNAs. Additionally, 
microRNAs were identified during differential analysis in response to TNF stimulation. 
In the light of the available literature regarding microRNAs and the emerging literature 
regarding long non-coding RNAs, it is very likely that the analysis of these sequences 
will be crucial in providing new key disease targets.  
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7 General discussion  
 
 
The central hypothesis of my thesis was that synovial fibroblasts from patients in 
different clinical outcome groups would display differing functional and transcriptional 
characteristics.   
 
This hypothesis was based on the knowledge that synovial fibroblasts from patients 
with Established RA are involved in disease pathogenesis at two fundamental levels: by 
perpetuating inflammation and by causing bone and cartilage destruction (Bottini et al. 
2013). It was also based on data indicating that treatment of RA during the early 
window of opportunity results in significantly better outcomes (van der Linden et al. 
2010) and that at molecular and histological levels, RA of symptom duration of 3 
months or less may be a distinct entity (Raza et al. 2005; Schumacher Jr. et al. 1994).  
 
Three comparisons were of particular interest:  
(1) By comparing synovial fibroblasts in the Resolving and VeRA groups I aimed to 
identify key differences between resolution and persistence of early inflammatory 
arthritis. 
(2) By comparing VeRA and Established RA fibroblasts I intended to gain insights into 
the progression from early RA to established, destructive disease. 
(3) By comparing the transcriptional response to TNF stimulation of fibroblasts in 
different outcome groups I aimed to determine generic as well as outcome group-
specific responses to a pro-inflammatory environment. 
 
7-230 
 
With this approach a number of assumptions were made. The main one being that 
synovial fibroblasts are implicated in the early stages of inflammatory arthritis. This 
hypothesis suggested that synovial fibroblasts might help decide the fate of these 
patients by determining whether their arthritis would resolve spontaneously or persist as 
RA. Further assumptions included that any of these suggested functional or 
transcriptional differences would be of biological relevance and that we would be able 
to find such differences by using the experimental methods of our choice.  
 
As I have described, when I assessed the functional characteristics of synovial 
fibroblasts in the different outcome groups, I failed to find differences between groups 
using some experimental methods (scratch test and invasion assay) but found 
differences with another (cell exclusion zone assay). Additionally, the characterisation 
of the transcriptomic profile of these cells using SAGE technology was fraught with 
problems but promising hypothesis-generating results were obtained with microarray 
experiments. 
 
The potential differences between techniques and the potential significance of these 
differing results have already been discussed and will not be repeated here. Instead, I 
will focus this discussion on the relevance of these findings and how they may provide a 
basis for further discoveries in this field. It is important to remember at this point that 
the study of Resolving, very early (VeRA) and Early RA synovial fibroblasts has never 
been approached before. It is thus the more remarkable that we did indeed find 
differences in the characteristics of cells in these groups.   
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One of the main findings to come out of this work is the observation of differential 
migration between synovial fibroblasts in different outcome groups. Through the novel 
application of a cell exclusion zone assay to the study of synovial fibroblast migration, I 
found that cells from patients with VeRA and Established RA displayed comparable 
and much slower migration rates than those from Normal joints. It is remarkable that 
fibroblasts that were obtained from patients and subsequently cultured for 4 to 6 
passages displayed such strong migratory phenotypes. This suggests that this is an 
important characteristic and that it may be an early feature of RA. Based on these 
findings further study of fibroblast migration is warranted to ascertain its role in disease 
pathogenesis. To this end, a number of experiments could be performed. Small 
molecule inhibitors or small interfering RNAs could be used to selectively inhibit the 
function of different proteins involved in cell migration including Rho, Rac and PI3K. 
Assessment of the effects of this inhibition on cell migration in different groups might 
help define important targets causing differential cell migration. Complementary 
experiments where overexpression of these proteins is induced prior to assessment of 
cell migration could also be performed. At the same time, data obtained from 
microarray experiments should be further analysed to identify genes involved in cell 
migration that are differentially expressed between groups of interest. It is however 
possible that, such genes may only be found when gene expression is studied in the 
context of migration. Thus, assessment of transcriptomic profiles of cells in different 
outcome groups during migration should strongly be considered.  
   
Another finding of interest to come out of this work is the identification of differentially 
expressed genes between very early and Established RA. These genes may provide keys 
to molecular mechanisms involved in progression to chronicity and/or severe disease. 
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Some validation work has already been started and microarray expression results have 
been replicated at PCR level for some of these genes. Determining whether the protein 
products of these genes are present and differentially expressed on synovial tissue 
samples from these patients should be the next step. This approach would enable 
confirmation that differential gene transcription leads to differential protein production 
for these genes (two processes that are not always associated owing to post-
transcriptional regulation of gene expression) and that the differences in expression are 
present ex vivo, indicating that these observations are not an artefact of in vitro culture.  
 
To fully capitalise on these microarray data, non-protein coding genes that were 
overlooked in the initial validation should be considered as they may provide key 
information to differential gene regulation between these groups. The study of 
epigenetic mechanisms that may be involved in the regulation of expression levels of 
those genes differentially expressed between groups has already begun. This work is 
being carried out through our collaboration with Professor Steffen Gay and his group, 
leading experts on the study of DNA methylation and miRNA expression in RA 
synovial fibroblasts. The methylation status of promoters of differentially expressed 
genes between these groups is being assessed to determine whether differential DNA 
methylation may account for the observed differences in gene expression. Furthermore, 
study of miRNA expression by cells in these outcome groups is also under way. If 
successful, this approach would provide mechanistic insight into how these differences 
are generated and maintained and, more importantly, may provide a tool to modify 
transcriptional phenotypes.  
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Although the type of analysis I performed did not identify statistically significant 
differentially expressed genes between the Resolving and VeRA groups, further work 
should be performed to conclusively prove a lack of difference. The simplest initial 
approach would be to make use of the existing microarray data and perform class 
prediction analysis. Even if no differences in gene expression were found with the 
parameters established during differential analysis, class prediction analysis may lead to 
identification of groups of expressed and co-expressed genes that would allow 
prediction of diagnostic category. This work has already been started through a 
collaboration with the Professor of computing sciences at the University of Groningen, 
Michael Biehl. Preliminary analysis of expression data suggests that discrimination of 
patients with resolving inflammatory arthritis and very early RA is feasible. By 
applying a linear classification scheme he found that data from TNF stimulated samples 
was predictive of disease outcome with an area under the curve value (AUC) of 0.69. 
Interestingly, data from unstimulated samples only yielded a random classification 
performance (AUC=0.49) (Figure 7.1). The same method was applied to data from 
Normal and Established RA samples, obtaining nearly perfect receiver operating 
characteristic curves with AUC close to 1.  
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Figure 7.1 Receiver operating characteristic curves indicating the performance of a binary 
classifier system applied to unstimulated and TNF stimulated microarray data from Resolving 
and VeRA samples. A class prediction model was created based on raw microarray data from 
unstimulated and TNF stimulated samples in the Resolving (n=15) and VeRA (n=13) groups. 
The classifier system was able to predict outcome for the TNF stimulated (AUC=0.69) but not 
for the unstimulated samples (AUC=0.49). Black line: TNF stimulated samples data, Blue line: 
unstimulated samples data. 
 
 
This observation is important for two reasons. It gives an indication that synovial 
fibroblasts may indeed be implicated in both the resolution of inflammatory arthritis and 
in RA during the very early (3 months) window of opportunity and that is thus 
important to continue work in this field. Furthermore, it also emphasises that in order to 
identify significant functional differences between these groups, characterisation should 
not be performed under resting conditions but rather through dynamic in vitro 
approaches such as after TNF stimulation (as described) or during migration.   
 
Additionally, the ex vivo study of gene expression of synovial fibroblasts isolated at the 
time of biopsy should be considered. Although these experiments were not possible at 
the time of initiation of this thesis, the development of a reliable technique for ex vivo 
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synovial fibroblast isolation in our group together with advances in microarray 
technologies where ever smaller RNA quantities are required for accurate 
transcriptomic analysis make it a feasible option. This approach would bypass any 
potential effects of in vitro culture on cellular phenotypes.  
 
Another area of promise that warrants further analysis and verification of results is the 
comparison between unstimulated and TNF stimulated samples. The study of the 
different ways in which synovial fibroblasts respond to pro-inflammatory stimuli may 
prove key to unravel pathogenic mechanisms. This observation is further strengthened 
by the preliminary results of the class prediction analysis. To take this work forward, 
filtering of microarray data should be performed to identify target genes for further 
validation. In this instance, it may be that the study of genes that are uniquely modified 
by TNF stimulation in each group may prove more useful so that outcome-group 
specific responses can be determined. As stated earlier, this filtering strategy should 
also include non-protein coding genes, especially given the observation that such 
regulatory genes are particularly prevalent in the Resolving group, suggesting that post-
transcriptional regulation of gene expression is crucial in the resolution of inflammatory 
arthritis. Interestingly, our data on lncRNAs may indeed prove complementary to that 
already discussed of Bertoncelj and colleagues (Bertoncelj et al. 2013; Bertoncelj et al. 
2014). 
 
 
Additionally, unsupervised hierarchical clustering of microarray data sets should be 
performed. This approach would provide completely unbiased information regarding 
relationships between these cells. We can speculate about what such analysis might 
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show. It is likely that TNF stimulated cells would cluster together and separately from 
unstimulated cells. Given our observations regarding HOX genes, it is also likely that 
cells will cluster according to joint of origin.  
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8 Future work 
 
In this body of work I have comprehensively functionally and transcriptionally 
characterised synovial fibroblasts in five different clinical outcome groups. In doing so, 
I have produced an extensive amount of data. The potential significance of these 
findings and possible areas of further work have been detailed in Chapter 7. However, 
given the wide-ranging possibilities for future study, I will in this chapter map out the 
most relevant approaches that should be taken as next steps in the mining of these data. 
Much of this work is currently being carried out through collaborations with experts in 
the molecular biology and computational biology fields.   
 
The focus of this continued effort is currently placed on further analysis and validation 
of data looking at the effect of TNF stimulation on gene expression signatures in 
different clinical outcome groups. This work is being undertaken at different levels 
simultaneously: 
 
1. Validation of differentially expressed transcripts in response to TNF stimulation: 
using the same techniques that I have described for the validation of differentially 
expressed genes between Early and Late RA samples, independent validation of results 
at PCR level is being undertaken. Making use of the lists of top 50 uniquely changed 
transcripts in response to TNF stimulation in each group (Tables 6.8 to 6.11), further 
filtering is being performed to select five protein coding genes in each list. This work 
involves literature search looking at transcript function and researcher guided selection 
of relevant genes. It also involves selection of genes for which reagents are available for 
validation at protein level.  Once a decision has been made on candidates, primers will 
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be designed and real time quantitative PCR undertaken for validation of expression 
data. In parallel, staining of synovial tissue sections looking for ex vivo expression of 
the protein products of these genes will also be undertaken. This body of work has been 
conceived as necessary validation of the response to TNF stimulation data analysis. The 
microarray data together with its validation at PCR and protein levels will hopefully be 
publishable as a paper describing outcome group specific signatures to TNF stimulation.  
 
To complement this work, further research into the kinetics of synovial fibroblast 
responses to TNF is being planned. This is because TNF induced genes can respond 
rapidly (within an hour of stimulation) and may have returned to baseline by 24 hours. 
Current efforts are directed to securing funding to investigate time-courses of genome 
wide transcriptional responses to TNF in synovial fibroblasts of different outcome 
groups. Independently of this, the patterns of expression of genes of interest identified 
in this section will be investigated over a 24 hour time-course using real time 
quantitative PCR. This is important in order to understand whether the identified 
differentially induced genes in response to TNF between outcome groups are really 
TNF-induced or not in one outcome group or another, or whether the snap-shot analysis 
has captured subtle differences of kinetics between groups.  
 
 2. Gene co-expression analysis. Computational analysis of data looking at co-expressed 
genes and their links across the different outcome groups. This body of work is 
designed to take the differential expression analysis that has already been performed a 
step further. During differential expression analysis, individual genes that are 
differentially induced in response to TNF stimulation between different clinical 
outcome groups have been identified. However, the individual identification of these 
8-239 
 
genes does not provide information about relationships between them. From a systems 
biology perspective, co-expression analysis is important as co-expressed genes are 
usually functionally related, often controlled by the same transcriptional regulatory 
programmes or members of the same pathway or protein complex. This type of analysis 
should help narrow down candidates for further in depth study as the description of 
genes that are part of a co-expressed gene network would be of higher biological 
relevance than that of isolated genes whose expression is modified in response to TNF 
stimulation. A two-step co-expression analysis will be performed. In the first step a co-
expression measure will be selected and a similarity score will be calculated for each 
pair of genes using this measure. In the second step a significance threshold for this 
measure will be determined and gene pairs that have a similarity score higher than the 
threshold will be considered to have a significant co-expression relationship. This work 
will be performed using the Differentially co-expressed Genes and Links (DCGL) 
package in the R software environment (Liu et al. 2010).   
 
3. Regulatory network analysis. Co-expression analysis establishes relationships 
between pairs of genes but does not determine the direction and type of this 
relationship. In order to identify the regulators that contribute to differential co-
expression, regulatory analysis will be performed. This will allow identification of co-
expressed genes that are regulated by a given transcription factor. Additionally, a 
regulatory impact factor will be calculated by applying a metric to each transcription 
factor that combines the change in co-expression between the transcription factor and 
the differentially co-expressed target genes.  This will enable ranking of transcription 
factors from most to least significant. The work outlined in points 2 and 3 will be 
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performed by specialists at the School of Computer Sciences of Birmingham University 
(Professor Peter Tino and Dr Shan He). 
 
4. Further computational analysis of data looking at relationships between protein 
coding and non-protein coding, regulatory, transcripts. In the analysis that has already 
been performed I identified several thousand transcripts that changed in response to 
TNF stimulation. Amongst these transcripts there are protein coding genes as well as 
non-protein coding, regulatory, sequences (long non-coding RNAs, micro-RNAs, small 
nucleolar RNAs and small nuclear RNAs). In an attempt to unravel the epigenetic 
mechanisms regulating expression of protein coding genes in response to TNF, the 
relationships between these and regulatory sequences will be analysed using 
computational algorithms. This work will be performed by specialists at the School of 
Computer Sciences of Birmingham University. Once these relationships are established 
and key regulatory sequences identified, molecular biology experiments will be 
performed to validate computational analysis and dissect molecular mechanisms.  
 
For illustrative purposes I will imagine that a given micro-RNA is identified as having a 
key regulatory role on the response to TNF stimulation. Further experiments for the 
study of this target will be designed that might include enforced expression of this 
micro-RNA (using transfection techniques) in synovial fibroblasts and analysis of the 
effect of this enforced expression on its target genes (by PCR). In parallel, 
complementary experiments involving target gene silencing using micro-RNA mimics 
and inhibition of target gene binding to micro-RNA using antagomirs could be used to 
demonstrate that target gene expression is being modified by that specific micro-RNA.  
Such experiments will be designed and performed in collaboration with Professor 
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Steffen Gay and his group at the University of Zurich. If successful, this approach 
would provide mechanistic insight into how differences in gene expression in response 
to TNF stimulation are generated and maintained and, may provide a tool to modify 
transcriptional phenotypes.  
 
5. The metabolic profiling of parallel unstimulated and TNF stimulated samples to those 
used in these project have been the subject of analysis in work performed by other 
researchers within our group. To ensure that target gene selection remains firmly in the 
context of biologically meaningful observations, these metabolic data will be combined 
with the microarray expression data described in this thesis. This work will enable 
identification of pathways common to both datasets and will be performed using the 
Stemformatics platform. This platform combines bioinformatics and biostatistics tools 
for integration of transcriptional and metabolic data (Wells et al. 2013). This work is 
being performed in collaboration with Dr Christine Wells at the School of Life Sciences 
of the University of Glasgow. 
 
6. Class prediction analysis. In the context of the TNF stimulated dataset and 
specifically in relation to the Resolving and VeRA groups, class prediction analysis is 
being performed. This work has already been started by Professor Michael Biehl 
(Professor of computing sciences at the University of Groningen). Preliminary results 
obtained using linear classification methods suggest that discrimination of patients with 
resolving inflammatory arthritis and very early RA is feasible at the time of onset of 
inflammatory arthritis. Through the application of a linear classification scheme, data 
from TNF stimulated samples was predictive of disease outcome with an area under the 
curve value (AUC) of 0.69. Interestingly, data from unstimulated samples only yielded 
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a random classification performance (AUC=0.49). The same method was applied to 
data from Normal and Established RA samples, obtaining nearly perfect receiver 
operating characteristic curves with AUC close to 1. This preliminary analysis is being 
followed up by further in depth analysis using matrix relevance learning vector 
quantization (RLVQ). This type of analysis makes use of an algorithm that allows 
introduction of a full matrix of relevance factors in the distance measure so that 
correlations between features and their relative importance for the classification scheme 
can be determined and automated (Schneider et al. 2009). Thus the algorithm is used to 
identify sets of transcripts that most effectively discriminate between sets of biological 
samples, in this case, synovial fibroblasts belonging to different outcome groups 
(Resolving vs. VeRA). Initial application of this analysis to the dataset has resulted on 
identification of a set of transcripts that strongly discriminate between both outcome 
groups. On further inspection, the majority of these transcripts have been found to be 
sex-linked. Given this observation, analysis is currently being repeated paying particular 
attention to hidden gender biases and results are awaited with interest. 
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9 APPENDIX 
 
 
Table 9.1Custom gene sets used in real time PCR assay in microfluidic cards. 
Assay ID Symbol Protein encoded by gene Function/Relevance 
Hs99999905_m1 GAPDH Glyceraldehyde 3 phosphate dehydrogenase Housekeeping gene. 
Hs00187842_m1 B2M Beta 2 microglobulin Housekeeping gene. 
Hs01003372_m1 VCAM1 Vascular cell adhesion protein 1 Cell adhesion molecule expressed by human RA synovial 
fibroblasts. Marker of activated lining layer synovial fibroblasts 
(Bottini et al. 2013).  
Hs00535586_s1 CD248 Endosialin Cell surface marker expressed human RA fibroblasts in the 
sublining layer (Filer 2013). Associated with synovial hyperplasia 
and leukocyte accumulation in animal models of arthritis (Maia et 
al. 2010).  
Hs00366766_m1 PDPN Podoplanin Cell surface marker expressed by RA fibroblasts in the lining 
layer and associated with expression of SMA (Ekwall et al. 
2011;Filer 2013). 
Hs00355202_m1 LGALS1 Galectin 1 Galectin family member with immunosuppressive and anti-
inflammatory role. Expressed by cultured RA synovial fibroblasts 
and in the sublining layer of RA synovial tissues (Dasuri et al. 
2004;Ohshima et al. 2003).   
Hs00371321_m1 LGALS9 Galectin 9 Galectin family member associated with anti-inflammatory 
properties. Induces apoptosis of cultured RA synovial fibroblasts 
(Seki et al. 2007).  
Hs00173587_m1 LGALS3 Galectin 3 Galectin family member associated with pro-inflammatory roles. 
Expressed in RA synovial tissues and by cultured RA synovial 
fibroblasts where it is particularly expressed at sites of attachment 
to cartilage and induces pro-inflammatory cytokine secretion 
(Neidhart et al. 2005;Ohshima et al. 2003).  
9-244 
 
Hs00263821_m1 LGALS12 Galectin 12 Galectin family member involved in cell cycle regulation and 
apoptosis. Expressed by cultured RA synovial fibroblasts (Dr 
Magdalena A Bik thesis).  
Hs00222859_m1 CXCL16 Chemokine ligand 16 CXC chemokine family member. Produced by RA synovial 
fibroblasts. Mediates T cell recruitment to the synovium (Muller-
Ladner et al. 2007;Ruth et al. 2006).  
Hs00899658_m1 MMP1 Matrix metalloproteinase 1 Matrix metalloproteinase secreted by RA synovial fibroblasts. 
Involved in cartilage destruction (Bottini et al. 2013). 
Hs01548727_m1 MMP2 Matrix metalloproteinase 2 Matrix metalloproteinase secreted by RA synovial fibroblasts. 
Involved in cartilage destruction (Bottini et al. 2013). 
Hs00968308_m1 MMP3 Matrix metalloproteinase 3 Matrix metalloproteinase secreted by RA synovial fibroblasts. 
Involved in cartilage destruction (Bottini et al. 2013;Okada et al. 
1989).  
Hs00234579_m1 MMP9 Matrix metalloproteinase 9 Matrix metalloproteinase secreted by RA synovial fibroblasts 
(Tolboom et al. 2002).   
Hs00233992_m1 MMP13 Matrix metalloproteinase 13 Matrix metalloproteinase secreted by RA synovial fibroblasts. 
Involved in cartilage destruction (Bottini et al. 2013;Lindy et al. 
1997).  
Hs00377632_m1 CTSL1 Cathepsin L1 Protease involved in cartilage destruction. Expressed in the RA 
synovium at sites of invasion (Muller-Ladner et al. 1996;Pap et al. 
2000b). 
Hs00947433_m1 CTSB Cathepsin B Protease involved in cartilage destruction.  Expressed in RA 
synovium at sites of invasion (Pap et al. 2000b).  
Hs02339312_g1 SUMO1 Small ubiquitin like modifier 1 Overexpressed by RA synovial fibroblasts conferring protection 
from Fas and TNF mediated apoptosis (Oslejskova et al. 
2009;Senolt et al. 2006).  
Hs00243201_m1 S100A4 Metastasin Calcium binding protein involved in diverse biological regulatory 
activities. Expressed in RA synovium and cultured synovial 
fibroblasts where it induces MMP (Senolt et al. 2006).  
Hs00183740_m1 DKK1 Dickkopf related protein Negative regulator of the Wnt signalling pathway that promotes 
bone destruction and is expressed on RA synovial tissue (Diarra 
et al. 2007;Goldring et al. 2007).   
Hs00237184_m1 NAMPT Nicotinamide phosphoribosyltransferase/visfatin Adipokine that promotes pro-inflammatory cytokine production 
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and motility of RA synovial fibroblasts (Meier et al. 2012). 
Hs00237119_m1 MMP14 Matrix metalloproteinase 14 Membrane type MMP that regulates MMP2 activity Expressed in 
RA synovium together with MMP2 (Goldbach-Mansky et al. 
2000).   
Hs00166156_m1 CTSK Cathepsin K Protease involved in cartilage destruction. Expressed by RA 
synovial fibroblasts and macrophages (Pap et al. 2000b).  
Hs99999901_s1 18S 18S ribosomal RNA Housekeeping gene.  
Hs00171254_m1 IGF2 Insulin like growth factor 2 Hormone protein with similar structure to insulin. Increased 
expression in cultured RA synovial fibroblasts (Kasperkovitz et 
al. 2005).  
Hs00909449_m1 ACTA2 Alpha smooth muscle actin Marker of secretory pro-fibrotic myofibroblasts. Expressed by a 
subset of fibroblasts in the RA synovium localising to the lining 
layer (Ekwall et al. 2011;Kasperkovitz et al. 2005).  
Hs01014511_m1 TLR2 Toll like receptor 2 Toll like receptor expressed by cultured RA synovial fibroblasts 
and RA synovial tissue of patients with disease of less than 12 
months duration (Ospelt et al. 2008).  
Hs00152933_m1 TLR3 Toll like receptor 3 Together with TLR4, the most abundantly expressed TLR by 
cultured RA synovial fibroblasts and RA synovial tissue of 
patients with disease of less than 12 months duration. Stimulation 
of TLR3 in these cells leads to increased expression ofIL-6, 
MMP3 and MMP13 (Bombardieri et al. 2011;Ospelt et al. 2008).  
Hs00152939_m1 TLR4 Toll like receptor 4 Together with TLR3, the most abundantly expressed TLR by 
cultured RA synovial fibroblasts and RA synovial tissue of 
patients with disease of less than 12 months duration (Ospelt et al. 
2008).    
Hs00243522_m1 TNFSF11 Receptor activator of nuclear factor kappa B ligand RANKL is expressed by RA synovial fibroblasts and promotes 
monocyte to osteoclast differentiation in co-culture models 
(Takayanagi et al. 2000).  
Hs00174774_m1 LGALS3BP Galectin 3 binding protein Galectin family member with a role in tumour invasion and host. 
Expressed on the lining layer of RA synovial tissue particularly at 
sites of invasion (Ohshima et al. 2003). 
Hs00171524_m1 SLIT3 Slit homolog 3 Member of the repellent factor family. Has repulsive functions in 
nervous system development when bound to its receptor ROBO3. 
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This receptor is expressed by cultured RA synovial fibroblast and 
treatment of cells with its ligand, Slit3, results in inhibition of 
fibroblast migration in vitro (Denk et al. 2010).  
Hs00363301_m1 TRERF1 Transcriptional regulating factor 1 Identified as differentially expressed between RA and OA 
synovial fibroblasts in previous microarray work from our group 
(Filer A, unpublished).  
Hs00230846_m1 SHOX Short statue homeobox Identified as differentially expressed between RA and OA 
synovial fibroblasts in previous microarray work from our group 
(Filer A, unpublished). 
Hs00184008_m1 PIAS1 Protein inhibitor of STAT1 Represses transcription of inflammatory gene promoters (Liu et 
al. 2008).   
Identified as differentially expressed between RA and OA 
synovial fibroblasts in previous microarray work from our group 
(Filer A, unpublished). 
Hs01099999_m1 EGF Epidermal growth factor Its receptor is expressed by cultured RA synovial fibroblasts. 
Stimulation of this receptor results in production of pro-
inflammatory cytokines such as IL8 and VEGF (Yamane et al. 
2008).  
Hs00266645_m1 FGF2 Fibroblast growth factor 2 Member of the fibroblast growth factor family involved in 
endothelial cell proliferation. Induces RANKL expression by 
cultured RA synovial fibroblasts and osteoclast maturation 
(Nakano et al. 2004).  
Hs00610488_m1 TP53BP2 Tumour suppressor p53 binding protein 2 Apoptosis regulator. Expression of mutants of the tumour 
suppressor protein p53 by RA synovial tissue and cultured has 
been associated to fibroblasts survival via apoptosis regulation 
(Firestein et al. 1996).   
Hs00167241_m1 HTR2A Serotonin receptor 2A Expressed by cultured RA synovial fibroblasts. Precise function 
unknown but thought to have a protective role in disease 
pathogenesis (Seddighzadeh et al. 2010).  
Hs00224228_m1 TNS3 Tensin 3 Involved in actin remodelling and cell migration (Katz et al. 
2007) 
Identified as differentially expressed between RA and OA 
synovial fibroblasts in previous microarray work from our group 
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(Filer A, unpublished). 
Hs01026149_m1 EPAS1 Endothelial PAS domain containing protein 1 
Encodes Hypoxia inducible factor 2 
Encodes part of a transcription factor involved in up-regulation of 
gene expression in response to hypoxia (Brahimi-Horn et al. 
2005).   
Identified as differentially expressed between RA and OA 
synovial fibroblasts in previous microarray work from our group 
(Filer A, unpublished). 
Hs00153153_m1 HIF1A Hypoxia inducible factor 1 Transcription factor activated by hypoxia and during 
inflammation. Expression is up-regulated in in RA lining layer 
and in cultured RA synovial fibroblasts exposed to pro-
inflammatory stimuli (Westra et al. 2007).  
Hs00202612_m1 PADI4 Peptidyl arginine deaminase 4  Enzyme that catalyses deamination of arginine residues to 
citrulline. Associated with susceptibility to RA. Expressed in 
synovial tissue and fluid (Arend et al. 2012).  
Hs00153408_m1 MYC MYC Proto-oncogene expressed by RA synovial fibroblasts thought to 
be involved in fibroblast activation and in tissue invasion and 
destruction (Huber et al. 2006).  
Hs00234119_m1 RAF1 RAF proto-oncogene Expressed by cultured RA synovial fibroblasts associated with 
aggressive behaviour (Pap et al. 2000b).  
Hs00381211_m1 SYVN1 Synoviolin 1 Pro-proliferative and antiapoptotic protein secreted by cultured 
RA synovial fibroblasts (Mor et al. 2005).  
Hs00170103_m1 INHBA Inhibin beta A Subunit of activin A. Activin A is expressed in RA synovial tissue 
and cultured synovial fibroblasts and associates with proliferation 
(Ota et al. 2003).  
Hs00171022_m1 CXCL12 Chemokine ligand 12 Constitutive chemokine produced by RA synovial fibroblasts 
involved in inappropriate leucocyte retention (Burger et al. 2001).  
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Table 9.2 List of primer pair sequences of target genes analysed by PCR identified in SAGE 
experiments. The sequences of all housekeeper genes tested are also shown here. 
Gene symbol Forward primer Reverse primer 
CAMLG AACTCGGAACAGCGCATCAA CACCCAGCACTACTCGCTTT 
Chordin GCGCATCAGTGGACACATTG GGTCACAGATCACCGTTCGT 
CHP ATTTCCGCCCCATTGAGGAT TTGTTGCTTCGGCTGTTGAG 
COMP TGCGTTCTTCTGCTCACCCTG TCCATCACCGTGTTTTTCAGGA 
DFFB AAGGCTTGGAGTCCCGATTT TGTCGAAGTAGCTGCCATTGT 
E2F2 GCCCAGCTACTGCTACCTACTA AATCCCCTCCAGATCCAGCTT 
F11R CGTGCCTTCAGCAACTCTTC GTCAAAGTGGCCTCGGCTAT 
FGF5 CCCGGATGGCAAAGTCAATG GAAAACGCTCCCTGAACTTGC 
MDM2 CCATGCCTGCCCACTTTAGA CAGGCTGCCATGTGACCTAA 
cMET TGACTTAGCCAACCGAGAGA TTGAGAGGTTCTTTCCACCAAGT 
PAK2 TTGATGGTGCTGCCAAGTCT CCAGAAGCCCCTTGTCCAAT 
PDPK1 GCCCACAGTGTTGCAGATTG GTGAAGCAGCACTGAACACG 
SNX1 GAGGGCCGCTTTAGAAAGGT TGCTGCAGCTTATCAGGCTT 
SOCS3 GACGGAGACTTCGATTCGGG AACTTGCTGTGGGTGACCAT 
TGFbR1 ACAACCGCACTGTCATTCAC TCTCCAAATCGACCTTTGCCA 
TRAIL-R4 GTGCACAGAGGGTGTGGATT TTCTACACGTCCGGCACATC 
VAMP A TGGAAGCTGTGTGGAAAGAGG TGACAGTCGGAGCATTCCCT 
XIAP CGGAGTTGGCATTTCCAGATT TGATGTCTGCAGGTACACAAG 
PRKCI CCAAGCCAAGCGTTTCAACA  TCCATGGGCATCACTGGTTC 
PTK2 TTGATGGTGCTGCCAAGTCT CCAGAAGCCCCTTGTCCAAT 
RAB3B TCACGAGAAGCGGGTGAAAC TAGCCCAGTCTTGGACAGCA 
GAPDH GTCAGCCGCATCTTCTTTTGC  AATCCGTTGACTCCGACCTTCC 
18S AACCCGTTGAACCCCATT CCATCCAATCGGTAGCG 
UBC CGGGATTTGGGTCGCAGTTCTTG CGATGGTGTCACTGGGCTCAAC 
HMBS AGGAGTTCAGTGCCATCATC GCAGCGAAGCAGAGTCTC 
RPL13a AAGGTCGTGCGTCTGAAG GAGTCCGTGGGTCTTGAG 
B2M GTATGCCTGCCGTGTGAAC AAAGCAAGCAAGCAGAATTTGG 
Bactin CGGCATCGTCACCAACTG AACATGATCTGGGTCATCTTCTC 
HPRT1 TGACACTGGCAAAACAATGA GGTCCTTTTCACCGCAAGCT 
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 
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Table 9.3 List of primer pair sequences of target genes analysed by PCR identified in 
microarray experiments. 
Gene symbol Forward primer Reverse primer 
ALX1 ATGGAGACGCTGGACAATGAG   CTTTCACGGGAGACATTCGGA   
CD300A TCAAAGCTGGTGACCATTCA GGAGGCCACAGTGCTGTATT 
DFNB31 GCTACGTCACCAACCACATC TTCTCATCCCCTCCTTGC 
EGR1 CAACTACCCTAAGCTGGAGGAGA CTCGTTGTTCAGAGAGATGTCAG 
FMN1 TATTTGGCGGGTGGAGA CAAGCTCCCTGTGATTCTCTG 
FOSB TCTTCCTCCCCTCAACAGTG CCTCCTGGAGAGGATGTGA 
HAS3 TTTGGCTGTTTTCCCTCTGC ACATTTGGAGGGCAAGCAAG 
HLX CCCTATGCTGTGCTCACGAA CTGCTTTCGGTCCGGCTT 
ISLR2 GGTTTGTCTCACGTGTTGCAG  GAACATCGCGGCTCCCAATA 
ISM2 TCATCAGCACCGACTTCTCA GAAAGTTCTCCCGTGCAACA 
KMT2E TGGGGATTGATAGGCAGCAT ACAGGAACCTCATCACCACT 
LRIG1 GTAAAGGCTGCTGGTGTTGG TTCCAGTCCCAGCTCAGTTT 
MIA2 ACAAAACTGCTGGCAGACCT  CCTGCCCACAAATCTTCCCT 
MME GTCAGGTTGGCTCTTCAGGTT TTCTGACTTGCCCATCACCT 
MPPED2 GCCTGCTTCCATCTTTTGCT TGTTGTAGTGCGTGAATGCC 
OLFM1 CCAGGCAGTTTAAGGGCTAA CTACAGTCGCATGCAAAGAGA 
OR2H1 TGAGGGCCTGCTTTCTGATT TGAGGCATGGGGCCTTTTGGG 
PABPC1L ACAAAGGCCGTGACAGAGAT ATGGCAGGCAGGAAGTAGC 
SKAP1 CTTCCCTCTCTCCTGCCTTT TGCCTCTTCCCACTTGTCTT 
TTC9C GAGACCAGCCTGACCAA CCCGAGTAGCTGGGTTTACA 
CSRNP1 CTGGATGAGAATGCCAACCT ATCTGGCAGAGCCTGGAGTA 
EN1 GCAACCCGGCTATCCTACTT ATGTAGCGGTTTGCCTGGAA 
ETV3 AGGAGGTGGAGGGTATCAGT GCCACCTCATCTGGATCCTT 
FOS AAGGAGAATCCGAAGGGAAA CCTTCTCCTTCAGCAGGTTG 
HES1 GGCCAGTTTGCTTTCCTCAT GAGGTGGGTTGGGGAGTTTA 
HLX GACACGTTTCCAGGTCCCTA GGCTTGTTTCCAGGTCCCTA 
LIMS3L CCCTGCATTATCCCAGAGAA GCTCCCCATTACTGTTCACG 
PER3 AGCTACCTGCACCCTGAAGA CGAACTTTATGCCGACCAAT 
PLEKHG4 CAGGCCCAAGGCTCTTTTCA TGGGCCAAAGCCCTAGAGAA 
RUNX1 CTACCGCAGCCATGAAGAAC GCTCGGAAAAGGACAAGCTC 
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 Figure 9.1 Melting curve analysis graphs of primer pairs used in validation of microarray 
data (unstimulated VeRA vs. Established RA comparison).   
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Figure 9.2 Melting curve analysis graphs for primer pairs used in validation of microarray 
data (TNF stimulated VeRA vs. Established RA comparison). The melting curves of primer 
pairs for genes in common with unstimulated samples are represented in Figure 8.1.  
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Table 9.4 RNA quantity and quality of samples used in SAGE experiments. Measured RNA 
quantity for each sample is represented (mean of triplicate measurement) together with RIN 
values indicating RNA quality (optimal 8-10).  
 
Sample SOLID 
ID 
Sample 
ID 
Total RNA (ng/µl) RIN value 
A1 BX081 207.0 9.00 
A2 BX016 186.6 9.10 
A3 BX022 77.8 8.80 
A4 BX003 379.6 9.10 
A5 BX063 403.4 9.00 
A6 BX038 272.3 8.90 
A7 BX010 317.1 8.90 
A8 BX082 518.9 9.00 
B1 BX055 632.4 9.00 
B2 BX066 630.1 9.00 
B3 BX031 579.0 9.00 
B4 BX014 305.6 8.70 
B5 BX004 272.1 9.10 
B6 BX064 453.1 9.10 
B7 BX070 654.4 8.90 
B8 BX083 312.9 9.00 
C1 BX077 304.8 9.10 
C2 BX018 621.8 9.10 
C3 BX015 225.3 9.10 
C4 BX048 185.6 8.80 
C5 BX069 543.4 8.00 
C6 BX076 148.5 9.10 
C7 BX088 214.3 9.00 
C8 BX033 341.7 8.90 
D1 BX075 655.1 8.00 
D2 BX093 595.4 8.00 
D3 BX042 522.2 8.00 
D4 BX013 557.1 7.80 
D5 BX005 803.3 7.90 
D6 BX095 463.4 8.00 
D7 BX089 474.3 7.80 
D8 BX008 213.8 8.00 
E1 RA06SY 221.9 9.20 
E2 RA15SY 101.3 9.60 
E3 RA20SY 124.6 9.80 
E4 RA23SY 159.4 9.20 
E5 RA25SY 93.1 9.80 
E6 RA28SY 59.9 9.40 
E7 RA29SY 51.4 9.70 
E8 RA37SY 112.1 9.80 
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Table 9.5 Measured RNA concentration and 260/280 and 260/230 ratios of synovial fibroblast 
samples used in microarray experiments.  
Sample Number Sample 
ID 
Total RNA 
Concentration 
(ng/µl) 
260/280 ratio 260/230 ratio 
Sample 1 Bx003 128.6 2.04 2.03 
Sample 2 Bx003 138.5 2.04 1.73 
Sample 3 Bx004 158.2 2.05 2.22 
Sample 4  Bx004 152.7 2.08 2.04 
Sample 5 Bx005 176.5 2.01 1.91 
Sample 6 Bx005 175.6 2.03 1.56 
Sample 7 BX008 187.9 2.02 2.07 
Sample 8 BX008 193.5 2.04 2.07 
Sample 9 BX010 175.8 2.03 2.11 
Sample 10 BX010 178.8 2.01 1.83 
Sample 11 BX011 180.1 1.97 1.82 
Sample 12 BX011 184.0 2.02 2.06 
Sample 13 BX013 180.6 2.01 1.74 
Sample 14 BX013 184.8 2.03 2.01 
Sample 15 BX015 178.4 2.03 2.09 
Sample 16 BX015 178.2 1.98 1.76 
Sample 17 BX020 169.3 2.02 1.87 
Sample 18 BX020 164.8 2.03 1.91 
Sample 19 BX024 177.4 2.02 2.06 
Sample 20 BX024 174.4 2.04 2.17 
Sample 21 BX028 180.6 2.01 1.96 
Sample 22 BX028 174.2 2.01 1.94 
Sample 23 BX030 181.2 1.98 1.93 
Sample 24 BX030 181.4 2.03 2.08 
Sample 25 BX031 171.4 2.01 1.98 
Sample 26 BX031 189.6 2.01 2.11 
Sample 27 BX033 192.4 2.04 2.09 
Sample 28 BX033 191.6 2.02 2.01 
Sample 29 BX038 184.2 2.03 1.94 
Sample 30 BX038 184.5 1.97 1.88 
Sample 31 BX040 182.9 2.02 2.05 
Sample 32 BX040 194.8 2.02 1.96 
Sample 33 BX042 149.1 2.04 2.11 
Sample 34 BX042 175.0 2.03 2.08 
Sample 35 BX045 172.1 2.01 2.03 
Sample 36 BX045 168.0 2.02 1.91 
Sample 37 BX048 196.9 2.05 2.11 
Sample 38 BX048 162.9 2.02 1.94 
Sample 39 BX049 185.6 2.04 2.03 
Sample 40 BX049 173.0 2.03 2.01 
Sample 41 BX054 110.7 2.01 1.75 
Sample 42 BX054 170.0 2.04 1.94 
Sample 43 BX063 179.8 2.04 2.11 
Sample 44 BX063 186.7 2.01 1.77 
Sample 45 BX064 171.7 2.04 2.02 
Sample 46 BX064 75.5 1.90 1.53 
Sample 47 BX065 184.2 2.04 1.51 
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Sample 48 BX065 181.8 2.07 1.51 
Sample 49 BX070 174.1 2.03 1.90 
Sample 50 BX070 161.9 2.02 1.81 
Sample 51 BX071 171.3 2.01 1.83 
Sample 52 BX071 163.8 2.09 1.54 
Sample 53 BX072 160.8 2.08 1.51 
Sample 54 BX072 176.7 2.05 1.97 
Sample 55 BX076 101.5 1.88 1.51 
Sample 56 BX076 167.3 1.93 1.52 
Sample 57 BX081 190.4 2.03 2.01 
Sample 58 BX081 176.6 2.02 1.98 
Sample 59 BX082 184.6 2.01 1.92 
Sample 60 BX082 183.1 2.05 1.88 
Sample 61 BX083 161.3 2.02 2.01 
Sample 62 BX083 119.9 1.98 1.69 
Sample 63 BX084 148.1 2.01 1.92 
Sample 64 BX084 173.9 1.98 2.03 
Sample 65 BX085 159.6 2.03 2.01 
Sample 66 BX085 190.8 1.91 1.51 
Sample 67 BX087 195.4 2.02 1.88 
Sample 68 BX087 136.5 2.04 2.05 
Sample 69 BX088 182.5 2.03 2.07 
Sample 70 BX088 120.4 2.01 1.91 
Sample 71 BX089 173.8 2.01 1.81 
Sample 72 BX089 114.5 1.98 1.92 
Sample 73 BX092 182.3 2.01 1.82 
Sample 74 BX092 132.1 1.78 1.57 
Sample 75 BX094 162.0 1.95 1.54 
Sample 76 BX094 148.6 1.99 1.83 
Sample 77 RA06SY 174.7 1.98 1.89 
Sample 78 RA06SY 185.3 2.01 1.89 
Sample 79 RA15SY 167.5 2.05 2.26 
Sample 80 RA15SY 179.9 2.01 1.85 
Sample 81 RA20SY 197.3 2.01 2.03 
Sample 82 RA20SY 180.9 2.04 2.14 
Sample 83 RA23SY 202.1 2.04 1.94 
Sample 84 RA23SY 185.1 2.04 1.97 
Sample 85 RA25SY 186.7 2.02 1.83 
Sample 86 RA25SY 187.9 2.01 1.79 
Sample 87 RA28SY 190.6 2.02 2.09 
Sample 88 RA28SY 187.0 2.04 2.05 
Sample 89 RA29SY 170.8 2.03 2.06 
Sample 90 RA29SY 183.8 2.01 1.88 
Sample 91 RA37SY 132.0 1.96 1.52 
Sample 92 RA37SY 173.7 1.96 1.80 
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Table 9.6  List of differentially expressed transcripts identified by microarray between unstimulated 
VeRA and Established RA samples at a fold difference of 2 and FDR<0.05.  
Agilent probe ID Gene symbol  p value 
A_21_P0000502 RNU11 (small nuclear RNA) 2.93E-08 
A_23_P83798 ALX1 3.15E-05 
A_33_P3279708 RNU2-2  (small nuclear RNA) 2.16E-06 
A_33_P3267263 RNU1-5  (small nuclear RNA) 1.63E-07 
A_23_P100730 SKAP1 2.16E-05 
A_33_P3413808 PABPC1L 2.43E-06 
A_33_P3423285 SETD5-antisense RNA (lncRNA) 1.61E-06 
A_21_P0005609 LOC100216545 4.50E-06 
A_33_P3388636 FLJ40606 5.65E-06 
A_21_P0004515 XLOC_004452 1.31E-06 
A_23_P344125 ISM2 3.26E-06 
A_33_P3399693 Protein LOC100128374 8.34E-05 
A_21_P0000385 SNORD88C 2.94E-05 
A_32_P105825 MPPED2 8.79E-05 
A_33_P3370094 MME 1.12E-05 
A_19_P00316370 LOC100506178 1.56E-05 
A_32_P379467 ISLR2 3.89E-05 
A_21_P0010269 XLOC_014003 5.94E-06 
A_21_P0014898 LOC100652951 1.40E-05 
A_33_P3248354 OLFM1 5.16E-05 
A_24_P940897 OR2H1 2.99E-05 
A_33_P3355371 TTC9C 4.14E-06 
A_33_P3290707 MME 3.96E-05 
A_23_P117387 MIA2 6.41E-05 
A_23_P126266 HLX 1.82E-05 
A_21_P0000269 SNORA52 (small nucleolar) 2.15E-05 
A_33_P3371204 BX098631 2.29E-05 
A_33_P3324505 KMT2E 1.01E-05 
A_33_P3379881 FMN1 3.44E-05 
A_24_P376129 DFNB31 2.83E-05 
A_23_P429998 FOSB 3.89E-05 
A_21_P0010386 LOC100271722 3.18E-05 
A_23_P214080 EGR1 2.58E-05 
A_21_P0004839 XLOC_005176 2.72E-05 
A_21_P0004050 XLOC_004524 5.74E-05 
A_33_P3348001 LOC100130458 4.74E-05 
A_23_P109636 LRIG1 3.90E-05 
A_23_P207037 CD300A 6.90E-05 
A_23_P393034 HAS3 4.03E-05 
A_33_P3346067 LOC388813 6.48E-05 
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Table 9.7 List of differentially expressed transcripts identified by microarray between TNF 
stimulated VeRA and Established RA samples at a fold difference of 2 and FDR<0.05.  
Agilent probe ID Gene symbol  p value 
A_32_P113812 ENST00000425161 1.30E-07 
A_33_P3423285 SETD5-antisense RNA (lncRNA) 1.93E-07 
A_23_P429998 FOSB 2.92E-07 
A_21_P0014532 LOC100287415 6.72E-07 
A_33_P3388636 FLJ40606 7.66E-07 
A_23_P6596 HES1 1.64E-06 
A_33_P3343452 ANKRD30B 2.05E-06 
A_33_P3267263 RNU1-5 (small nuclear RNA) 3.82E-06 
A_23_P106194 FOS 3.96E-06 
A_21_P0005609 LOC100216545 4.28E-06 
A_33_P3282205 AK026419 4.82E-06 
A_21_P0000502 RNU11 (small nuclear RNA) 5.22E-06 
A_33_P3295173 HSPB11 6.31E-06 
A_24_P34155 RUNX1 7.05E-06 
A_33_P3392405 C10orf99 8.70E-06 
A_21_P0014498 LOC100506978 8.82E-06 
A_23_P83798 ALX1 9.91E-06 
A_23_P345460 PLEKHG4 1.31E-05 
A_21_P0008322 XLOC_010804 1.33E-05 
A_23_P117387 MIA2 1.45E-05 
A_21_P0008666 XLOC_011338 1.86E-05 
A_21_P0004691 XLOC_005480 2.05E-05 
A_23_P214080 EGR1 2.14E-05 
A_21_P0003803 XLOC_004182 2.23E-05 
A_33_P3370094 MME 2.33E-05 
A_23_P43337 FREM1 2.61E-05 
A_23_P126266 HLX 2.78E-05 
A_33_P3279708 RNU2-2 (small nuclear RNA) 2.83E-05 
A_33_P3324505 KMT2E 2.90E-05 
A_21_P0010386 LOC100271722 3.00E-05 
A_21_P0001232 XLOC_001230 3.23E-05 
A_33_P3385161 EFCAB9 3.40E-05 
A_19_P00321096 XLOC_001394 4.09E-05 
A_33_P3237050 OR4K14 4.13E-05 
A_33_P3314468 IMMT 4.39E-05 
A_33_P3268310 LIMS3L 4.66E-05 
A_23_P400945 ETV3 4.68E-05 
A_21_P0014451 LOC100287506 4.91E-05 
A_23_P254688 TMEM108 4.95E-05 
A_23_P157333 EPHA1 5.08E-05 
A_21_P0010510 LOC100133612 5.21E-05 
A_24_P927325 C2CD3 5.43E-05 
A_24_P732099 HBBP1 5.74E-05 
A_23_P139635 DAO 5.88E-05 
A_21_P0012315 XLOC_l2_009302 6.09E-05 
A_23_P121011 CSRNP1 6.52E-05 
A_23_P89981 CYP2F1 6.69E-05 
A_21_P0009749 XLOC_013275 7.05E-05 
9-257 
 
A_33_P3282305 ADARB2 7.10E-05 
A_33_P3285799 AKD1 7.17E-05 
A_21_P0008263 XLOC_010693 7.21E-05 
A_21_P0007249 XLOC_009233 7.43E-05 
A_33_P3332414 ABCB1 7.58E-05 
A_21_P0014359 LOC100506418 8.05E-05 
A_21_P0014657 LOC100506502 8.52E-05 
A_21_P0010481 XLOC_014404 8.58E-05 
A_33_P3248610 ASXL2 8.65E-05 
A_33_P3409337 C14orf45 8.68E-05 
A_21_P0014898 LOC100652951 9.35E-05 
A_33_P3290707 MME 9.60E-05 
A_24_P230948 PER3 9.70E-05 
A_19_P00316897 ENST00000514376 0.000101 
A_33_P3839897 RNU4ATAC (small nuclear RNA) 0.000103 
A_33_P3245238 SULT1C2 0.00011 
A_23_P66682 HOXB6 0.000111 
A_33_P3224070 CSRNP1 0.000123 
A_23_P41599 PCDHB8 0.00013 
A_33_P3269109 GUCY1A3 0.000133 
A_24_P260101 MME 0.000133 
A_21_P0011683 ZNF729 0.000144 
A_33_P3298440 LOC729324 0.000155 
A_23_P5679 CFC1 0.000155 
A_23_P56404 EN1 0.000165 
A_21_P0000269 SNORA52 (small nucleolar RNA) 0.000194 
A_33_P3407746 PPM1B 0.000213 
A_33_P3892710 SNORA22 (small nucleolar RNA) 0.000214 
A_23_P393034 HAS3 0.000216 
A_33_P3385002 ELK1 0.000232 
A_21_P0005421 XLOC_006223 0.000248 
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Figure 9.3 Expression levels of selected target genes assessed by microarray in unstimulated 
samples. Raw microarray data representing expression levels of 20 target genes in unstimulated 
Normal (n=8), Resolving (n=15), VeRA (n=13) and Established RA (n=7) samples are represented. 
Expression levels expressed as arbitrary fluorescence units (FU).  
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Figure 9.4 Expression levels of selected target genes assessed by microarray in TNF stimulated 
samples. Raw microarray data representing expression levels of 14 target genes in TNF stimulated 
Normal (n=8), Resolving (n=15), VeRA (n=13) and Established RA (n=7) samples are represented. 
Expression levels expressed as arbitrary fluorescence units (FU). 
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